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Drug metabolism is recognised as a key component of the drug discovery and development 
process. It exerts an influence on the action, duration of action and toxicity of a drug in vivo. 
The integration of drug metabolism studies is therefore crucial to compound progression 
through the various stages of the development process. This work details the in vitro 
metabolism work conducted during the early development of aminoquinoline tetrazoles, and 
derivatives of metergoline and fusidic acid as potential antiplasmodial and/or 
antimycobacterial agents. 
An investigation of the in vitro metabolism of a series of deoxyamodiaquine tetrazoles found 
that the most active compounds were rapidly metabolised by oxidation and dealkylation on 
the tertiary nitrogen substituents. The compounds were also potent CYP450 inhibitors, with 
submicromolar IC50s for CYP450 2C8 and 3A4 and moderate inhibition of most other 
CYP450s. While these compounds did not show glutathione adduct formation as reported for 
amodiaquine, compounds with cycloalkyl substituents on the tertiary nitrogen formed 
cyanide adducts. 
The chloroquine tetrazole analogues were in general less metabolically stable than 
chloroquine. The main metabolic pathway for these derivatives was aminoquinoline N-
oxidation and tert-butyl hydroxylation. While the P450 inhibition potency of these 
compounds was lower than that of the deoxyamodiaquine tetrazoles, they displayed 
submicromolar inhibition of CYP3A4. Interestingly, for a series of chloroquine analogues, 
these compounds also show evidence of glutathione adduct formation on the 4-
aminoquinoline nucleus. This is hypothesised to result from the ‘masked aniline’ nature of 
the aminoquinoline ring.  
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The metergoline analogues investigated were in general more metabolically stable than 
metergoline. This was attributable to the better stability of the amide linker relative to its 
carbamate counterpart in metergoline, as evidenced by the lack of formation of 8β-
aminomethyl-1,6-dimethylergoline in incubations of the amide derivatives. Metabolism was 
mainly on the ergoline nucleus by hydroxylation and N-demethylation. However, alkyl 
hydroxylation was also observed among derivatives with alkyl chains longer than ethyl, 
either substituted directly on the amide bond, or substituted on a phenyl ring.  
Fusidic acid underwent species specific metabolism to a metabolite tentatively identified as 
3-epifusidic acid that was only formed in rat and mouse liver microsomes. This metabolite 
was detected in all derivatives with a free C-3 OH and in 3-ketofusidic acid. The formation of 
this metabolite is hypothesised to result from C-3 oxidation followed by non-stereoselective 
reduction to give fusidic acid and 3-epifusidic acid. Fusidic acid and most of its derivatives 
were also metabolised by C-3 oxidation to the respective 3-keto- derivatives and by 
hydroxylation. C-3 esters but not their C-21 counterparts were hydrolysed in microsomes and 
plasma to fusidic acid. Fusidic acid was also found to undergo metabolism in a 
Mycobacterium smegmatis lysate but not in Mycobacterium tuberculosis supernatant or in the 
buffer control, to form fusidic acid lactone. This process has been associated with fusidic acid 
resistance in certain species of Nocardia and Streptomyces. 
These findings will be useful in the further exploration of these compounds as antiplasmodial 
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“The Road goes ever on and on 
Down from the door where it began. 
Now far ahead the Road has gone, 
And I must follow, if I can, 
Pursuing it with eager feet, 
Until it joins some larger way 
Where many paths and errands meet. 
And whither then? I cannot say.” 
 
----------------------------------------------------------------------- 
“Still round the corner there may wait 
A new road or a secret gate, 
And though we pass them by today, 
Tomorrow we may come this way 
And take the hidden paths that run 
Towards the Moon or to the Sun.” 
 















Chapter 1  
INTRODUCTION & LITERATURE REVIEW 
“In order to understand the actions of drugs it is an absolute necessity to have knowledge of 
the transformations they undergo in the body. It is obvious that we must not judge drugs 
according to the form and amount administered, but rather according to the form and 




1.1 Chapter overview 
In this chapter, a broad introduction on the relevance of metabolism to xenobiotic clearance is 
provided. The major classes involved in the metabolism of drugs and drug-like compounds 
are presented and their relevance to the medicinal chemistry process in drug discovery 
discussed, followed by a discussion on drug metabolism systems. An overview of LC-MS as 
an analytical tool in early drug metabolism studies is also provided. Finally, the justification 
and aims of this work are provided. 
1.2 Absorption Distribution Metabolism and Excretion (ADME)  
The activity of a drug in vivo is dependent not only on its ability to act at the relevant target 
but on the concentration of the drug that is available at the site of action and the duration for 
which it is available. For many drugs, these factors are determined by the interplay of four 






Orally administered drugs first undergo dissolution in the gastrointestinal tract and are then 
either passively or actively absorbed through the gastrointestinal walls into the systemic 
circulation. They then distribute into various body compartments based on the drug’s 
physicochemical characteristics. Drugs in systemic circulation are also subject to metabolic 
and excretory processes. The interaction of all these processes results in a change in drug 




Figure 1.1: Drug pharmacokinetics following oral dosing
3
 
The pharmacokinetics of a drug will determine whether the minimum effective concentration 
is reached, how long it is maintained for and whether toxic effects are produced. From this 
perspective, it is unsurprising that failure rates of 40% were observed in drug discovery eras 
where pharmacokinetic studies were not closely integrated into the development process 
(Figure 1.2).
4
 This figure has been suggested to be even higher because pharmacokinetics 








































1.3 Drug metabolism 
 Xenobiotics, foreign compounds present in living systems, pose a continuing danger to the 
organism and constantly need to be eliminated to maintain life.
6
 Metabolism is the process by 
which xenobiotics are chemically modified so as to facilitate their elimination and/or to 
detoxify them. The same enzymes systems are also involved in the biosynthesis and 
homeostasis of various endogenous molecules required to maintain normal function e.g. 
steroid hormones. Metabolism is thus important in preventing accumulation of xenobiotics 
and endogenous molecules.
7
 As will be discussed later, metabolism, while primarily a 
detoxifying process, is also implicated in the formation of toxic species which may adversely 
affect biological processes.  
Metabolism usually proceeds by reducing the lipophilicity of the targeted xenobiotic 
therefore preventing its reabsorption during excretion. This point underlies an important 
relationship – the physicochemical characteristic of a drug are important in determining the 
route of its excretion. This knowledge has been distilled into various predictive systems most 
of all the Biopharmaceutics Drug Disposition Classification System (BDCS) – an extension 
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of the previously reported Biopharmaceutics Classification System (BCSD) – which attempts 








        




This relationship exists because highly permeable drugs – usually lipophilic as well – will 
tend to diffuse more efficiently into drug metabolising cells like hepatocytes and will also be 
more efficiently reabsorbed following renal excretion ensuring that they stay in circulation 
until metabolic processes make them hydrophilic enough for excretion. 
Metabolism has traditionally been divided into phase I metabolism, consisting mostly of 
oxidoreductive and hydrolytic processes and phase II metabolism which mainly involves 
conjugation of endogenous molecules to polar functional groups in the drug either originally 
present in the drug, or introduced/unmasked during phase I metabolism.
9,10
 These phases are 
not necessarily sequential and will not necessarily occur on the same compound. Testa and 
co-workers reported that redox reactions account for up to 70% of first generation 
metabolites with the importance of conjugation reactions increasing with the generation until 






















Elimination by metabolism 
Elimination of unchanged drug 
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1.4 Drug metabolising enzymes 
Drug metabolism mainly occurs in the liver though other organs like skin, lungs and blood 
(both cells and plasma) make important contributions to the biotransformation of certain 
drugs. In line with the role of metabolism in the clearance of xenobiotics, many drug 
metabolising enzymes with widely differing substrate specificities are expressed in man. A 
recent review of over 1000 xenobiotics, cytochrome P450 enzymes were found to account for 
up to 40% of metabolites formed, with uridine diphosphate-glucuronyl transferases (UGTs), 
dehydrogenases, hydrolases, glutathione transferases and sulfotransferases also making 
significant contributions.
11
 An overview of the major classes follows.  
1.4.1 Cytochrome P450 enzymes 
1.4.1.1 Nomenclature 
The Cytochrome P450 enzymes (P450s) are a super-family of haem containing mono-
oxygenases with more than 21000 named members across different species.
12,13
 The ‘P450’ 
name was ascribed based on a characteristic spectrophotometric absorbance maximum at 
450nm.
14
 The human genome contains at least 57 genes involved in P450 expression.
12,13
  
The P450s are expressed as membrane-bound enzymes in almost all tissues, usually in the 
endoplasmic reticulum but also in mitochondria. They are classified based on amino acid 
sequence identity, with those sharing at least 40% identity being grouped into a family 
denoted by a number e.g. CYP1. These families are further divided into subfamilies denoted 
by a letter – members of a subfamily have at least 55% sequence identity for example 
CYP1A. Finally, a number is assigned to each isoform in a subfamily e.g. CYP1A1 and 
CYP1A2.
15
 Mammals have 18 families and 43 subfamilies of P450s.
12,13
 Families 1-3 are the 
most involved in xenobiotic metabolism, while the others are predominantly involved in the 
biosynthesis of sterols, fatty acids and other endogenous compounds.
16
 In mice, it has been 
shown that deletion of Cyp2c, Cyp2d, and Cyp3a  gene clusters results in viable and fertile 
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individuals with minor phenotypic changes, showing that these genes are mostly involved in 
xenobiotic metabolism. A review of the primary clearance mechanism for 200 drugs showed 
that CYP 3A4, 2C9, 2C19, 2D6 and 1A2 in that order are the most important for drug 
metabolism, accounting for the metabolism of more than 90% of the reviewed drugs that 










P450s usually consist of 480 – 560 amino acids and a ferriprotoporphyrin-9 prosthetic group 
anchored to the protein by a cysteine residue. As already mentioned, variations in the amino 
acid sequence lead to the different isoforms while the FP-9 is preserved across all P450s. FP-
9 in its resting state consists of iron as Fe
3+
 in a hexacooordinated state with 4 pyrrole 







In general, P450s act by activating molecular oxygen to reactive species which can 
participate in reactions with less active reaction centres in their substrates leading to their 
chemical transformation. The general catalytic cycle is shown in Figure 1.5. 
 




The cycle begins by the binding of the substrate to the enzyme displacing a molecule of water 
and resulting in changes in the electronic configuration of the iron to its high spin 
pentacoordinated form. This low to high spin change facilitates the electron transfer from 
NADPH in the second step by increasing the redox potential of heme.
20
 The ferrous 
intermediate produced from the second step is also responsible for the characteristic 
spectrophotometric absorbance of P450s through reversible binding to carbon monoxide. 
This ferrous intermediate binds to oxygen (step 3) producing an unstable complex which 
receives the second electron from NADPH reductase (step 4). This is followed by protonation 
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(step 5) and then heterolytic cleavage of the O-O bond (step 6) to yield a highly reactive 
FeO
3+
 complex which is the oxidising species in most P450 reactions.  This complex 
abstracts an electron or proton from the substrate (step 7) and the subsequent rebound leads to 




Several points arising from this catalytic cycle are of relevance to subsequent discussions on 
drug metabolism and to its prediction by in silico tools. First, binding of the substrate in step 
1 is governed by the 3D structure of the substrate and the enzyme. However, the structure of 
the metabolite formed is not necessarily discernible from this step as it is more dependent on 
the geometry and chemical reactivity of the complex formed in step 7.
24
 Secondly the high 
reactivity of the (FeO)
3+ 
species means that unlike in other enzymes, the structure of the 
protein is not important in determining the mechanism of metabolism. This accounts for the 
high substrate and reaction promiscuity observed with P450s relative to other enzymes.
25
 
Thirdly, when considering a particular reaction by a specific P450 enzyme on a group of 
related substrates, step 7, i.e. the abstraction of hydrogen or an electron, is the rate limiting 
step.
23
 Reaction regioselectivity is thus partially controlled by the energy involved in 
hydrogen abstraction and by the stability of the resulting carbon radical. It should be 
emphasised though that as mentioned under the first point, the orientation of the substrate, as 
determined by its 3-dimensional interaction with the active site and nearby amino acids is 
also crucial to the determination of regioselectivity. 
Based on variations in the structure and subsequent rearrangement of the (FeO)
3+
 - substrate 
complex formed in step 7, P450 reactions may be divided into six categories; carbon (sp
3
) 
hydroxylation, heteroatom release, heteroatom oxygenation, epoxidation, oxidative group 
transfer and olefinic suicide destruction. 
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Carbon hydroxylation involves abstraction of a hydrogen radical by (FeO)
3+
 with the 
resulting ‘oxygen rebound’ – reaction of the carbon radical with the –OH on the iron – 
leading to the hydroxylated product.
23
 The implications of this mechanism is that a C-H bond 
is required on the carbon to be hydroxylated although a C-H bond on an adjacent carbon may 
rearrange after hydrogen radical abstraction to form a more stable intermediate.
26
 In addition, 
subject to the orientation of the substrate in the active site, the reactivity of the C-H bond will 
determine the regioselectivity. Based on the energy required for hydrogen abstraction, 
benzylic carbons are the most easily hydroxylated, followed by allylic and then aliphatic 
carbons. Branching increases the stability of the radical intermediate and tertiary carbons are 
therefore more susceptible than secondary carbons.
26
 For long chain hydrocarbons with no 
activated positions, substrate orientation in relation to the active site leads to ω and ω-1 
hydroxylation despite the less favourable energetics. The basic features of this mechanism 
(hydrogen abstraction followed by oxygen rebound) are also implicated in alcohol oxidation 
to carbonyl and subsequently carboxylic acid.
19,27
 
 Heteroatom oxygenation occurs with substrates containing N, S, P and I. The mechanism is 
thought to involve sequential electron abstraction from the heteroatom followed by oxygen 
rebound to form the heteroatom oxide.  
Heteroatom release may be seen as a mix of heteroatom oxygenation and carbon 
hydroxylation. It occurs by electron abstraction from the heteroatom with subsequent radical 
delocalisation and proton abstraction on the carbon α to the heteroatom yielding a carbon 




Epoxidation, oxidative group migration and olefinic suicide inactivation all occur when the 
substrate has double bonds or is aromatic in nature. The mechanism of oxidation of these 
10 
 
groups of compounds is thought to involve an epoxide intermediate. With alkenes the 
reactivity of this epoxide leads to reaction with the home leading to inactivation of the 
enzyme (olefinic suicide inactivation). In some cases though, the epoxide is stable enough to 
be observed as a metabolite. In most cases it rearranges through protonation to form a phenol 
(in the case of phenyl rings) or other hydroxylated aromatic group. With aromatic groups, the 
observation of a 3,4 hydrogen shift was previously thought to be evidence of the epoxide 
intermediate. However, other mechanisms, for example electrophilic addition of FeO
3+
 to the 
aromatic group have also been shown to be plausible. Based on these mechanistic 













































































Oxidative cleavage of 
esters
35
 (and amides, 
carbamates, ureas etc) 
 












1.4.1.4 Prediction of CYP450 metabolism 
The role of CYP450s in the metabolism of drugs has led to a high level of interest in 
predicting such metabolism in silico. The ultimate aim of such work is to improve the 
efficiency of medicinal chemistry programs by identifying such metabolically labile sites 
before synthesis, leading to production of metabolically stable compounds from the 
beginning. In silico models for CYP450 metabolism prediction can be broadly classified into 
quantitative structure activity relationship-(QSAR)-based and structure-based methods. 
QSAR-based models are statistical relationships between calculated molecular properties and 
the rate of metabolism or an equivalent surrogate.
38
 They are by their nature heavily 
dependent on the robustness of the data used in their creation and this may sometimes limit 
their application. In contrast, structure-based methods consider the structure of the compound 
and/or enzyme, either in its entirety as 2D or 3D model or as fragments derived from the 
parent structure. These methods will often use rule-based, docking, quantum mechanical 
criteria or a combination of some or all of these (sometimes in combination with QSAR 
models) to predict CYP450 metabolism.
39
 
StarDrop, the in silico tool used in this work, uses a quantum mechanical-based model for the 
prediction of metabolism by CYP3A4, CYP2D6 and CYP2C9, which together account for 
the metabolism of more than 90% of clinical compounds.
40
 The software predicts the 
regioselectivity of metabolism for the three CYP450s and in addition gives a measure of the 
lability of the site of metabolism for CYP3A4. The regioselectivity is calculated based on the 
intrinsic vulnerability to metabolism of a given site and the accessibility of the site as 
determined from the 3D structure of the compound. Since the rate limiting step in CYP450 
metabolism is often the hydrogen atom abstraction, the Arrhenius equation can be applied to 
relate the rate of metabolism at a particular site to the negative exponent of the activation 
energy of hydrogen atom abstraction at the site. This activation energy must be calculated for 
14 
 
each site of metabolism, and the calculations are, therefore, computationally intensive if done 
ab initio. Instead, StarDrop uses the AM1 semi-empirical technique, and corrects for 
systematic errors  using data from ab initio calculations.
41,42
 This dramatically lowers the 
computational resources required for the prediction but still requires a few minutes per 
compound on an ordinary desktop. This was about 5 – 10min for compounds reported in this 
work. As discussed earlier, the similarity in oxidising species (FeO
3+
) between CYP450s, 
implies that the mechanistic aspects of metabolism are independent of the enzyme and can be 
determined using the structure of the compound only. However, the relative contribution of 
intrinsic reactivity and accessibility for a given site of metabolism will vary based on the 
structure of the CYP450 being considered and the model parameters in StarDrop are 
therefore trained using a set of experimentally observed metabolites. The overall success of 
StarDrop in predicting the top 3 metabolites formed is comparable to that of docking-based 
algorithms like MetaSite.
39
 StarDrop was selected for this work because it offers an 
integrated tool, able to perform not only P450 modelling, but a range of ADME predictions, 
de novo design and library management, allowing more efficient collaboration between the 










1.4.2 Molybdenum hydroxylases 
1.4.2.1 Structure and occurrence 
Molybdenum hydroxylases are a family of molybdenum-containing flavoenzymes found in 
almost all organisms.
43,44
 In higher organisms, the molybdenum is typically present in the 
form of a tetracyclic pterin-based complex referred to as molybdenum-cofactor (MoCo).
43–45
 
In human and experimental animal drug metabolism, the most relevant of the 
molybdoflavoenzymes are aldehyde oxidase and xanthine oxidase. The physiological role of 
aldehyde oxidase is still unclear though vitamin and serotonin catabolism have been 
proposed, xanthine oxidase has a clearer role in the catabolism of purine nucleotides.
45
 Both 
enzymes share a similar protein structure and are located in the cell cytosol predominantly in 
the liver, but also in plasma, lungs, gastrointestinal tract and kidneys.
46
 While xanthine 
oxidase activity is similar across species, there are significant differences in the activity of 
aldehyde oxidase across common lab species, complicating inter-species extrapolation of 
pharmacokinetic data.
46–48
 Aldehyde oxidase activity is highest in monkeys and humans, 
lower in rodents and completely absent in dogs. There are also significant inter-strain and 
inter-individual differences in rats and even sex differences in mice.
46,47,49
 Aldehyde oxidase 
is of greater importance amongst the molybdenum hydroxylases and the discussions that 
follow therefore centre on it. 
1.4.2.2 Mechanism 
The general mechanism for the metabolism of substrates by aldehyde and xanthine oxidase is 
broadly similar and involves the nucleophilic attack of the substrate by Mo-Co followed by 
substrate release through a reaction between water and the tetrahedral substrate enzyme 
complex. An example of this mechanism for the oxidation of phtalazine by aldehyde oxidase 




Figure 1.6: Oxidation of phthalazine by aldehyde oxidase (Modified from Pryde et al
47
) 
The catalytic cycle starts with base-catalysed deprotonation of the Mo-OH. This has been 
proposed to occur through a glutamate residue, with Glu-1261 being the most obvious by 
nature of its position in the active site of the enzyme. This facilitates nucleophilic attack of 
the substrate to form a tetrahedral substrate-enzyme complex.
43,46–48
   The free energy of this 
intermediate has been reported to be predictive of the metabolite formed for AO but not 
XO.
50
 Hydride transfer from the substrate to the enzyme then occurs changing the oxidation 
state of molybdenum from +6 to +4. A nucleophilic attack by water releases the oxidised 
substrate and the enzyme is regenerated by a transfer of 2e
-
 to FAD and by loss of a 
proton.
43,46–48
  The net reaction is:  





This catalytic cycle differs from that of P450s in two key aspects: first the oxygen atom 
incorporated into substrates arises from water and not from molecular oxygen; secondly, 
reducing equivalents are generated as a result of the reaction whereas they are consumed 





1.4.2.3 Medicinal chemistry relevance 
A possible unintended effect of the literature trove that exists for CYP450 metabolism has 
been the growth in medicinal chemistry approaches to minimise or avoid P450 metabolism, 
resulting in a growing importance of otherwise minor metabolic pathways.
47
  As an example, 
the synthesis of electron deficient heterocycles reduces the potential for P450 metabolism but 
increases the potential of metabolism by aldehyde oxidase, which relies upon nucleophilic 
attack. A recent review found that up to 56% of compounds in selected libraries contain 
substructures that could predispose them to aldehyde oxidase metabolism.
47
  
1.4.2.3.1 Oxidation of aromatic heterocycles 
From a medicinal chemistry point of view, the most important reaction of aldehyde oxidase is 
the oxidation of aromatic heterocyclic moieties, usually on a carbon next to nitrogen.
47
 This is 
particularly important because of the increasing presence of nitrogen containing aromatic 
heterocycles in drug discovery. As would be expected based on the nucleophilic mechanism, 
the rate of metabolism of these compounds correlates with the electron density of the ring; 
electron withdrawing groups will therefore increase the rate of metabolism while electron 










1.4.2.3.2    Oxidation of aldehydes and iminium ions 
Aldehyde oxidase is involved in the oxidation of aldehyde groups and iminium ions, usually 
as a secondary step in the metabolism of alcohols and cyclic amines respectively.
46,47,49
 
Aldehydes are converted to the respective carboxylic acids while iminium ions are converted 
to lactams. In general the activity of this enzyme in this reactions has been reported to be 
lower than that during aromatic heterocycle oxidation.
49
 The production of reactive oxygen 
species by the aldehyde oxidase-mediated metabolism of acetaldehyde, derived from alcohol 
metabolism, has been reported as a possible cause of alcohol-induced liver injury.  
 










1.4.3.1  Structure and occurrence 
Hydrolases – enzymes which catalyse the water-catalysed breakdown of susceptible 
compounds are comprised of many structurally and mechanistically diverse members. 
Amongst the most important of these are esterases which primarily hydrolyse esters but are 
also involved in the hydrolysis of amides, carbamates and other related molecules.
25,55,56
 
Their distribution varies in different tissues. In plasma for example, butyrylcholinesterase, 
paraoxonase, albumin and acetylcholinesterase are the main ones present. While the catalytic 
activity of albumin is low, it is present in amounts of up to 50-60 g/l in plasma leading to 
significant catalytic activity.
57
 The membranes of red blood cells contain additional esterases 
particularly esterase D and acetylcholinesterase and drug hydrolysis will therefore differ 
between plasma and whole blood.
57,58
 In the liver and small intestines, the main hydrolases 
present  are the carboxylesterases (human carboxylesterase-1, -2) with human 
carboxylesterase-1 (hCE1) being predominant in the liver and hCE-2 being predominant in 
the small intestines.
59,60
 Species differences in esterase distribution and activity have been 
reported. For example, in human blood, the esterase activity is mainly due to cholinesterases 
while in rat and mouse blood, carboxylesterases are more predominant. Rodent blood also 
has higher total esterase activities than human blood and this should therefore be taken into 
account when extrapolating esterase hydrolysis between these models and man.
61
 Ester 
hydrolysis by carboxylesterases is more substrate specific and the discussion that follows 
therefore focuses more on these enzymes.  
The active site of carboxylesterases is characterised by a catalytic triad containing serine, 
histamine and glutamate which participate in the mechanism of these enzymes.
62–64
 While the 
catalytic site is mostly conserved, differences in other parts of the enzymes result in different 
substrate specificities between hCE-1 and hCE-2. hCE-1 is mostly involved in the hydrolysis 
20 
 
of compounds containing a large acyl group and a small alcohol moiety while hCE-2 
hydrolyses substrates with small acyl groups and large alcohol groups.
59,64
  
1.4.3.2  Mechanism 
Carboxylesterase hydrolysis of esters proceeds by nucleophilic attack of the substrate by a 
serine residue at the active site. This attack is facilitated by deprotonation of the serine by a 
histidine residue, which is in turn facilitated by hydrogen bond-mediated stabilisation by 
glutamate. This catalytic triad Serine – Histidine – Glutamate is highly conserved and is a 








The resulting rearrangement of the intermediate releases the alcohol and gives an acyl 
enzyme complex. The alcohol formed or any other alcohol present in a high enough 
concentration may attack this complex leading to transesterification.
64
 An analogous process 
then occurs with the histidine catalysed nucleophilic attack of the acyl enzyme complex to 




1.4.3.3  Medicinal chemistry relevance 
Esterases are often involved in activation of prodrugs, usually designed to facilitate 
absorption by masking more polar groups. A number of compounds are, however, only active 
as their ester forms and they are therefore deactivated by these enzymes. The 
transesterification reactions may also have relevance as in the example of cocaine, where 
transesterification with ethanol, either from the hydrolysis of cocaine or from co-ingested 




Figure 1.10: Reactions catalysed by carboxylesterases as exemplified by cocaine. The 








1.4.4 UDP Glucuronosyl transferases 
1.4.4.1 Structure and occurrence 
Uridine-5’-diphosphate glucuronosyl transferases (UGTs) are a super-family of enzymes, 
which as their name implies catalyse the transfer of glucuronic acid from their co-factor 
UDP-α-D-glucuronic acid (UDPGA) to nucleophilic sites of substrates.
69–71
 The UGT genetic 
super-family contains 117 genes encoding enzymes that have been divided into four families 
– UGT1, UGT2, UGT3 and UGT8.
72
 In humans and experimental animals the UGT1 and 2 
families are the most important for drug metabolism. Like P450s, these enzymes are 
membrane-bound and are found bound to the endoplasmic reticulum, though they are mostly 
lumenal – incorporated within the endoplasmic reticulum (≈95%), in contrast to P450s which 
have a significant cytosolic portion.
70,73
 This subcellular location is also responsible for the 
latency in activity seen in drug metabolism studies with hepatocytes and microsomes because 




UGTs have important endogenous substrates, bilirubin being one of the better known ones. 
Because of their broad and overlapping substrate specificity, drugs sometimes compete with 
endogenous molecules for glucuronidation leading to physiological disturbances.
69,75
 UGTs 
are referred to as low affinity, high capacity enzymes which means that at low doses in the 
presence of a competing pathway, the drug will probably be metabolised by the competing 




Glucuronidation proceeds through a nucleophilic (SN2) attack of C1 on UDPGA, displacing 
UDP and forming the glucuronide. The mechanism necessitates an inversion of configuration 
from α- in UDPGA to β in glucuronides. While the specific aspects of this mechanism are 
23 
 
still under investigation, it has been proposed that a histidine, aspartate or glutamate residue 




Figure 1.11: Mechanism of glucuronidation
70
 
1.4.4.3 Medicinal chemistry relevance 
Glucuronidation is the most important conjugation reaction and UGTs rank second to P450s 
in the number of drugs they metabolise. Based on their mechanism, substrates must contain a 
nucleophilic atom usually O, N or S but also C if nucleophilic enough. This functional group 
can be introduced as part of phase I metabolism or may be already present in the molecule. 
O-glucuronides can be formed from alcohols, carboxylic acids and even 
hydroxylamines/hydroxylamides.
25,78
 O-glucuronides formed from carboxylic acids are 
referred to as acyl glucuronides and are potentially reactive towards nucleophilic cell 
constituents leading to toxicity.
79
   Transesterification with glycerol has also been reported as 
an artefact in vitro.
80
 N-glucuronides can be formed from amines (1°, 2°, 3°), amides, 
sulphonamides and even aromatic N-heterocycles.
78,81
 The formation of quaternary N-
glucuronides shows wide species differences, being highest in higher primates (man, 
chimpanzees) and virtually absent in lab animals (dogs and rodents), the formation of non-
quaternary glucuronides is less species dependent.
81
 C-glucuronides are much rarer and as 
alluded to, require acidic carbons or enolic acids.
82,83






1.4.6 Glutathione S-transferases 
1.4.6.1 Structure and occurrence 
Glutathione S-transferases (GSTs) are an enzyme superfamily found in most aerobic 
organisms. They typically make up about 1% of the total cellular protein and are involved in 
the protection of cells against oxidative stress and chemical toxicity due to alkylation of 
cellular components.
46,85,86
 This function is served by catalysis of reactions between the thiol 
group of reduced glutathione (GSH) and electrophilic centres in substrates. They exist as 
dimers with each subunit having a hydrophilic site – where GSH is bound through hydrogen 
bonds – and a hydrophobic site for substrate binding.
87–89
 The enzymes exist as two broad 
families; soluble/cytosolic enzymes and membrane associated proteins. Their detoxification 
role is mainly associated with the cytosolic family of enzymes. Based on sequence identity, 
mammalian cytosolic GSTs can be classified into 8 classes – designated α, μ, π etc and 4 
additional classes in bacteria insects and plants.
86
 In line with their detoxification role, the 
enzymes have broad and overlapping substrate specificities. In addition, it has been reported 
that some GSTs directly bind some carcinogenic compounds and also that some classes of 





Glutathione conjugation occurs through nucleophilic attack of the substrate by the thiolate 
anion of GSH. This implies that conjugation can occur even in the absence of enzyme. GSTs, 
however, increase the rate of this reaction by activating the GSH through deprotonation of the 
thiol. This is thought to involve a tyrosine residue at the active site and may either be through 
a base-mediated mechanism or through hydrogen-bond stabilisation. The result is that the 
thiol pKa of glutathione bound to GST is about two units lower than the pKa of free 
25 
 
glutathione (pH6.4-6.7 vs pH 9.0), therefore increasing the amount of ionised glutathione 
available for the conjugation reaction.
87–89
 
1.4.6.3 Medicinal chemistry relevance 
Glutathione conjugation is primarily a detoxification mechanism and will usually occur 
following activation of the compound by P450s or other oxidising enzymes to create reactive 
intermediates. While the primary mechanism is the same, the reaction type may vary based 
on the nature of the substrate. Common reactions are nucleophilic aromatic substitution, 
Michael addition, epoxide ring opening and reduction of hydroperoxides. Amodiaquine 
metabolism, which is discussed in more detail in Chapter 2, is a well-known example of the 
relevance of glutathione conjugation in the elimination of reactive drug metabolites. 















1.4.6 Other Phase II enzymes 





 Is a high affinity low capacity process 
and is therefore more relevant at low 
concentrations and is easily saturated. 
 Mechanism is similar to glucuronidation 








 Catalyse transfer of an acetyl group from 
acetyl CoA to usually to primary 
aromatic amines but also to 





 Catalyse transfer of a methyl group from 
S-adenosylmethionine to catechols, 








 First drug metabolism reaction to be 
described.  
 Is a two-step reaction involving 
formation of an acylCoA thioester 
followed by acyl transfer to the –NH2 of 
amino acids. 
 
1.5 Systems for the study of drug metabolism 
Drug metabolism studies are an integral part of the drug discovery and development process. 
Ultimately, the aim of these studies is to identify all metabolic outcomes relevant to a drug 
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and its metabolites in man and to understand and thus anticipate the interaction of the drug 
with the metabolism of other drugs or endogenous substrates (FDA guidance). The choice of 
system depends both on convenience (cost, throughput etc) and biological relevance. The 
ultimate system is of course in vivo studies in man, for drugs being developed for humans. 
However, cost and ethical concerns mean that this can only realistically be done in later 
phases of drug discovery, when the safety and efficacy in animal models has been 
comprehensively demonstrated. Various systems have therefore been developed to model 
drug metabolism in man and therefore allow for comprehensive metabolism studies before 
human trials. The systems are discussed in decreasing order of their biological complexity.  
1.5.1 Animal models of drug metabolism 
While there are occasional species differences in metabolism between man and animal 
models, experimental animals provide the best picture of drug metabolism in vivo. This is 
partly because metabolism in vivo is subject to many processes that are difficult to model in 
vitro. Most regulatory guidelines suggest that metabolism should be studied in at least one 
rodent and one non-rodent species to allow a better prediction of human metabolism and 
anticipate potential problems such as metabolic toxicity. The choice of model is dependent on 
the similarity of pathways between the model and man as predicted from in vitro data or 
literature.  
More recently advances in genetics and immunology have allowed development of chimeric 
mice, which have human livers. These models are created by destroying hepatocytes of 
immunocompromised mice (e.g. SCID mouse) and repopulating their livers with human 
hepatocytes.
96–98
  The resulting models express most human hepatic enzymes and transporters 
and the metabolic and excretory processes have been shown to be similar to humans.
99–102
 
Mice models in which various enzymes have been deleted have also recently been reported 
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1.5.2 In vitro models of drug metabolism 
While animal models offer a biological complex and relevant model, the cost and ethical 
concerns that arise with their use means that it is often more practical to study in vitro  
metabolism first. Here again there is a broad variety of choices based on the question to be 
answered, for example whether the aim is to study the totality of metabolism or to study one 
particular metabolic process.  
Given the central role of the liver in drug metabolism, most in vitro models are hepatic. 
However, equivalents exist for most of these models when another organ is to be studied. The 
first models were whole organ models where the entire liver or part of it was used, for 
example the perfused liver model and liver slices. These models offer a biological complex 
system where the 3D architecture of the cells is maintained and which preserve all relevant 
metabolic and excretory processes. However, the cost, throughput and difficulty in handling 
make these unsuited for routine use. In addition, to maintain viability, the models have to be 
used as soon as they are prepared which means that they are not commercially available. 
Most routine drug metabolism studies are therefore done on a variety of cellular and sub-
cellular fractions depending on the level of complexity required.
105,106
  
Hepatocytes provide the most direct way to study hepatic drug metabolism. However, to offer 
a direct comparison to metabolism in vivo, it should be recalled that metabolism in vivo 
depends not only on a complete enzyme complement but also on transporter activity, cell-cell 
contact etc. The degree to which hepatocytes model the in vivo process is therefore dependent 
on how close they are to modelling all these processes. Hepatocytes can be freshly isolated 
(primary hepatocytes) or cultured. Freshly isolated hepatocytes suffer the disadvantage that 
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they can only be used for several hours following their isolation, making it difficult to 
perform experiments on demand.  Various techniques have therefore emerged for their 
cryopreservation.
107–109
 These cells, however, lack the 3D architecture of hepatocytes in vivo 
and may therefore not adequately model some in vivo processes. In addition, the short 
viability period of hepatocytes in suspension (about 4hours) means that metabolites of slowly 
metabolised compounds and even secondary metabolites of other compounds are often 
absent.
110,111
 This is of particular concern since a lot of medicinal chemistry work targets 
reducing the degree of metabolism, therefore increasing the proportion of slowly metabolised 
compounds in drug discovery. These disadvantages have been overcome by the development 
of culture technologies which extend viabilities to several days. Recent improvements to 
culture models include the co-culture of hepatocytes with non-parenchymal cells which 
improves hepatocyte function and allows enzyme activity to be retained for longer.
112–114
  
Subcellular fractions derived from hepatocytes are often the first system used in the screening 
of compounds in early drug discovery. They give a good representation of the metabolic 
processes involved for a drug and often give good in vitro/in vivo correlations. They also 
solve problems with inter-individual variation since they can easily be pooled. Other 
advantages are their stability in storage, low cost and easy commercial availability. However, 
they only model the metabolic process and the in vivo scaling may therefore be affected if 
other processes e.g. transport play important roles in the clearance. Co-factor 
supplementation e.g. NADPH for P450s and UDPGA for UGTs must be provided since the 
cellular biosynthetic processes are no longer functional. In addition, their activity reduces 
during incubation limiting their use for slowly metabolised compounds. They are produced 
by differential centrifugation of the liver to produce either membranes or supernatant. The S9 
fraction is obtained following centrifugation at 9000g and contains most phase I and II 
enzymes. It is therefore the most complete subcellular fraction based on enzyme activity. 
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Further ultracentrifugation produces a pellet containing the membrane bound enzymes which 
is reconstituted to give microsomes, and a supernatant containing the soluble enzymes 
referred to as the cytosol. Microsomes are the most widely used fractions in early drug 
discovery due to the significance of P450 metabolism for most drugs.
106
 As alluded to earlier, 
the similar preparative processes can be used to obtain subcellular fractions of other organs 
for metabolism studies. Intestinal microsomes and S9 have for example been used to model 
first pass metabolism in the gut wall.
115
  
When the aim of the metabolism study is to investigate a particular enzymatic reaction, 
isolated enzymes offer the most direct strategy. These enzymes are most often used to study 
kinetic processes (e.g. determination of Km and Vmax) and in the identification of enzymes 
responsible for formation of specific metabolites. The enzymes are expressed recombinantly 











1.6 Analytical strategies in drug metabolism studies  
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Analytical methodologies for drug metabolism studies are needed for quantitative reasons for 
example when monitoring drug concentrations and for qualitative reasons for example when 
identifying metabolites formed. Both quantitative and qualitative methods must be specific 
enough because the drugs and metabolites are present in a complex biological matrix, and 
sensitive enough because drug and/or metabolite concentrations are typically low (pM - µM). 
The degree of specificity and sensitivity required may increase as a drug advances through 
the discovery and development chain.  
In early drug discovery, the most widely used techniques for drug metabolism studies are 
liquid-chromatography – mass spectrometry (LC-MS) methods.
119
 LC-MS provides high 
sensitivity and specificity while maintaining the capacity for high throughput required in 
early drug discovery. The chromatography part of the set-up separates the drug and/or 
metabolites from the biological matrices allowing for more sensitive detection of the 
analytes. The mass spectrometer will typically use atmospheric pressure ionisation methods – 
most commonly electrospray or atmospheric pressure chemical ionisation to ionise the 
analytes which are then directed further into the MS for sorting and detection based on mass-
charge (m/z) ratios.  
The first application of LC-MS techniques in drug metabolism studies is usually in the 
determination of metabolic stability of drug compounds to guide structural modification. 
Analytically, this involves comparison of the amount of drug remaining at a predetermined 
time point against the amount of drug at T0.
120–122
 Absolute quantification is therefore not 
required though a generic internal standard is included to minimise effects due to variations 
in MS sensitivity. This assay is most often performed using multiple reaction monitoring 
(MRM), an analysis mode present on triple quadrupole mass spectrometers, which allows for 
the selective monitoring of the parent precursor ion (M+H) and fragment ion. The results are 
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reported as percentage compound remaining, half-life or as scaled figures representing whole 
liver metabolism e.g clearance or hepatic extraction.
123,124
  
Metabolic stability assays give an indication of the stability of the compound in the presence 
of drug metabolising enzymes. The next logical step is the determination of the metabolites 
responsible for the observed reductions in parent concentrations. The metabolic profiling or 
metabolite identification studies vary in complexity as the drug development process 
continues. In early drug discovery, the main objective of these studies is often to identify the 
major metabolites formed so as to identify the metabolically labile positions in the molecule 
and guide strategies to block these positions. Broadly, this is accomplished by analysing 
incubations of the compound in the presence of drug metabolising enzymes and identifying 
the new peaks present. From an LC-MS perspective, two levels of data are required – first the 
precursor ions of the metabolites formed and secondly their fragmentation patterns.
125,126
 For 
metabolites forming by direct modification of the molecule by addition or unmasking of 
functional groups with no rearrangement, the mass shifts between the precursor ions of the 
parent and metabolite are usually diagnostic of the type of metabolite formed. By this 
principle a gain of 16 units most commonly indicates oxidation while a loss of 14 units may 
indicate demethylation.
127
 The strength of these assumptions has increased with the growth of 
high resolution MS (HRMS) where they can be more accurately measured and the molecular 
formula of the resulting metabolite confirmed from the accurate mass. The second level of 
data required for MS identification of metabolites is the fragment ion data most commonly 
obtained through collision-induced dissociation. Comparison of the fragments of the 
metabolite and parent should allow determination of the region of the molecule modified.
128
 
The acquisition of these two levels of metabolite data can be done through data dependent 
acquisition where a survey MS scan, usually the enhanced mass spectrum (EMS) scan is used 
to trigger the acquisition of product ion data for ions that meet a set of predefined criteria. 
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The entire approach is then referred to as MS/MS, MS
2
 or tandem mass spectrometry because 
ions identified through one mass scan are fragmented in another scan. Based on instrument 
capability these can be improved to MS
3
 usually in an attempt to understand the 
fragmentation pathway. These approaches of generating fragmentation data have been 
referred to as MS
n
 to account for all possible iterations of the process as defined by the 
instrument capability.
129
 On Quadrupole Time of flight (QTof) instruments, the approach 
often used to acquire the 2 levels of data is referred to as MS
E
. The instrument first operates 
at low collision energy (5-10V) so that the precursor ions are identified. The collision energy 
is then ramped up to give the collision induced fragments. A major advantage of this 
approach is that all ions are therefore fragmented with the resulting advantage that 
unexpected metabolites may be easier to find. The data set created is potentially quite big, 
though software approaches have been developed to help in the data mining. 
130,131
 Where the 
metabolites are known either from literature or predicted through in silico software, MRM 
can be used for analysis. While the sensitivity of the method is an advantage, the selectivity 




The comparison of collision induced dissociation (CID) spectra will often provide a tentative 
identification of the metabolite and this is often the limit of MS metabolite identification. 
Based on the fragmentation pattern of the compound, comparison of the CID spectra of the 
parent and metabolite will often lead to a tentative identification of the region of the molecule 
undergoing metabolic change. This is often the limit of MS techniques and it is usually more 
difficult to pinpoint the specific atom modified using MS data alone. This challenge is 
gradually being overcome with the development of in silico metabolite identification 
techniques.
39,134
 These techniques have evolved to consider MS fragmentation and therefore 
combine data of the most likely sites of metabolism and CID fragmentation to generate 
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proposed structures of metabolites.
135–137
 Early tests on some of the software show correct 
assignment in about 80% of the model set.
130
 Further advances in these approaches should 
allow automated data processing, greatly increasing the throughput of early metabolite 
identification studies and improving the detection of unexpected metabolites formed through 
rearrangement reactions.  
While the focus of the earliest studies is in identifying the pathways that contribute to the 
highest metabolic clearance, there is a gradual shift towards understanding all metabolites 
and metabolic pathways as the discovery and development process continues. This is 
essential first in understanding any toxicological consequences of the metabolic processes but 
also in allowing for a fair inter species extrapolation of data. More advanced studies may 
therefore require radiolabeling of the drug and mass balance studies to ensure that the entirety 
of the pathways is known and accounted for
138
. This also necessitates LC-NMR approaches 












1.7 Relevance of metabolism and metabolites in drug discovery and development 
1.7.1 Metabolism and pharmacological activity 
Drug metabolism is generally a clearance process contributing to the decrease in 
concentration of the parent drug with time. This generally results in reduction of the 
pharmacological activity exerted by the parent drug with time, preventing accumulation and 
toxicity.
2
 However, since metabolism results in formation of metabolites, the activity and 
toxicity of the metabolites is also relevant to the overall evaluation of the drug.
139
 Most 
regulatory authorities prescribe a limit for in vivo metabolites beyond which the metabolite 
must be characterised to the same degree as the parent.
140,141
  
Like for the parent drug, the pharmacological activity of the metabolite will depend on its 
ability to get to the site of action in sufficient concentrations and also on its ability to bind 
productively to the target.
142
 Because metabolism usually involves a slight modification of 
structure, most metabolites possess a degree of pharmacological activity similar to that of the 
parent.
142,143
 The degree to which this intrinsic activity translates to overall pharmacological 
activity depends on the extent to which the change in structure influences binding to the drug 
target and also on the degree to which the change in physicochemical properties influences 
the concentration at the drug target. Metabolites produced from lipophilic drugs therefore 
tend to retain some pharmacological activity since the structural changes introduced by 
metabolism are often minor and because like their respective parent drugs, they retain a good 
degree of their lipoidal permeability.
142,143
 This is, however, very dependent on the respective 
drug and target involved. An example of these factors is the glucuronidation of morphine to 




Figure 1.12: Morphine and its glucuronides 
 
While the metabolic change occurring is the same, morphine-6-glucuronide is effective for 
analgesia in man and shows a better side effect profile than morphine while morphine-3-
glucuronide is inactive.
144,145
 This implies that the 3 position is less able to tolerate this 
change than the 6 position, which is supported by intrinsic activity data. The reasons for the 
better profile of morphine-6-glucuronide compared to morphine are still unclear.
146
 However, 
it is known that the pharmacokinetic profile and brain accumulation of this compound is 
superior to morphine. It has been suggested that the increased hydrophilicity may reduce 
protein binding and the resulting increase in free plasma concentration may lead to higher 
levels of accumulation in the cerebrospinal fluid.
146
 This example also demonstrates the 
potential advantages of pharmacologically active metabolites. These advantages and further 
examples of pharmacologically active metabolites have been extensively reviewed.
143,147–149
  
In summary, metabolism can lead to either pharmacologically active or inactive metabolites 







1.7.3 Metabolism and toxicity 
Many exceptions exist to the role of metabolism as a detoxifying process. The toxicity may 
result from the interaction of the metabolite with a drug target, either relevant or not to its 
mechanism of action. This type of toxicity is dose dependent and is predictable based on the 
known pharmacological activities of the drug. A bigger problem is often the metabolism of 
drugs to chemically reactive electrophilic species, which may bind to cell macromolecules 
leading to toxicity either directly by impairing their function or through involvement of the 
immune system. The time course of such toxicity may vary from immediately the drug is 
taken to several years after the drug was administered, in the case of teratogenicity and 
carcinogenicity.
150,151
 A common example is acetaminophen. At its usual doses, the 
compound is metabolised by sulfation and glucuronidation. These pathways become 
saturated in an overdose increasing the significance of a CYP450-mediated process which 





Figure 1.13: Metabolism and bioactivation of acetaminophen
152
 
NAPQI is conjugated to glutathione to minimise its toxicity but if the dose is high enough, 
the glutathione is gradually depleted and at levels above 70% depletion, NAPQI reacts with 
cellular nucleophiles leading to hepatocyte damage. 
153–156
 
The toxicity and pharmacological activity of metabolites is therefore a key concern that 











From the foregoing discussions, it is clear that the integration of metabolism studies in early 
drug discovery and development is an important strategy in minimising the probability of 
failure in later stages. Further, the proper application of metabolism studies can help guide 
structural modifications of compounds and explain or predict their activity in the presence of 
drug metabolising systems. Finally, both the intrinsic activity and physicochemical properties 
of the metabolites are important in understanding the contribution of metabolites to the 
overall pharmacological activity of a compound.  
This project explores the in vitro metabolism of tetrazole aminoquinolines and derivatives of 
metergoline and fusidic acid. In each chapter, the metabolic stability is considered and 
metabolite identification studies are used to understand the contribution of various metabolic 
pathways to the metabolic stability of the compounds. The experimentally observed 
metabolites are then compared to predicitions from StarDrop to understand whether the sites 
of metabolism could have been accurately predicted a priori. Finally, the predicted 
physicochemical properties of selected metabolites are compared to those of the parent 









1.9 Objective and specific aims 
1.9.1 Objective 
To investigate the in vitro metabolism of tetrazole deoxyamodiaquines, tetrazole 
chloroquines, metergoline derivatives and fusidic acid derivatives. 
1.9.2 Specific aims 
i) To select compounds for drug metabolism studies based on biological activity. 
ii) To evaluate the metabolic stability of the selected compounds in vitro  
















(1)  Conti, A.; Bickel, M. H. History of Drug Metabolism : Discoveries of the Major 
Pathways in the 19th Century. Drug Metab. Rev. 1977, 6, 1–50. 
(2)  Caldwell, J.; Gardner, I.; Swales, N. An Introduction to Drug Disposition: The Basic 
Principles of Absorption, Distribution, Metabolism, and Excretion. Toxicol. Pathol. 
1995, 23, 102–114. 
(3)  Mehrotra, N.; Gupta, M.; Kovar, A.; Meibohm, B. The Role of Pharmacokinetics and 
Pharmacodynamics in Phosphodiesterase-5 Inhibitor Therapy. Int. J. Impot. Res. 2006, 
19, 253–264. 
(4)  Kola, I.; Landis, J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nat. Rev. 
Drug Discov. 2004, 3, 711–715. 
(5)  Smith, D. A.; Schmid, E.; Jones, B. Do Drug Metabolism and Pharmacokinetic 
Departments Make Any Contribution to Drug Discovery? Clin. Pharmacokinet. 2002, 
41, 1005–1019. 
(6)  Jakoby, W. B.; Ziegler, D. M. The Enzymes of Detoxication. J. Biol. Chem. 1990, 265, 
20715–20718. 
(7)  Meyer, U. A. Endo-Xenobiotic Crosstalk and the Regulation of Cytochromes P450. 
Drug Metab. Rev. 2007, 39, 639–646. 
(8)  Wu, C.-Y.; Benet, L. Z. Predicting Drug Disposition via Application of BCS: 
Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics 
Drug Disposition Classification System. Pharm. Res. 2005, 22, 11–23. 
(9)  Williams, R. . Detoxification Mechanisms; 2nd ed.; Chapman & Hall: London, 1959. 
(10)  Caldwell, J. Drug Metabolism and Pharmacogenetics: The British Contribution to 
Fields of International Significance. Br. J. Pharmacol. 2006, 147 Suppl , S89–99. 
(11)  Testa, B.; Pedretti, A.; Vistoli, G. Reactions and Enzymes in the Metabolism of Drugs 
and Other Xenobiotics. Drug Discov. Today 2012, 17, 549–560. 
(12)  Cytochrome P450 Homepage http://drnelson.uthsc.edu/CytochromeP450.html 
(accessed Mar 25, 2014). 
(13)  Nelson, D. R. The Cytochrome p450 Homepage. Hum. Genomics 2009, 4, 59–65. 
(14)  Omura, T.; Sato, R. A New Cytochrome in Liver Microsomes. J. Biol. Chem. 1962, 
237, 1375–1376. 




(16)  Guengerich, F. P.; Wu, Z.-L.; Bartleson, C. J. Function of Human Cytochrome P450s: 
Characterization of the Orphans. Biochem. Biophys. Res. Commun. 2005, 338, 465–
469. 
(17)  Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; 
Peterkin, V.; Koup, J. R.; Ball, S. E. Drug-Drug Interactions for UDP-
Glucuronosyltransferase Substrates: A Pharmacokinetic Explanation for Typically 
Observed Low Exposure (AUCi/AUC) Ratios. Drug Metab. Dispos. 2004, 32, 1201–
1208. 
(18)  Danielson, P. B. The Cytochrome P450 Superfamily: Biochemistry, Evolution and 
Drug Metabolism in Humans. Curr. Drug Metab. 2002, 3, 561–597. 
(19)  Guengerich, F. P. Common and Uncommon Cytochrome P450 Reactions Related to 
Metabolism and Chemical Toxicity. Chem. Res. Toxicol. 2001, 14, 611–650. 
(20)  Guengerich, F. P.; Johnson, W. W. Kinetics of Ferric Cytochrome P450 Reduction by 
NADPH-Cytochrome P450 Reductase: Rapid Reduction in the Absence of Substrate 
and Variations among Cytochrome P450 Systems. Biochemistry 1997, 36, 14741–
14750. 
(21)  Hamdane, D.; Zhang, H.; Hollenberg, P. Oxygen Activation by Cytochrome P450 
Monooxygenase. Photosynth. Res. 2008, 98, 657–666. 
(22)  Guengerich, F. P.; Isin, E. M. Mechanisms of Cytochrome P450 Reactions. Acta Chim. 
Slov. 2008, 55, 7–19. 
(23)  Guengerich, F. P.; Macdonald, T. L. Chemical Mechanisms of Catalysis by 
Cytochromes P-450: A Unified View. Acc. Chem. Res. 1984, 17, 9–16. 
(24)  Smith, D. A.; van de Waterbeemd, H.; Walker, D. K. Pharmacokinetics and 
Metabolism in Drug Design; Smith, D. A.; van de Waterbeemd, H.; Mannhold, R.; 
Kubinyi, H.; Timmerman, H., Eds.; 1st ed.; Wiley-VCH Verlag GmbH & Co. KGaA: 
Weinheim, 2001. 
(25)  Uetrecht, J.; Trager, W. Drug Metabolism: Chemical and Enzymatic Aspects; Informa 
Healthcare USA, Inc.: New York, 2007. 
(26)  Drug Metabolism Handbook: Concepts and Applications; Nassar, A. F.; Hollenberg, 
P. F.; Scatina, J., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009. 
(27)  Bell-Parikh, L. C.; Guengerich, F. P. Kinetics of Cytochrome P450 2E1-Catalyzed 
Oxidation of Ethanol to Acetic Acid via Acetaldehyde. J. Biol. Chem. 1999, 274, 
23833–23840. 
(28)  Dowers, T. S.; Rock, D. A.; Rock, D. A.; Perkins, B. N. S.; Jones, J. P. An Analysis of 
the Regioselectivity of Aromatic Hydroxylation and N-Oxygenation by Cytochrome 
P450 Enzymes. Drug Metab. Dispos. 2004, 32, 328–332. 
43 
 
(29)  Rydberg, P.; Ryde, U.; Olsen, L. Prediction of Activation Energies for Aromatic 
Oxidation by Cytochrome P450. J. Phys. Chem. A 2008, 112, 13058–13065. 
(30)  Hamman, M. A.; Thompson, G. A.; Hall, S. D. Regioselective and Stereoselective 
Metabolism of Ibuprofen by Human Cytochrome P450 2C. Biochem. Pharmacol. 
1997, 54, 33–41. 
(31)  Miners, J. O.; Smith, K. J.; Robson, R. A.; McManus, M. E.; Veronese, M. E.; Birkett, 
D. J. Tolbutamide Hydroxylation by Human Liver Microsomes. Biochem. Pharmacol. 
1988, 37, 1137–1144. 
(32)  Hyland, R. Identification of the Cytochrome P450 Enzymes Involved in the N-
Oxidation of Voriconazole. Drug Metab. Dispos. 2003, 31, 540–547. 
(33)  Wójcikowski, J.; Boksa, J.; Daniel, W. A. Main Contribution of the Cytochrome P450 
Isoenzyme 1A2 (CYP1A2) to N-Demethylation and 5-Sulfoxidation of the 
Phenothiazine Neuroleptic Chlorpromazine in Human Liver--A Comparison with 
Other Phenothiazines. Biochem. Pharmacol. 2010, 80, 1252–1259. 
(34)  Blake, M. J.; Gaedigk, A.; Pearce, R. E.; Bomgaars, L. R.; Christensen, M. L.; Stowe, 
C.; James, L. P.; Wilson, J. T.; Kearns, G. L.; Leeder, J. S. Ontogeny of 
Dextromethorphan O- and N-Demethylation in the First Year of Life. Clin. 
Pharmacol. Ther. 2007, 81, 510–516. 
(35)  Funaki, T.; Soons, P. A.; Guenoerich, F. P.; Breimer, D. D. In Vivo Oxidative 
Cleavage of a Pyridinecarboxylic Acid Ester Metabolite of Nifedipine. Biochem. 
Pharmacol. 1989, 38, 4213–4216. 
(36)  Masubuchi, Y.; Hosokawa, S.; Horie, T.; Suzuki, T.; Ohmori, S.; Kitada, M.; 
Narimatsu, S. Cytochrome P450 Isozymes Involved in Propranolol Metabolism in 
Human Liver Microsomes. The Role of CYP2D6 as Ring-Hydroxylase and CYP1A2 
as N-Desisopropylase. Drug Metab. Dispos. Biol. fate Chem. 1994, 22, 909–915. 
(37)  Kerr, B. M.; Thummel, K. E.; Wurden, C. J.; Klein, S. M.; Kroetz, D. L.; Gonzalez, F. 
J.; Levy, R. Human Liver Carbamazepine Metabolism. Biochem. Pharmacol. 1994, 47, 
1969–1979. 
(38)  Li, H.; Sun, Æ. J.; Fan, Æ. X.; Sui, Æ. X.; Zhang, Æ. L.; Wang, Y.; He, Æ. Z. 
Considerations and Recent Advances in QSAR Models for Cytochrome P450-
Mediated Drug Metabolism Prediction. 2008, 843–855. 
(39)  T’jollyn, H.; Boussery, K.; Mortishire-Smith, R. J.; Coe, K.; De Boeck, B.; Van 
Bocxlaer, J. F.; Mannens, G. Evaluation of Three State-of-the-Art Metabolite 
Prediction Software Packages (Meteor, MetaSite, and StarDrop) through Independent 
and Synergistic Use. Drug Metab. Dispos. 2011, 39, 2066–2075. 
(40)  StarDrop - Optibrium www.optibrium.com/StarDrop (accessed Jun 12, 2014). 
(41)  Segall, M. D. ISSX 2011: Predicting Regioselectivity and Lability of Cytochrome 
P450 Metabolism using Quantum Mechanical Simulations 
44 
 
http://www.optibrium.com/news/presentations/ISSX Poster 2011 - P450.pdf (accessed 
Nov 29, 2014). 
(42)  Dewar, M.; Zoebisch, E. Development and Use of Quantum Mechanical Molecular 
Models. 76. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. 
Am. Chem. Soc. 1985, 107, 3902–3909. 
(43)  Kisker, C.; Schindelin, H.; Rees, D. C. Molybdenum-Cofactor-Containing Enzymes: 
Structure and Mechanism. Annu. Rev. Biochem. 1997, 66, 233–267. 
(44)  Schwarz, G.; Mendel, R. R.; Ribbe, M. W. Molybdenum Cofactors, Enzymes and 
Pathways. Nature 2009, 460, 839–847. 
(45)  Garattini, E.; Fratelli, M.; Terao, M. Mammalian Aldehyde Oxidases: Genetics, 
Evolution and Biochemistry. Cell. Mol. Life Sci. 2008, 65, 1019–1048. 
(46)  Enzyme Systems That Metabolise Drugs and Other Xenobiotics; Ioannides, C., Ed.; 
John Wiley & Sons, Ltd: Chichester, UK, 2001. 
(47)  Pryde, D. C.; Dalvie, D.; Hu, Q.; Jones, P.; Obach, R. S.; Tran, T. Aldehyde Oxidase: 
An Enzyme of Emerging Importance in Drug Discovery. J. Med. Chem. 2010, 53, 
8441–8460. 
(48)  Alfaro, J. F.; Joswig-Jones, C. A.; Ouyang, W.; Nichols, J.; Crouch, G. J.; Jones, J. P. 
Purification and Mechanism of Human Aldehyde Oxidase Expressed in Escherichia 
Coli. Drug Metab. Dispos. 2009, 37, 2393–2398. 
(49)  Kitamura, S.; Sugihara, K.; Ohta, S. Drug-Metabolizing Ability of Molybdenum 
Hydroxylases. Drug Metab. Pharmacokinet. 2006, 21, 83–98. 
(50)  Torres, R. A.; Korzekwa, K. R.; McMasters, D. R.; Fandozzi, C. M.; Jones, J. P. Use 
of Density Functional Calculations to Predict the Regioselectivity of Drugs and 
Molecules Metabolized by Aldehyde Oxidase. J. Med. Chem. 2007, 50, 4642–4647. 
(51)  Pryde, D. C.; Tran, T.-D.; Jones, P.; Duckworth, J.; Howard, M.; Gardner, I.; Hyland, 
R.; Webster, R.; Wenham, T.; Bagal, S.; et al. Medicinal Chemistry Approaches to 
Avoid Aldehyde Oxidase Metabolism. Bioorg. Med. Chem. Lett. 2012, 22, 2856–2860. 
(52)  Dalvie, D.; Sun, H.; Xiang, C.; Hu, Q.; Jiang, Y.; Kang, P. Effect of Structural 
Variation on Aldehyde Oxidase-Catalyzed Oxidation of Zoniporide. Drug Metab. 
Dispos. 2012, 40, 1575–1587. 
(53)  McDaniel, H. G.; Podgainy, H.; Bressler, R. The Metabolism of Tolbutamide in Rat 
Liver. J. Pharmacol. Exp. Ther. 1969, 167, 91–97. 
(54)  Brandänge, S.; Lindblom, L. The Enzyme “Aldehyde Oxidase” Is an Iminium 
Oxidase. Reaction with Nicotine Delta 1’(5') Iminium Ion. Biochem. Biophys. Res. 
Commun. 1979, 91, 991–996. 
45 
 
(55)  Satoh, T.; Hosokawa, M. Structure, Function and Regulation of Carboxylesterases. 
Chem. Biol. Interact. 2006, 162, 195–211. 
(56)  Fukami, T.; Yokoi, T. The Emerging Role of Human Esterases. Drug Metab. 
Pharmacokinet. 2012, 27, 466–477. 
(57)  Li, B.; Sedlacek, M.; Manoharan, I.; Boopathy, R.; Duysen, E. G.; Masson, P.; 
Lockridge, O. Butyrylcholinesterase, Paraoxonase, and Albumin Esterase, but Not 
Carboxylesterase, Are Present in Human Plasma. Biochem. Pharmacol. 2005, 70, 
1673–1684. 
(58)  Cossum, P. A. Role of the Red Blood Cell in Drug Metabolism. Biopharm. Drug 
Dispos. 1988, 9, 321–336. 
(59)  Imai, T.; Taketani, M.; Shii, M.; Hosokawa, M.; Chiba, K. Substrate Specificity of 
Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human 
Liver and Small Intestine. Drug Metab. Dispos. 2006, 34, 1734–1741. 
(60)  Taketani, M.; Shii, M.; Ohura, K.; Ninomiya, S.; Imai, T. Carboxylesterase in the 
Liver and Small Intestine of Experimental Animals and Human. Life Sci. 2007, 81, 
924–932. 
(61)  Rudakova, E. V.; Boltneva, N. P.; Makhaeva, G. F. Comparative Analysis of Esterase 
Activities of Human, Mouse, and Rat Blood. Bull. Exp. Biol. Med. 2011, 152, 73–75. 
(62)  Satoh, T.; Taylor, P.; Bosron, W. F.; Sanghani, S. P.; Hosokawa, M.; La Du, B. N. 
Current Progress on Esterases: From Molecular Structure to Function. Drug Metab. 
Dispos. 2002, 30, 488–493. 
(63)  Bencharit, S.; Morton, C. L.; Hyatt, J. L.; Kuhn, P.; Danks, M. K.; Potter, P. M.; 
Redinbo, M. R. Crystal Structure of Human Carboxylesterase 1 Complexed with the 
Alzheimer’s Drug Tacrine: From Binding Promiscuity to Selective Inhibition. Chem. 
Biol. 2003, 10, 341–349. 
(64)  Imai, T. Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug 
Design. Drug Metab. Pharmacokinet. 2006, 21, 173–185. 
(65)  Bencharit, S.; Morton, C. L.; Xue, Y.; Potter, P. M.; Redinbo, M. R. Structural Basis 
of Heroin and Cocaine Metabolism by a Promiscuous Human Drug-Processing 
Enzyme. Nat. Struct. Biol. 2003, 10, 349–356. 
(66)  Bourland, J. A.; Martin, D. K.; Mayersohn, M. In Vitro Transesterification of 
Cocaethylene (Ethylcocaine) in the Presence of Ethanol. Esterase-Mediated Ethyl 
Ester Exchange. Drug Metab. Dispos. 1998, 26, 203–206. 
(67)  Pindel, E. V; Kedishvili, N. Y.; Abraham, T. L.; Brzezinski, M. R.; Zhang, J.; Dean, R. 
A.; Bosron, W. F. Purification and Cloning of a Broad Substrate Specificity Human 
Liver Carboxylesterase That Catalyzes the Hydrolysis of Cocaine and Heroin. J. Biol. 
Chem. 1997, 272, 14769–14775. 
46 
 
(68)  Brzezinski, M. R.; Abraham, T. L.; Stone, C. L.; Dean, R. A.; Bosron, W. F. 
Purification and Characterization of a Human Liver Cocaine Carboxylesterase That 
Catalyzes the Production of Benzoylecgonine and the Formation of Cocaethylene from 
Alcohol and Cocaine. Biochem. Pharmacol. 1994, 48, 1747–1755. 
(69)  Tukey, R. H.; Strassburg, C. P. Human UDP-Glucuronosyltransferases: Metabolism, 
Expression, and Disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581–616. 
(70)  Ouzzine, M.; Barré, L.; Netter, P.; Magdalou, J.; Fournel-Gigleux, S. The Human 
UDP-Glucuronosyltransferases: Structural Aspects and Drug Glucuronidation. Drug 
Metab. Rev. 2003, 35, 287–303. 
(71)  Fisher, M. B.; Paine, M. F.; Strelevitz, T. J.; Wrighton, S. A. The Role of Hepatic and 
Extrahepatic UDP-Glucuronosyltransferases in Human Drug Metabolism. Drug 
Metab. Rev. 2001, 33, 273–297. 
(72)  Mackenzie, P. I.; Bock, K. W.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; 
Miners, J. O.; Owens, I. S.; Nebert, D. W. Nomenclature Update for the Mammalian 
UDP Glycosyltransferase (UGT) Gene Superfamily. Pharmacogenet. Genomics 2005, 
15, 677–685. 
(73)  Radominska-Pandya, A.; Ouzzine, M.; Fournel-Gigleux, S.; Magdalou, J. Structure of 
UDP-Glucuronosyltransferases in Membranes. Methods Enzymol. 2005, 400, 116–147. 
(74)  Hänninen, O.; Alanen, K. The Competitive Inhibition of P-Nitrophenyl-Beta-D-
Glucopyranosiduronic Acid Synthesis by Aliphatic Alcohols in Vitro. Biochem. 
Pharmacol. 1966, 15, 1465–1467. 
(75)  Wells, P. G.; Mackenzie, P. I.; Chowdhury, J. R.; Guillemette, C.; Gregory, P. A.; 
Ishii, Y.; Hansen, A. J.; Kessler, F. K.; Kim, P. M.; Chowdhury, N. R.; et al. 
Glucuronidation and the UDP-Glucuronosyltransferases in Health and Disease. Drug 
Metab. Dispos. 2004, 32, 281–290. 
(76)  Morris, M. E.; Pang, K. S. Competition between Two Enzymes for Substrate Removal 
in Liver: Modulating Effects due to Substrate Recruitment of Hepatocyte Activity. J. 
Pharmacokinet. Biopharm. 1987, 15, 473–496. 
(77)  Locuson, C. W.; Tracy, T. S. Comparative Modelling of the Human UDP-
Glucuronosyltransferases: Insights into Structure and Mechanism. Xenobiotica. 2007, 
37, 155–168. 
(78)  Testa, B.; Krämer, S. D. The Biochemistry of Drug Metabolism--an Introduction: Part 
4. Reactions of Conjugation and Their Enzymes. Chem. Biodivers. 2008, 5, 2171–
2336. 
(79)  Grillo, M. P.; Knutson, C. G.; Sanders, P. E.; Waldon, D. J.; Hua, F.; Ware, J. A. 
Studies on the Chemical Reactivity of Diclofenac Acyl Glucuronide with Glutathione: 
Identification of Diclofenac-S-Acyl-Glutathione in Rat Bile. Drug Metab. Dispos. 
2003, 31, 1327–1336. 
47 
 
(80)  Obach, R. S. Glycerolysis of Acyl Glucuronides as an Artifact of in Vitro Drug 
Metabolism Incubations. Drug Metab. Dispos. 2009, 37, 1581–1586. 
(81)  Chiu, S. H.; Huskey, S. W. Species Differences in N-Glucuronidation. Drug Metab. 
Dispos. 1998, 26, 838–847. 
(82)  Argikar, U. A. Unusual Glucuronides. Drug Metab. Dispos. 2012, 40, 1239–1251. 
(83)  Nishiyama, T.; Kobori, T.; Arai, K.; Ogura, K.; Ohnuma, T.; Ishii, K.; Hayashi, K.; 
Hiratsuka, A. Identification of Human UDP-Glucuronosyltransferase Isoform(s) 
Responsible for the C-Glucuronidation of Phenylbutazone. Arch. Biochem. Biophys. 
2006, 454, 72–79. 
(84)  Müller, A.; Gabriel, H.; Sies, H.; Terlinden, R.; Fischer, H.; Römer, A. A Novel 
Biologically Active Selenooorganic Compound--VII. Biotransformation of Ebselen in 
Perfused Rat Liver. Biochem. Pharmacol. 1988, 37, 1103–1109. 
(85)  Ketterer, B.; Coles, B.; Meyer, D. J. The Role of Glutathione in Detoxication. Environ. 
Health Perspect. 1983, 49, 59–69. 
(86)  Armstrong, R. N. Glutathione S-Transferases: Reaction Mechanism, Structure, and 
Function. Chem. Res. Toxicol. 1991, 4, 131–140. 
(87)  Dirr, H.; Reinemer, P.; Huber, R. X-Ray Crystal Structures of Cytosolic Glutathione S-
Transferases. Implications for Protein Architecture, Substrate Recognition and 
Catalytic Function. Eur. J. Biochem. 1994, 220, 645–661. 
(88)  Párraga, A.; García-Sáez, I.; Walsh, S. B.; Mantle, T. J.; Coll, M. The Three-
Dimensional Structure of a Class-Pi Glutathione S-Transferase Complexed with 
Glutathione: The Active-Site Hydration Provides Insights into the Reaction 
Mechanism. Biochem. J. 1998, 333 ( Pt 3, 811–816. 
(89)  Ji, X.; Johnson, W. W.; Sesay, M. A.; Dickert, L.; Prasad, S. M.; Ammon, H. L.; 
Armstrong, R. N.; Gilliland, G. L. Structure and Function of the Xenobiotic Substrate 
Binding Site of a Glutathione S-Transferase as Revealed by X-Ray Crystallographic 
Analysis of Product Complexes with the Diastereomers of 9-(S-Glutathionyl)-10-
Hydroxy-9,10-Dihydrophenanthrene. Biochemistry 1994, 33, 1043–1052. 
(90)  Habig, W. H.; Pabst, M. J.; Fleischner, G.; Gatmaitan, Z.; Arias, I. M.; Jakoby, W. B. 
The Identity of Glutathione S-Transferase B with Ligandin, a Major Binding Protein of 
Liver. Proc. Natl. Acad. Sci. U. S. A. 1974, 71, 3879–3882. 
(91)  Meyer, D. J. Significance of an Unusually Low Km for Glutathione in Glutathione 
Transferases of the Alpha, Mu and Pi Classes. Xenobiotica. 1993, 23, 823–834. 
(92)  Townsend, D. M.; Tew, K. D. The Role of Glutathione-S-Transferase in Anti-Cancer 
Drug Resistance. Oncogene 2003, 22, 7369–7375. 
48 
 
(93)  Buhl, A. E.; Waldon, D. J.; Baker, C. A.; Johnson, G. A. Minoxidil Sulfate Is the 
Active Metabolite That Stimulates Hair Follicles. J. Invest. Dermatol. 1990, 95, 553–
557. 
(94)  Ellard, G. A. Variations between Individuals and Populations in the Acetylation of 
Isoniazid and Its Significance for the Treatment of Pulmonary Tuberculosis. Clin. 
Pharmacol. Ther. 1976, 19, 610–625. 
(95)  Dingemanse, J.; Jorga, K.; Zurcher, G.; Schmitt, M.; Sedek, G.; Prada, M.; 
Brummelen, P. Pharmacokinetic-Pharmacodynamic Interaction between the COMT 
Inhibitor Tolcapone and Single-Dose Levodopa. Br. J. Clin. Pharmacol. 1995, 40, 
253–262. 
(96)  Mercer, D. F.; Schiller, D. E.; Elliott, J. F.; Douglas, D. N.; Hao, C.; Rinfret, A.; 
Addison, W. R.; Fischer, K. P.; Churchill, T. A.; Lakey, J. R.; et al. Hepatitis C Virus 
Replication in Mice with Chimeric Human Livers. Nat. Med. 2001, 7, 927–933. 
(97)  Dandri, M.; Burda, M. R.; Török, E.; Pollok, J. M.; Iwanska, A.; Sommer, G.; Rogiers, 
X.; Rogler, C. E.; Gupta, S.; Will, H.; et al. Repopulation of Mouse Liver with Human 
Hepatocytes and in Vivo Infection with Hepatitis B Virus. Hepatology 2001, 33, 981–
988. 
(98)  Strom, S. C.; Davila, J.; Grompe, M. Chimeric Mice with Humanized Liver: Tools for 
the Study of Drug Metabolism, Excretion, and Toxicity. Methods Mol. Biol. 2010, 640, 
491–509. 
(99)  Tateno, C.; Yoshizane, Y.; Saito, N.; Kataoka, M.; Utoh, R.; Yamasaki, C.; Tachibana, 
A.; Soeno, Y.; Asahina, K.; Hino, H.; et al. Near Completely Humanized Liver in Mice 
Shows Human-Type Metabolic Responses to Drugs. Am. J. Pathol. 2004, 165, 901–
912. 
(100)  Foster, J. R.; Lund, G.; Sapelnikova, S.; Tyrrell, D. L.; Kneteman, N. M. Chimeric 
Rodents with Humanized Liver: Bridging the Preclinical/clinical Trial Gap in 
ADME/toxicity Studies. Xenobiotica. 2014, 44, 109–122. 
(101)  Ohtsuki, S.; Kawakami, H.; Inoue, T.; Nakamura, K.; Tateno, C.; Katsukura, Y.; 
Obuchi, W.; Uchida, Y.; Kamiie, J.; Horie, T.; et al. Validation of uPA/SCID Mouse 
with Humanized Liver as a Human Liver Model: Protein Quantification of 
Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases by LC-MS/MS. 
Drug Metab. Dispos. 2014, 42, 1039–1043. 
(102)  Bateman, T. J.; Reddy, V. G. B.; Kakuni, M.; Morikawa, Y.; Kumar, S. Application of 
Chimeric Mice with Humanized Liver for Study of Human-Specific Drug Metabolism. 
Drug Metab. Dispos. 2014, 42, 1055–1065. 
(103)  Scheer, N.; McLaughlin, L. A.; Rode, A.; MacLeod, A. K.; Henderson, C. J.; Wolf, C. 
R. Deletion of Thirty Murine Cytochrome P450 Genes Results in Viable Mice with 
Compromised Drug Metabolism. Drug Metab. Dispos. 2014, dmd.114.057885–. 
49 
 
(104)  Xiang, Z.; Snouwaert, J. N.; Kovarova, M.; Nguyen, M.; Repenning, P. W.; Latour, A. 
M.; Cyphert, J. M.; Koller, B. H. Mice Lacking Three Loci Encoding 14 Glutathione 
Transferase Genes: A Novel Tool for Assigning Function to the GSTP, GSTM, and 
GSTT Families. Drug Metab. Dispos. 2014, 42, 1074–1083. 
(105)  Cross, D. M.; Bayliss, M. K. A Commentary on the Use of Hepatocytes in Drug 
Metabolism Studies during Drug Discovery and Development. Drug Metab. Rev. 
2000, 32, 219–240. 
(106)  Brandon, E. F. .; Raap, C. D.; Meijerman, I.; Beijnen, J. H.; Schellens, J. H. . An 
Update on in Vitro Test Methods in Human Hepatic Drug Biotransformation Research: 
Pros and Cons. Toxicol. Appl. Pharmacol. 2003, 189, 233–246. 
(107)  Li, A. P.; Lu, C.; Brent, J. A.; Pham, C.; Fackett, A.; Ruegg, C. E.; Silber, P. M. 
Cryopreserved Human Hepatocytes: Characterization of Drug-Metabolizing Enzyme 
Activities and Applications in Higher Throughput Screening Assays for 
Hepatotoxicity, Metabolic Stability, and Drug-Drug Interaction Potential. Chem. Biol. 
Interact. 1999, 121, 17–35. 
(108)  Lloyd, T. D. R.; Orr, S.; Skett, P.; Berry, D. P.; Dennison, A. R. Cryopreservation of 
Hepatocytes: A Review of Current Methods for Banking. Cell Tissue Bank. 2003, 4, 
3–15. 
(109)  McGinnity, D. F.; Soars, M. G.; Urbanowicz, R. A.; Riley, R. J. Evaluation of Fresh 
and Cryopreserved Hepatocytes as in Vitro Drug Metabolism Tools for the Prediction 
of Metabolic Clearance. Drug Metab. Dispos. 2004, 32, 1247–1253. 
(110)  Skett, P. Problems in Using Isolated and Cultured Hepatocytes for Xenobiotic 
Metabolism/metabolism-Based Toxicity Testing-Solutions? Toxicol. In Vitro 1994, 8, 
491–504. 
(111)  Gebhardt, R.; Hengstler, J. G.; Müller, D.; Glöckner, R.; Buenning, P.; Laube, B.; 
Schmelzer, E.; Ullrich, M.; Utesch, D.; Hewitt, N.; et al. New Hepatocyte in Vitro 
Systems for Drug Metabolism: Metabolic Capacity and Recommendations for 
Application in Basic Research and Drug Development, Standard Operation 
Procedures. Drug Metab. Rev. 2003, 35, 145–213. 
(112)  Khetani, S. R.; Bhatia, S. N. Microscale Culture of Human Liver Cells for Drug 
Development. Nat. Biotechnol. 2008, 26, 120–126. 
(113)  Wang, W. W.; Khetani, S. R.; Krzyzewski, S.; Duignan, D. B.; Obach, R. S. 
Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major 
Human Excretory and Circulating Drug Metabolites. Drug Metab. Dispos. 2010, 38, 
1900–1905. 
(114)  Ramsden, D.; Tweedie, D. J.; St George, R.; Chen, L.-Z.; Li, Y. Generating an in 
Vitro-in Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus 
Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac). Drug Metab. Dispos. 
2014, 42, 407–414. 
50 
 
(115)  Dalvie, D.; Obach, R. S.; Kang, P.; Prakash, C.; Loi, C.-M.; Hurst, S.; Nedderman, A.; 
Goulet, L.; Smith, E.; Bu, H.-Z.; et al. Assessment of Three Human in Vitro Systems 
in the Generation of Major Human Excretory and Circulating Metabolites. Chem. Res. 
Toxicol. 2009, 22, 357–368. 
(116)  Friedberg, T. Recombinant in Vitro Tools to Predict Drug Metabolism and Safety. 
Pharm. Sci. Technolo. Today 2000, 3, 99–105. 
(117)  Schroer, K.; Kittelmann, M.; Lütz, S. Recombinant Human Cytochrome P450 
Monooxygenases for Drug Metabolite Synthesis. Biotechnol. Bioeng. 2010, 106, 699–
706. 
(118)  Tang, W.; Wang, R. W.; Lu, A. Y. H. Utility of Recombinant Cytochrome P450 
Enzymes : A Drug Metabolism Perspective. 2005, 503–517. 
(119)  Prakash, C.; Shaffer, C. L.; Nedderman, A.; Editor, G.; Baker, T. R. Analytical 
Strategies for Identifying Drug Metabolites. Mass Spectrom. Rev. 2007, 26, 340–369. 
(120)  Korfmacher, W. A. Principles and Applications of LC-MS in New Drug Discovery. 
Drug Discov. Today 2005, 10, 1357–1367. 
(121)  Korfmacher, W. A.; Palmer, C. A.; Nardo, C.; Dunn-Meynell, K.; Grotz, D.; Cox, K.; 
Lin, C. C.; Elicone, C.; Liu, C.; Duchoslav, E. Development of an Automated Mass 
Spectrometry System for the Quantitative Analysis of Liver Microsomal Incubation 
Samples: A Tool for Rapid Screening of New Compounds for Metabolic Stability. 
Rapid Commun. Mass Spectrom. 1999, 13, 901–907. 
(122)  Li, A. P. Screening for Human ADME/Tox Drug Properties in Drug Discovery. Drug 
Discov. Today 2001, 6, 357–366. 
(123)  Di, L.; Kerns, E. H.; Gao, N.; Li, S. Q.; Huang, Y.; Bourassa, J. L.; Huryn, D. M. 
Experimental Design on Single-Time-Point High-Throughput Microsomal Stability 
Assay. J. Pharm. Sci. 2004, 93, 1537–1544. 
(124)  Obach, R. S. Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic 
Microsomal Intrinsic Clearance Data: An Examination of in Vitro Half-Life Approach 
and Nonspecific Binding to Microsomes. Drug Metab. Dispos. 1999, 27, 1350–1359. 
(125)  Clarke, N. J.; Rindgen, D.; Korfmacher, W. A.; Cox, K. A. Peer Reviewed: Systematic 
LC/MS Metabolite Identification in Drug Discovery. Anal. Chem. 2001, 73, 430 A–
439 A. 
(126)  Kostiainen, R.; Kotiaho, T.; Kuuranne, T.; Auriola, S. Liquid 
Chromatography/atmospheric Pressure Ionization-Mass Spectrometry in Drug 
Metabolism Studies. J. Mass Spectrom. 2003, 38, 357–372. 
(127)  Baranczewski, P.; Stańczak, A.; Kautiainen, A.; Sandin, P.; Edlund, P.-O. Introduction 
to Early in Vitro Identification of Metabolites of New Chemical Entities in Drug 
Discovery and Development. Pharmacol. Rep. 2006, 58, 341–352. 
51 
 
(128)  Prasad, B.; Garg, A.; Takwani, H.; Singh, S. Metabolite Identification by Liquid 
Chromatography-Mass Spectrometry. TrAC Trends Anal. Chem. 2011, 30, 360–387. 
(129)  Tozuka, Z.; Kaneko, H.; Shiraga, T.; Mitani, Y.; Beppu, M.; Terashita, S.; Kawamura, 
A.; Kagayama, A. Strategy for Structural Elucidation of Drugs and Drug Metabolites 
Using (MS)n Fragmentation in an Electrospray Ion Trap. J. Mass Spectrom. 2003, 38, 
793–808. 
(130)  Bonn, B.; Leandersson, C.; Fontaine, F.; Zamora, I. Enhanced Metabolite 
Identification with MS(E) and a Semi-Automated Software for Structural Elucidation. 
Rapid Commun. Mass Spectrom. 2010, 24, 3127–3138. 
(131)  Bateman, K. P.; Castro-Perez, J.; Wrona, M.; Shockcor, J. P.; Yu, K.; Oballa, R.; 
Nicoll-Griffith, D. A. MSE with Mass Defect Filtering for in Vitro and in Vivo 
Metabolite Identification. Rapid Commun. Mass Spectrom. 2007, 21, 1485–1496. 
(132)  Huang, J.; Bathena, S. P. R.; Alnouti, Y. Metabolite Profiling of Praziquantel and Its 
Analogs during the Analysis of in Vitro Metabolic Stability Using Information-
Dependent Acquisition on a Hybrid Triple Quadrupole Linear Ion Trap Mass 
Spectrometer. Drug Metab. Pharmacokinet. 2010, 25, 487–499. 
(133)  Gao, H.; Materne, O. L.; Howe, D. L.; Brummel, C. L. Method for Rapid Metabolite 
Profiling of Drug Candidates in Fresh Hepatocytes Using Liquid Chromatography 
Coupled with a Hybrid Quadrupole Linear Ion Trap. Rapid Commun. Mass Spectrom. 
2007, 21, 3683–3693. 
(134)  Pähler, A.; Brink, A. Software Aided Approaches to Structure-Based Metabolite 
Identification in Drug Discovery and Development. Drug Discov. Today. Technol. 
2013, 10, e207–17. 
(135)  Zimmerlin, A.; Kiffe, M. Fixing Clearance as Early as Lead Optimization Using High 
Throughput in Vitro Incubations in Combination with Exact Mass Detection and 
Automatic Structure Elucidation of Metabolites. Drug Discov. Today Technol. 2013, 
10, e191–e198. 
(136)  Zamora, I.; Fontaine, F.; Serra, B.; Plasencia, G. High-Throughput, Computer 
Assisted, Specific MetID. A Revolution for Drug Discovery. Drug Discov. Today. 
Technol. 2013, 10, e199–205. 
(137)  Stranz, D. D.; Miao, S.; Campbell, S.; Maydwell, G.; Ekins, S. Combined 
Computational Metabolite Prediction and Automated Structure-Based Analysis of 
Mass Spectrometric Data. Toxicol. Mech. Methods 2008, 18, 243–250. 
(138)  Roffey, S. J.; Obach, R. S.; Gedge, J. I.; Smith, D. A. What Is the Objective of the 
Mass Balance Study? A Retrospective Analysis of Data in Animal and Human 
Excretion Studies Employing Radiolabeled Drugs. Drug Metab. Rev. 2007, 39, 17–43. 
(139)  Smith, D. A.; Obach, R. S. Metabolites and Safety: What Are the Concerns, and How 
Should We Address Them? Chem. Res. Toxicol. 2006, 19, 1570–1579. 
52 
 
(140)  EMA. ICH Guideline M3 ( R2 ) on Non-Clinical Safety Studies for the Conduct of 
Human Clinical Trials and Marketing Authorisation for Pharmaceuticals; 2009; Vol. 
3. 
(141)  FDA. Guidance for Industry Safety Testing of Drug Guidance for Industry Safety 
Testing of Drug Metabolites; 2008. 
(142)  Smith, D. A.; Dalvie, D. Why Do Metabolites Circulate? Xenobiotica. 2012, 42, 107–
126. 
(143)  Obach, R. S. Pharmacologically Active Drug Metabolites: Impact on Drug Discovery 
and Pharmacotherapy. Pharmacol. Rev. 2013, 65, 578–640. 
(144)  Janicki, P. K. Pharmacology of Morphine Metabolites. Curr. Pain Headache Rep. 
1997, 1, 264–270. 
(145)  Romberg, R.; Sarton, E.; Teppema, L.; Matthes, H. W. D.; Kieffer, B. L.; Dahan, A. 
Comparison of Morphine-6-Glucuronide and Morphine on Respiratory Depressant and 
Antinociceptive Responses in Wild Type and Mu-Opioid Receptor Deficient Mice. Br. 
J. Anaesth. 2003, 91, 862–870. 
(146)  Kilpatrick, G. J.; Smith, T. W. Morphine-6-Glucuronide: Actions and Mechanisms. 
Med. Res. Rev. 2005, 25, 521–544. 
(147)  Kang, M. J.; Song, W. H.; Shim, B. H.; Oh, S. Y.; Lee, H. Y.; Chung, E. Y.; Sohn, Y.; 
Lee, J. Pharmacologically Active Metabolites of Currently Marketed Drugs: Potential 
Resources for New Drug Discovery and Development. Yakugaku zasshi J. Pharm. Soc. 
Japan 2010, 130, 1325–1337. 
(148)  Fura, A. Role of Pharmacologically Active Metabolites in Drug Discovery and 
Development. Drug Discov. Today 2006, 11, 133–142. 
(149)  Fura, A.; Shu, Y.; Zhu, M.; Hanson, R. L.; Roongta, V.; Humphreys, W. G. 
Discovering Drugs through Biological Transformation: Role of Pharmacologically 
Active Metabolites in Drug Discovery. J. Med. Chem. 2004, 47, 4339–4351. 
(150)  Edwards, I. R.; Aronson, J. K. Adverse Drug Reactions: Definitions, Diagnosis, and 
Management. Lancet 2000, 356, 1255–1259. 
(151)  Smith, D. A.; Obach, R. S. Seeing through the Mist: Abundance versus Percentage. 
Commentary on Metabolites in Safety Testing. Drug Metab. Dispos. 2005, 33, 1409–
1417. 
(152)  Laine, J. E.; Auriola, S.; Pasanen, M.; Juvonen, R. O. Acetaminophen Bioactivation by 
Human Cytochrome P450 Enzymes and Animal Microsomes. Xenobiotica. 2009, 39, 
11–21. 
(153)  Bessems, J. G.; Vermeulen, N. P. Paracetamol (acetaminophen)-Induced Toxicity: 
Molecular and Biochemical Mechanisms, Analogues and Protective Approaches. Crit. 
Rev. Toxicol. 2001, 31, 55–138. 
53 
 
(154)  Davis, D. C.; Potter, W. Z.; Jollow, D. J.; Mitchell, J. R. Species Differences in 
Hepatic Glutathione Depletion, Covalent Binding and Hepatic Necrosis after 
Acetaminophen. Life Sci. 1974, 14, 2099–2109. 
(155)  Van de Straat, R.; de Vries, J.; Debets, A. J. J.; Vermeulen, N. P. E. The Mechanism of 
Prevention of Paracetamol-Induced Hepatotoxicity by 3,5-Dialkyl Substitution. 
Biochem. Pharmacol. 1987, 36, 2065–2070. 
(156)  Vermeulen, N. P.; Bessems, J. G.; Van de Straat, R. Molecular Aspects of 
Paracetamol-Induced Hepatotoxicity and Its Mechanism-Based Prevention. Drug 

















Chapter 2  
TETRAZOLE AMINOQUINOLINES  
2.1 Chapter overview 
In this chapter the in vitro metabolism of two compound series; tetrazole deoxyamodiaquines 
and tetrazole chloroquines, is investigated. The tentative structure of the metabolites formed 
is suggested based on the fragmentation and H/D exchange data. The CYP450 inhibition of 
selected compounds is evaluated and in silico modelling is used to suggest an explanation for 
the potent CYP450 inhibition. Finally, the StarDrop prediction of the sites of metabolism is 
compared to the experimentally observed metabolites.   
2.2 Tetrazole deoxyamodiaquines 
2.2.1  Background 
Amodiaquine is a 4-aminoquinoline-based antimalarial compound that was once widely used 
in prophylaxis and treatment of malaria.
1
 However, accumulating evidence on its links to 
incidents of hepato-toxicity and agranulocytosis led to its withdrawal as a prophylactic and it 
is now more commonly used in combination therapy in the treatment of acute malaria.
2–4
 The 
toxicity of amodiaquine has been suggested to arise from its metabolic activation to a reactive 
quinone-imine.
5–7
 This reactive metabolite is trapped by glutathione and N-acetylcysteine in 
the cell and the conjugates have been observed in polymorphonucleocytes and in vivo in 
rats.
6,8
 Once glutathione is depleted, the quinone-imine reacts with other soft nucleophiles in 
the cell leading to toxicity. Other metabolites of amodiaquine with the 4-aminophenol feature 






Figure 2.1: Metabolic bioactivation of amodiaquine
10
 
 Various chemical approaches have been explored to reduce the toxicity while retaining the 
good antimalarial activity associated with amodiaquine. The earliest modifications involved 
fluorine substitution at the 4’-position replacing the –OH group. The fluoroamodiaquine 
derivative thus derived does not form the quinoneimine metabolite and is metabolised 
primarily by N-dealkylation.
11
 The more metabolically stable tert-butyl derivative, in which 
the diethyl side chain is replaced with a tert-butyl group, has been suggested as a candidate 
for clinical evaluation.
12
 Another approach has involved the switching of the 3’ and 4’-groups 
to give isoquine. This compound retains the antiplasmodial activity of amodiaquine and does 
not form the quinone-imine but was shown to have low bioavailability, attributable to its 
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rapid first pass metabolism by dealkylation. The tert-butyl substituted derivative is more 
stable and was evaluated as a clinical candidate.
13
 Its development has been recently 
discontinued due to its inability to show superiority over chloroquine.
1
  
The approach presented in this work considers deoxyamodiaquine derivatives, where the 4’-
hydroxyl group is removed.
14
 The compounds are further fused to a tert-butyl substituted 
tetrazole ring, to improve their physicochemical characteristics. The metabolism of the most 
active compounds was evaluated and their corresponding derivatives without a tert-butyl 
group, was evaluated. The antiplasmodial activity of these derivatives against chloroquine 
susceptible and chloroquine resistant strains is shown in Table 2.1 below.
14
 





Code R R’ P. falciparum IC50 (µM) 
   3D7 K1 W2 
TK1 
 
t-Bu 0.052 ± 0.003 0.150 ± 0.030 0.227 ± 0.003 
TK2 
 
t-Bu 0.100 ± 0.014 0.006 ± 0.004 0.066 ± 0.003 
TK3 
 
t-Bu 0.010 ± 0.002 0.0096 ± 0.003 0.077  ± 0.0002 
TK4 
 
t-Bu 0.050 ± 0.004  0.170 ± 0.014 0.082 ± 0.006 
TK1B3 N
 
H 0.487 ± 0.066 2.979 ± 0.307 1.168 ± 0.105 
TK2B3 
 
H 0.164 ± 0.012 0.054 ± 0.009 0.475 ± 0.011 
TK3B3 
 
H 1.097 ± 0.058 0.049 ± 0.014 0.181 ± 0.036 
TK4B3 
 
H 0.286 ± 0.024 1.264 ± 0.088 0.487 ± 0.017 




2.2.2 Metabolism studies 
2.2.2.1 Microsomal Metabolic stability 
The microsomal metabolic stability of the eight derivatives was assessed in human and rat 
liver microsomes using a single point assay. TK1 –TK4 were rapidly metabolised with less 
than 5% of the parent remaining after a 30 minutemin incubation at 0.1mg/ml microsomal 
protein. This rate of metabolism was comparable to amodiaquine in human, but not in rat 
microsomes, where amodiaquine was more stable.  
Table 2.2: Metabolic stability of tetrazole deoxyamodiaquines 
Compound Microsomal stability  
(% remaining at 30 min) 
Log P* 
HLM RLM 
TK1 <5 <5 4.31 
TK2 <5 <5 4.96 
TK3 <5 <5 4.52 
TK4 <5 <5 5.02 
TK1B3 91 >99 2.89 
TK2B3 92 >99 3.57 
TK3B3 >99 >99 3.14 
TK4B3 83 >99 3.68 
Amodiaquine <5 55 4.24 
*Predicted using StarDrop v.5.5 
The removal of the tert-butyl group leads to about a 1 unit drop in predicted log P, and this 
reduction in lipophilicity may explain the better microsomal stability of these compounds. 
Another possible explanation is that the tert- butyl group is metabolically labile, but this was 
discounted, as discussed in the sections below.   
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2.2.2.2 Metabolite identification in microsomes 
To further understand the structural issues underlying the metabolism of these derivatives, 
two representative compounds, TK2 and TK3 and their respective B3 derivatives were 
selected for metabolite identification experiments.  
A typical extracted ion chromatogram of TK2 and its metabolites in HLMs is shown below.  
 
Figure 2.2: Extracted ion chromatogram of TK2 and its metabolites in HLMs 
Two metabolites were detected which were -28Da and -56Da respectively, compared to the 
precursor ion of the parent. No metabolism occurred in the absence of NADPH or 
microsomes. These losses suggest deethylation and di-deethylation and the product ion 
spectra are consistent with this.  
XIC of +EMS: Exp 1, 464 to 465 Da from Sample 10 (TK2 T60 EMS IDA ) of TK MetID.wiff (Turbo Spray) Max. 1.1e9 cps.


































Figure 2.3: Product ion spectra of TK2 and its metabolites 
 The metabolism of TK3 appears to be more complex and at least 8 phase I metabolites were 
detected in human and rat liver microsomal experiments. The fragmentation pathway of TK3 
was considered in more detail in order to better assign the tentative structures of the 
metabolites. 
 +EPI (464.30) Charge (+1) CE (50) CES (20) FT (44.4643): Exp 2, 5.808 min from Sample 12 (TK2 HLM 10µl x1conc 1:1 split) of TK ser... Max. 2.4e7 cps.









































 +EPI (436.22) Charge (+1) CE (50) CES (20) FT (250): Exp 2, 4.972 to 5.003 min from Sample 12 (TK2 HLM 10µl x1conc 1:1 split) of T... Max. 8.4e6 cps.



































 +EPI (408.20) Charge (+1) CE (50) CES (20) FT (197.454): Exp 2, 4.813 min from Sample 12 (TK2 HLM 10µl x1conc 1:1 split) of TK ser... Max. 5.0e6 cps.
















































Figure 2.4: Product ion spectrum of TK3 
The m/z 406 fragment is suggested to arise from a loss of the tert-butyl group followed by 
protonation of the tetrazole nitrogen. The proposed molecular formula for the m/z 336 
fragment suggests that it arises from heterolytic cleavage of the tetrazole ring. A different 
fragmentation pathway involving loss of the pyrrolidine ring and loss of the tetrazole 
nitrogens likely produces the m.z 279 fragment, as suggested by its molecular formula. The 
precursor ion and the fragments shown, display the typical chlorine isotope pattern, giving an 
extra criterion for assessing metabolites.  
Human Microsome 5uM 60 min -GSH TK3
m/z













Waters QTof Premier 
CE: 20V 
Mass Formula Δppm 
462.2164 C25H29N7Cl -1.9 
406.1550 C25H21N7Cl 0.7 
336.1227 C20H19N7Cl -12.2 





Figure 2.5: Key fragments of TK3 
This fragmentation pathway is common to all derivatives in the series and the analogous 
fragments (-56Da, -126Da, m/z 279) can be seen in TK2 and its metabolites in Figure 2.3 
above. Depending on the ease with which substitutions on the nitrogen can be cleaved, a 
fragment with m/z 282 (or 280 following loss of 2H through double bond formation) may 
also form by loss of the substituted tetrazole ring accompanied by heterolytic cleavage of the 
substitutions on the nitrogen.  
Based on this fragmentation pathway, a neutral loss (NL) scan of 126Da was performed, in 
addition to the other scan modes discussed in the methods, to detect the metabolites.  
C17H12N2Cl 






Figure 2.6: Neutral loss scan of 126Da showing HLM metabolites of TK3 
 
The rapid metabolism of TK3 is evident here since almost no parent remains after a 60 
minute incubation. A similar metabolite profile was observed in rat liver microsomes. The 
product ion spectra of all the metabolites contain the same neutral losses as the parent (-56Da, 
-126Da) suggesting that metabolism does not occur on substituted tetrazole. In addition, the 
metabolites have the m/z 279 fragment (or m/z 280/282) implying that the N-phenyl-7-
chloroaminoquinoline core remains unchanged. A summary of the MS/MS data of TK3 and 
the metabolites is presented below.  
TIC of +NL (126.11): Exp 1, from Sample 8 (TK3 T60 NL 126 IDA) of TK metabolism.wiff (Turbo Spray) Max. 3.1e6 cps.






































Table 2.3: Summary of HLM metabolites of TK3 
 
Code Rt m/z Fragments 






M1 7.23 408 352 282 279 
M2 7.60 478 422 352 279 
M3 7.96 494 438 368 279 
M4 8.13 480 424 354 279 
M5 9.17 492 436 366 279 
M6 9.37 492 436 366 279 
M7 9.90 476 420 350 279 
M8 11.28 458 402 332 279 
TK3 7.66 462 406 336 279 
 
The data therefore strongly suggest that metabolism occurs on the pyrrolidine ring. Further 
experimental work was therefore carried out to verify this hypothesis. 
2.2.2.2.1 Further investigations into pyrrolidine ring metabolism  
The analysis of the incubations was conducted using a NL scan of 27Da to detect the cyanide 
adducts and, as in the other metabolite identification experiments, using an enhanced mass 
spectrum scan coupled to enhanced product ion scans using information dependent 
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acquisition (EMS-IDA-EPI). When TK3 was incubated with cyanide in HLMs, three adducts 
with m/z 503 (A1) and 487 (A2 and A3) were detected in the NL scan. No adducts were 
detected in the absence of NADPH or microsomes. A2 and A3 were, however, formed even 
in the absence of cyanide. 
  
Figure 2.7: Total ion chromatogram of NL 27 in the +KCN and -KCN incubations 
The fragmentation spectra of these adducts confirmed that they were parent related. The 
formation of cyanide adducts A2 and A3 even in the absence of the trapping agent could be 
due to reactions with cyanide produced from acetonitrile. Acetonitrile was used to stop the 
reactions and has been previously reported as the source of cyanide adducts formed in 
cycloalkylamine metabolism.
15
 To confirm this hypothesis, the incubations were repeated 
with methanol in place of acetonitrile as the quenching reagent. 
 
TIC of +NL (27.11): from Sample 3 (TK3 T60 + KCN) of TK MetID.wiff (Turbo Spray) Max. 3.5e6 cps.

























TIC of +NL (27.11): from Sample 4 (TK3 T60) of TK MetID.wiff (Turbo Spray) Max. 1.7e6 cps.
































Figure 2.8: Total ion chromatogram of NL 27 in the presence and absence of cyanide, using 
different quenching reagents 
 
A2 and A3 were absent in the incubation with no trapping agent, when methanol was used to 
stop the reaction. Even when acetonitrile is used, the intensity of A2 and A3 is slightly 
increased in the presence of potassium cyanide. These observations suggest that the same 
adducts are formed by potassium cyanide and acetonitrile and that the adducts are only 
formed when cyanide is present, whether from potassium cyanide, the trapping agent, or from 
acetonitrile, when it is used to quench the reaction. 
 
 
TIC of +NL (27.11): from Sample 1 (TK3 T60 MeOH) of HLM.wiff (Turbo Spray) Max. 8.9e4 cps.
























4.963.57 4.163.813.282.70 3.102.95 4.713.43 4.622.602.431.571.04 1.81 5.111.961.36 2.290.910.750.14
TIC of +NL (27.11): from Sample 2 (TK3 T60 ACN) of HLM.wiff (Turbo Spray) Max. 6.4e5 cps.




























TIC of +NL (27.11): from Sample 3 (TK3 T60 KCN MeOH) of HLM.wiff (Turbo Spray) Max. 7.4e5 cps.



























TIC of +NL (27.11): from Sample 4 (TK3 T60 KCN ACN) of HLM.wiff (Turbo Spray) Max. 1.1e6 cps.





































 Stop reagent: Methanol 
 –KCN 
 Stop reagent: Acetonitrile 
 +KCN 
 Stop reagent: Acetonitrile 
 +KCN 
 Stop reagent: Methanol 
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2.2.2.3 Metabolite identification in hepatocytes 
To further explore the metabolism of TK3, metabolite identification experiments were 
conducted in human and rat hepatocytes. In addition to the metabolites reported in Table 2.4, 
a number of glucuronides were also detected. However, unlike amodiaquine, no glutathione 
adducts were present.  










Difference of mea- 









   (ppm) (Da)
 
M1 408 C21H23N7Cl -0.7 4 
M2 478 C25H29N7OCl -2.7 3 
M3 494 C25H29N7O2Cl -4.2 4 
M5 492 C25H27N7O2Cl -3.7 3 
M6 492 C25H27N7O2Cl -1.0 3 
M7 476 C25H27N7OCl -2.7 2 
M8 458 C25H25N7Cl 2.2 2 
M9 584 C27H31N7O6Cl -0.7 7 
M10 510       C25H29N7O3Cl 3.3 5 
M11 650 C31H25N7O7Cl 0.8 6 
M12 654 C31H37N7O7Cl -3.2 6 
M13 670 C31H37N7O8Cl -1.9 7 
M14 670 C31H37N7O8Cl 1.2 7 
M15 670 C31H37N7O8Cl -2.8 7 
M16 668 C31H35N7O8Cl -2.8 6 
M17 496 C25H31N7O2Cl -3.2 5 
M18 494 C25H29N7O2Cl 6.5 4 
M19 494 C25H29N7O2Cl 5.9 4 
M20 474 C25H25N7OCl -2.5 2 
TK3 462 C25H29N7Cl -5.8 2 
a
For consistency, the same codes as in Table 2.3 were used and all newly detected 

















The two data sets can be interpreted together to elucidate the structures of the metabolites. As 
alluded to earlier, all the metabolites appear to form on the pyrrolidine ring. The involvement 
of an iminium ion intermediate suggests that M2, is the α-hydroxylated metabolite, most 
likely formed from the endocyclic iminium ion. The molecular formula of M12 and the 4 
additional exchangeable protons relative to the parent, and a loss of 176Da on fragmentation 
imply that this metabolite is a glucuronide, most likely the O-glucuronide of M2.  
 
. 
HepInc Rat 5uM 6 hrs TK3 
Time 
































Figure 2.10: In vitro metabolism of TK3
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While the fragmentation pattern of M17 is inconclusive, the additional 34Da and three 
exchangeable protons compared to the parent strongly imply that M17 is a hydroxylated 
aminoalcohol. M4, which is 16Da lower than M17, and 18Da higher than the parent could 
therefore be the aminoalcohol, produced through reduction of the aminoaldehyde.  
M3, M18 and M19 are isobaric and their molecular formula suggests they are the 
dihydroxylation metabolites of TK3. The fragmentation is ambiguous but one of them should 
be the amino acid produced from M16, while the other two would be hydroxylations on the 
pyrrolidine ring. All three metabolites undergo glucuronidation to form M13-15.  
The α-hydroxy group of M2 can be further oxidised to form the lactam M7, which can be 
further hydroxylated to give M5 and M6. This is suggested by the loss of 28Da from the 
MS/MS spectra of these metabolites, which probably results from the loss of CO following 
opening up of the lactam ring. M6/M7 finally undergo glucuronidation to form M11.  
As proposed for other carbinolamines in Figure 2.7, M2 probably exists in equilibrium with 
the respective enamine. This equilibrium and further metabolism are proposed to result in M8 
and M20. 
Finally, any of the open chain metabolites can be dealkylated or undergo amide hydrolysis to 






2.2.3 P450 inhibition 
Current guidelines recommend the administration of antimalarials in combination, to forestall 
resistance selection. It is therefore important to consider the inhibition of metabolic enzymes, 
particularly P450s, by antimalarial agents in development. Such inhibition would interfere 
with plasma levels of any co-administered compounds metabolised by the inhibited enzyme. 
TK2 and TK3 were selected for P450 inhibition experiments with CYP450s and the results 
were as shown in table 4 below. 
Table 2.5: CYP450 inhibition by TK2 and TK3 
 IC50 value (µM) 
CYP 
enzyme 
Probe reaction TK2 TK3 
CYP1A2 phenacetin O-deethylation 4.33 ± 0.6 2.54 ± 0.2 




CYP2B6 bupropion hydroxylation 16.89 ± 5.9 ≈ 35.7 ± 6.2
a 
CYP2C8 paclitaxel 6 -hydroxylation 0.22 ± 0.0 0.12 ± 0.0 
CYP2C9 diclofenac 4’-hydroxylation 2.43 ± 0.4 3.14 ± 0.4 
CYP2C19 S-mephenytoin 4’-hydroxylation 12.20 ± 2.4 13.8 ± 1.8 
CYP2D6 bufuralol 1’-hydroxylation 2.31 ± 0.1 3.46 ± 0.3 
CYP2E1 chlorzoxazone 6-hydroxylation 24.94 ± 6.6
a 
≈ 32.9 ± 7.7
a 
CYP3A4 midazolam 1’-hydroxylation 0.006 ± 0.0 1.45 ± 0.1 
CYP3A4 testosterone 6β-hydroxylation 0.01 ± 0.0 4.24 ± 0.6 
a
estimated by extrapolation of experimental data. 
b
No inhibition seen in concetration range used 
The experiments were carried out between 0-20µM because 20µM was the solubility limit of 
the compounds in the experimental conditions, as assessed by visual inspection of turbidity. 
For 2B6 and 2E1, the results were extrapolated from the available data because the IC50 was 
71 
 
above the concentration range used (See Figure 2.11C). These values are, however, above the 
solubility limit of the compounds and may therefore not be a true reflection of the IC50. No 
curve inflection was seen in the concentration range used for CYP2A6 (See Figure 2.11D). 
Representative examples of the inhibition curves are shown below.  
 
 
Figure 2.11: Selected inhibition curves 
The results show that both compounds strongly inhibited CYP2C8 and CYP3A4 and were 
moderate to weak inhibitors of almost all other P450s tested. In most cases, inhibition by 
TK2 was slightly stronger which may reflect its higher lipophilicity (4.96 vs 4.52). 
Time dependent inhibition was investigated for CYP450s 1A2, 2C9, 2D6 and 3A4. TK3 
showed time dependent inhibition of CYP3A4 (Figure 2.12), with KI (concentration of 







Figure 2.12: Time dependent inhibition of CYP3A4 by TK3 
 Further experimental work was conducted to investigate 3A4 inhibition in the entire 
compound set, in order to elucidate general trends in this property. Fluorescence inhibition 
with recombinant CYP3A4 was used because of its more rapid turnover. The results are 
presented in figure 2.15 below. 
 
Figure 2.13: Fluorescence inhibition of recombinant CYP3A4 by the selected derivatives 
2.2.3.1 In silico rationalisation of P450 inhibition 
To understand the basis of the CYP3A4 inhibition by these compounds, the lowest energy 
conformations of TK2, TK3 and amodiaquine were docked onto CYP3A4 (PDB ID: 2V0M) 
using Glide and Autodock 4.2.
16,17
  The most favoured poses were similar for TK2 and TK3 





























      
      
Figure 2.14: Lowest energy conformations of TK3 (A, B) and Amodiaquine (C,D) in the active site of CYP3A4 (PDB ID: 2V0M). (A and C were 






The docked conformations are different in the two programs which may be expected because 
the large volume of the CYP3A4 active site allows molecules to rotate and may lead to 
multiple favoured conformations. However, a similarity in both cases for TK3 (and for TK2, 
data not shown) is that the lowest energy conformation is docked such that the 7-chloro-
aminoquinoline nucleus lies parallel to the heme. This would maximise π-π and π-cation 
interactions between this ring and heme. The rest of the molecule orients close to a number of 
hydrophobic residues and increased lipohilicity in this portion of the molecule could also 
contribute to hydrophobic interactions with these residues. In addition, Amodiaquine is 
smaller and less lipophilic and would therefore be expected to have less interaction with the 














The most active compounds TK1 – TK4 were rapidly metabolised in both HLM and RLM. 
The site of metabolism for all compounds evaluated was the attachment on the tertiary 
nitrogen. TK1 and TK2 which have alkyl substituents on the tertiary nitrogen were 
metabolised by dealkylation and then didealkylation to the primary amine. The metabolism of 
TK3 and TK4, which have cycloalkyl substituents (pyrrolidine and piperidine respectively), 
was mainly by hydroxylations on this ring.  
Cycloalkylamine containing compounds are widely reported to undergo hydroxylation on the 
carbon adjacent to the nitrogen.
18
 This hydroxylation is reported to proceed through a reactive 
iminium ion intermediate, which exists in equilibrium with the respective carbinolamine, 
enamine and aminoaldehyde.  
 
Figure 2.15: Iminium ion equilibrium for pyrrolidine and other cycloalkylamines
18
 
The involvement of this pathway in the metabolism of TK3 was confirmed by trapping the 
iminium ion using cyanide. Three cyanide adducts were identified for this compound. TK3 
contains two non-equivalent carbons α to the nitrogen, one endocyclic and one exocyclic. 
These are probably responsible for the formation of these adducts. The endocyclic iminium 
ion is more stable because it is stabilised by the equilibrium forms as shown in Figure 2.16 
76 
 
and is therefore the one that is further converted to the hydroxylated products. This 
preference for an endocyclic over an exocyclic pathway is precedented in literature.
18
 More 
specifically for these compounds, this preference  is demonstrated by the fact that TK1 and 
TK2, which also have a carbon α to the nitrogen, but are not cyclic, do not form cyanide 
adducts, while adducts were detected for both TK3 and TK4 which are cyclic.  
 
Figure 2.16: Proposed reactions in the formation of cyanide adducts A1 - A3 
A similar metabolic pathway has been reported for pyronaridine, which also has a pyrrolidine 
ring. However, unlike TK3 pyronaridine has a much longer half-life and the fraction 
metabolised is also much lower.
19,20
  
The tetrazole deoxyamodiaquines were also found to be potent CYP450 inhibitors with TK2 
and TK3 showing submicromolar IC50s for CYP 2C8 and CYP 3A4 and moderate inhibition 
of most other CYP450s except CYP 2A6 and CYP 2E1. The weak inhibition of CYP2A6 and 
CYP 2E1 may reflect the difficulty of these two compounds in accessing the binding cavity 





  Amodiaquine has been reported to competitively inhibit 2C8 and 2D6, with 
the latter inhibition reported to be strong enough to cause clinical interactions.
13,23
 The 
inhibition of these two enzymes by these compounds could therefore be an extension of this 
effect with more lipophilic compounds.  
CYP3A4 inhibition as measured using fluorescence assays was lower in the compounds 
lacking a tert-butyl substitution, an effect probably related to their lower lipophilicity (Figure 
2.17). 
 
Figure 2.17: Variation in CYP3A4 inhibition with lipophilicity 
 
This relationship between CYP3A4 activity and lipophilicity is reported for many other 
compound series.
24,25
 Amodiaquine clearly differs from these compounds in its lack of 3A4 
inhibition and even in literature, is reported to not inhibit CYP3A4. In silico work suggests 























  TK1B3 – TK4B3 
TK1 – TK4 
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Because metabolic stability was identified as a significant liability for these compounds, the 
ability of StarDrop to predict the main sites of metabolism was assessed. A good correlation 
between the predicted and the observed sites of metabolism would indicate the utility of this 
tool in the in silico evaluation of other generations of these compounds synthesised to 





Figure 2.18: StarDrop predicted sites of metabolism for TK3 assuming metabolism by CYP3A4, CYP2D6 or CYP2C9. (The percentages show the 
expected proportion of metabolites that would result from metabolism at the indicated position. For CYP3A4, the colors indicate the lability of the positions; red – labile, yellow – 
moderately labile, green – moderately stable, blue – stable) 




From the experimental data, the metabolism of TK3 involved α-hydroxylation of the pyrrolidine ring 
followed by formation of secondary metabolites by further metabolic and rearrangement reactions. The 
α-position on the pyrrolidine ring is indeed identified as the site that would contribute most (28%) to the 
metabolism of TK3 by CYP3A4. In addition, this position is identified as moderately labile indicating 
the ease of proton abstraction at this position during CYP3A4 metabolism. Interestingly, both CYP2D6 
and CYP2C9 predict position 8 of the aminoquinoline ring (C17 in Figure 2.18) as the major site of 
metabolism. No metabolites were observed in the experimental data on the aminoquinoline ring. The 
position is predicted to be metabolically labile by the CYP3A4 model and the absence of the 
corresponding metabolite in the experimental data may indicate poor accessibility in the active site of 
the enzyme. This may indicate that the correction factor for metabolic site accessibility is inadequately 
applied for this compound. Alternatively, the metabolism at the primary site (α-position of pyrrolidine) 
may be efficient and fast enough that it is formed preferentially over other sites of metabolism.  
The same pattern of predictions was observed for TK2 with CYP3A4 predicting metabolism α- to the 
tertiary nitrogen – in this case N-dealkylation, as the main metabolite. This was also predicted by the 
CYP2C9 model while the CYP2D6 model still had 8-hydroxylation as the main predicted metabolite.  
For both compounds the CYP3A4 model offers a reasonable approximation of the experimental data 
regarding the identification of the major site of metabolism. This may partly be because CYP3A4 is 
more promiscuous, relying more heavily on the physicochemical characteristics of the compounds than 
on the presence of specific structural features in the compound. While StarDrop only has models for 
CYP3A4, CYP2D6 and CYP2C9, other CYP450s likely contribute to the metabolism of these 
compounds. In addition metabolism of cycloalkylamines following iminium ion formation is known to 
involve aldehyde oxidase and this enzyme is also a likely possible contributor to the rapid metabolism 





Figure 2.19: StarDrop predicted sites of metabolism for TK2 assuming metabolism by CYP3A4, CYP2D6 or CYP2C9. (The percentages show the expected 
proportion of metabolites that would result from metabolism at the indicated position. For CYP3A4, the colors indicate the lability of the positions; red – labile, yellow – moderately labile, 
green – moderately stable, blue – stable) 
 
 
CYP3A4 CYP2D6 CYP2C9 
82 
 
StarDrop was also used to predict the physicochemical properties of the tentatively identified 
metabolites.  
Table 2.6: Predicted physicochemical properties of the metabolites 
Compound   MW LogP LogD TPSA 
TK3 462 4.52 1.99 72 
Hydroxylation (M2) 478 3.94 1.56 92 
Keto- formation (M7) 476 4.21 4.21 88 
Amino acid 
(M3/M18/M19) 
494 1.28 -0.36 118 
Hydroxyketo O-
glucuronidation (M16) 
668 1.8 -0.18 205 
The metabolite numbers correspond to those used in Figure 2.10 and elsewhere for these compounds  
There were no large differences in physicochemical properties between the various isobaric 
metabolites (except the amino acid and dihydroxylation metabolites), and the structures used 
are therefore just representative of the possible metabolites. For example, the conclusions 
drawn do not change, if the β-position is hydroxylated on M16 rather than the α-position. 
There is a progressive decrease in log P and log D as the compound is hydroxylated (to M2) 
then converted to the amino acid (M3/18/19). As expected, keto- formation (M7), increases 
the log D of the resulting metabolite, and glucuronidation of this metabolite (to M16) leads to 
a further drop in Log P and Log D. Overall though, M2 and M7 remain in the optimal zone 
for lipoidal permeability and their passive diffusion is possibly comparable to that of TK3. 
The amino acid metabolite and the glucuronide, however, have much lower log D and much 
higher TPSA and their ability to passively diffuse across membranes is likely to be 
significantly lower than the parent. This could have implications on their ability to reach the 
site of action and their contribution to in vivo antimalarial activity, might therefore be 
minimal, compared to the other two metabolites.  
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As discussed in Chapter I, the in vivo contribution of a metabolite depends not only on its 
intrinsic activity and lipoidal permeability, but also on the rate of its formation from the 
parent and its subsequent clearance through further metabolism or excretion. TK3 is almost 
completely metabolised in both hepatocytes and microsomes. However, the presence of so 
many metabolites, coupled with the fact that most of these are second or third generation 
metabolites implies that the first and second generation metabolites are also liable to 
extensive metabolism. In each successive generation, the metabolites in general become more 
polar, less lipoidally permeable and therefore more likely to be excreted than to remain in 
circulation. In contrast, while amodiaquine is rapidly metabolised to desethylamodiaquine, 
the latter is quite metabolically stable and has a much longer half-life relative to amodiaquine 
(10days vs 12h).
26
 The findings for these compounds suggest that most of the metabolites 
will have similar or only slightly higher half-lives relative to the parent. These compounds 










2.3 Tetrazole chloroquines 
2.3.1 Background 
Chloroquine was the first of the synthetic aminoquinolines, synthesised based on the quinine 
template, and was once the most widely used antimalarial drug. The emergence of resistant 
strains has unfortunately greatly limited its usefulness.
27
 The pharmacokinetics and 
metabolism of chloroquine have been reviewed by several authors.
1,28–30
 The key points are 
that it is extensively distributed in tissues (Vd 200 – 800L/Kg), and has a very long half-life 
(20 – 60 days).
3030
 Its main metabolic pathway in vivo is deethylation to mono- and 
dideseethyl metabolites. Monodesethylchloroquine retains some antiplasmodial activity, and 
is usually present at about 20-50% of the parent plasma concentration, while 
didesethylchloroquine is formed to about 10-15%.
31,32
 This dealkylation pathway is driven 
mostly by CYP2C8, with contribution by CYP3A4 and CYP2D6.
31,32
 This dealkylation 
pathway is driven mostly by CYP2C8, with contribution by CYP3A4 and CYP2D6.  Side 










Various approaches have been adopted to give derivatives with no cross-resistance with 
chloroquine.
1
 The approach explored to produce the derivatives considered in this work 
involves shortening the side chain and incorporation of a bulky N-alkyl substituent fused to a 
tetrazole moiety.
3535
 Shorter side chain analogues of chloroquine have been reported to retain 
the antiplasmodial activity of chloroquine and importantly, are also more active than 
chloroquine against chloroquine-resistant strains. Such derivatives are, however, reported to 
be more susceptible to N-dealkylation, and while the metabolites may retain antiplasmodial 
activity, the reduced lipid solubility is postulated to reduce activity against chloroquine 
resistant strains.
36













2.3.2 Compound selection 
 Several derivatives were selected, based on activity, and investigations on their metabolism 
conducted as reported in this section. Two derivatives without a tert-butyl substitution on the 
tetrazole ring were also selected to evaluate the effect of this group on the metabolism of the 
compounds. The derivatives considered are shown below.  











 3D7 K1 W2 
TK900A H H t-Bu 0.005 0.038 0.069 
TK900C CH3 H t-Bu 0.001 0.002 0.0311 
TK900D Cl Cl t-Bu 0.0004 0.008 0.0305 
TK900E Cl H t-Bu 0.002 0.001 0.0255 
TK900DB3 Cl Cl H nd 4.39 nd 
TK900EB3 Cl H H nd 2.38 nd 








2.3.3 Metabolism studies 
The microsomal stability of the selected derivatives was determined in human and rat liver 
microsomes using a single point assay at 0.4mg/ml microsomal protein, for 30 minutes.
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Table 2.8: Microsomal metabolic stability of tetrazole chloroquines 
Compound Microsomal stability  
(% remaining at 30 min) 
Log P* 
HLM RLM 
TK900A 38 8 4.49 
TK900C 35 <5 4.85 
TK900D 48 66 5.24 
TK900E 52 55 4.88 
TK900DB3 >99 80 3.83 
TK900EB3 >99 92 3.42 
Chloroquine >99 76 4.63 
 
In HLMs, chloroquine was stable with no reduction in the parent concentration observed, but 
its metabolism was faster in RLM, where only 76% of the initial concetration remained. For 
comparison, the data for chloroquine translates to a microsomal half-life >200min in HLMs 
and 77min in RLMs which is consistent with literature data for microsomal incubations.
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TK900A – TK900E had poor to moderate stability in both species, while the derivatives 
lacking a tert-butyl were more stable.  
2.3.3 Metabolite identification  
Metabolite identification studies were conducted for the derivatives, first in microsomal 
incubations supplemented with NADPH, to understand the drivers of the microsomal 
instability observed, and subsequently in hepatocytes to gain a broader picture of the 
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metabolism of these compounds. For simplicity in presentation, TK900E will be discussed as 
the prototypical compound but significant deviations in the metabolism of the other 
compounds in the series will also be pointed out.  





 spectra of TK900E 
 
There are similarities between the fragmentation of TK900E and that of the tetrazole 
deoxyamodiaquines, especially regarding the fragmentation of the tert-butyl substituted 
tetrazole ring. This proceeds by a loss of the tert-buytl group, followed by, or in parallel with, 
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Mass Formula Δppm 
470.1616 C23H26N7Cl2 -2.3 
414.0987 C19H18N7Cl2 -3.4 
344.0710 C18H16N3Cl2 -3.2 
279.0677 C17H12N2Cl -4.3 
 
Mass Formula Δppm 
205.0539 C11H10N2Cl 2.9 
191.0382 C10H8N2Cl 3.1 
   




the loss of the tetrazole ring. The side chain nitrogen and its substituent are then lost with 
charge transfer to the methylene, to give the m/z 205 fragment, which then undergoes 
sequential methylene losses to give the remaining fragments.   
2.3.3.1 Microsomal metabolism 
Unlike the tetrazole deoxyamodiaquines, the peak corresponding to the unmetabolised parent, 
TK900E, was the major peak in the chromatogram. A number of mono-hydroxylated 
metabolites were also observed 
 
Figure 2.22: Extracted ion chromatograms of TK900E and its HLM metabolites 
Similar metabolites were detected in rat liver microsomes. The collision induced dissociation 
of the metabolites was then considered in order to elucidate the metabolically labile positions.  
All major fragments produced from M1 are similar to the fragments of the precursor ion of 
the parent compound. This suggests hydroxylation on the tert-butyl group, since this group is 
XIC of +EMS: Exp 1, 484 to 485 Da from Sample 3 (TK900E) of TK900 MetID.wiff (Turbo Spray) Max. 2.7e8 cps.











































the first to be lost during fragmentation, and any modifications occurring here would be lost 
together with this fragment. 
Table 2.9: Microsomal metabolites of TK900E 
 
 
Code Rt m/z Fragments  







M1 6.45 486 414 344 205 191, 177 
M2 6.69 486 430 360 221 193, 207 
M3 6.89 486 430 360 221 193, 207 
M4 7.04 486 430 360 221 195, 166 
M5 7.39 486 430 360 221 207, 191 
M6 7.53 468 412 342 205 191, 177 
M7 7.61 484 428 358 205 191,177  
M8 7.90 484 428 358 205 400,354 
Parent 7.19 470 414 344 205 191, 177 
 
M2 – M5 all fragment to give m/z 430, 360 and 221, which are 16 Da higher than the 
corresponding fragments in the parent. This suggests that metabolism occurs on the left side 
of the molecule, on the ethylaminochloroquinoline. For M2 and M3, the sequential loss of 
methylene units to give the m/z 207 and 193 fragments, also higher than the corresponding 
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parent fragments by 16 Da, suggests that metabolism occurs on the 7-chloroaminoquinoline 
core.  The position of metabolism for M4 is less clear; while the 221 fragment indicates that 
metabolism occurs somewhere on the ethylchloroaminoquinoline, the absence of fragments 
that would correspond to the methylene losses and/or the aminoquinoline core make it 
difficult to conclusively assign the metabolite. M5-M8 were similarly difficult to assign, 
beyond excluding the right side of the molecule as the metabolic site. 
An additional route of metabolism in TK900A and TK900C is hydroxylation of the phenyl 
ring. This is particularly the case in TK900C where this metabolite accounts for more than 
50% of the total metabolites present, as assessed by DAD peak area. A number of di 
hydroxylated metabolites were also detected. These additional metabolic routes possibly 
account for the reduced stability of these compounds relative to TK900E.   
The metabolism of TK900DB3 and TK900EB3 is similar to that described for TK900E. The 
stability of these compounds is at least in part due to the absence of the tert-butyl group, 
which is a site of metabolism in TK900D and TK900E. 
2.3.3.3 Metabolite identification in hepatocytes 
The metabolism of TK900E was explored in rat and human hepatocytes.  
In addition to the metabolites already described in microsomes, a number of glucuronides 
were detected, possibly resulting from O-glucuronidation of the hydroxylation metabolites 
described. N-glucuronidation to the side chain nitrogen was also observed, but at a much 





Table 2.10: Hepatic metabolites of TK900E 
Component M+H
+













M2 486  C23H26N7OCl2  3.2 4 
M9 662  C29H34N7O7Cl2  2.0 7 
M10 646  C29H34N7O6Cl2  0.5 nd 
M11 791
 
 C33H41N10O7Cl2S  4.3 nd 
M12 662  C29H34N7O7Cl2  0.8 nd 
M13 662  C29H34N7O7Cl2  6.8 nd 
M14 662  C29H34N7O7Cl2  3.5 7 
M7 484  C23H24N7OCl2  2.1 3 
M4 486  C23H26N7OCl2  0.8 4 
M5 486  C23H26N7OCl2  2.7 3 
M1 486  C23H26N7OCl2  1.4 4 
M8 484  C23H24N7OCl2  2.1 2 
M3 486  C23H26N7OCl2  0.2 4 
M6 468  C23H24N7Cl2  0.6 2 
TK900E 470  C23H24N7Cl2  -2.3 3 
      
 
Figure 2.23: Extracted ion chromatogram of TK900E human hepatocyte metabolites  
TK009E HepInc Human 24h
Time

























Figure 2.24: In vitro metabolites of TK900E 
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The H/D data for M5 shows that although it is a hydroxylation metabolite, it has the same 
number of exchangeable protons as the parent, suggesting that it is an N-oxide.
39
 Quinoline 




The intensity of the glutathione adduct formed was not sufficient to give good fragmentation 
data. The experiment was, therefore, repeated in microsomes using a higher compound 
concentration. For comparison, TK900A was also incubated under the same conditions.  
 
Figure 2.25: Product ion spectra of the glutathione adducts of TK900A and TK900E 
 
 +EPI (757.20) CE (40) CES (25): 3.047 to 3.183 min from Sample 14 (TK900A + GSH EPI 757) of GSH screen.wiff (Turbo Spray) Max. 5.3e4 cps.
























315.1 484.3270.2 428.3 721.1218.2 701.4
 +EPI (791.20) CE (40) CES (25): 2.964 to 3.024 min from Sample 17 (TK900E + GSH EPI 791) of GSH screen.wiff (Turbo Spray) Max. 1.3e4 cps.


































In addition to the loss of 126 Da characteristic of these compounds, a loss of 129 Da (to give 
m/z 628 in TK900A and 662 in TK900E) is also observed. This neutral loss is considered 
diagnostic of glutathione adducts and is commonly used to screen for adducts.
41–43
 The low 
intensity of these glutathione adducts led to inconclusive results with the neutral loss scan. 
The adducts could however be detected using EMS-IDA-EPI methods, and also when EPI 
scans were used in isolation as survey. The fragments of m/z 502 and 536Da in TK900A and 
TK900E respectively are produced from a loss of 129Da from m/z 628 and 662Da, which are 
produced as described earlier. The presence of these fragments means that the substituted 
tetrazole is not the site of conjugation. 
It is postulated that m/z 358 and 392 (for TK900A and TK900E respectively) are produced 
by a loss of the cysteinyl moiety from m/z 628 and 662Da, leaving the sulfur attached to the 
aminoquinoline nucleus. This loss of 273Da is also characteristic of glutathione adducts.
41–43
 
In the product ion spectra obtained in the negative mode, the corresponding fragment of m/z 
272 was also observed. The fragment with m/z 253 in both spectra probably corresponds to 
m/z 205 in the parent compound, produced by loss of the side chain nitrogen and its 
substituent. Finally, m/z 227, which is also in both spectra, is proposed to arise from cleavage 
of the entire alkyl side chain to give the mercaptoquinoline derivative. A summary of this 




In addition to the loss of 126Da characteristic of these compounds, a loss of 129Da (to give 
m/z 628 in TK900A and 662 in TK900E) is also observed. This neutral loss is considered 
diagnostic of glutathione adducts and is commonly used to screen for adducts.
41–43
 The low 
intensity of these glutathione adducts led to inconclusive results with the neutral loss scan. 
The adducts could however be detected using EMS-IDA-EPI methods, and also when EPI 
scans were used in isolation as the survey scans. The fragments of m/z 502 and 536Da in 
TK900A and TK900E respectively are produced from a loss of 129Da from m/z 628 and 
662Da, which are produced as described earlier. The presence of these fragments means that 
the substituted tetrazole is not the site of conjugation. 
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It is postulated that m/z 358 and 392 (for TK900A and TK900E respectively) are produced 
by a loss of the cysteinyl moiety from m/z 628 and 662Da, leaving the sulfur attached to the 
aminoquinoline nucleus. This loss of 273Da is also characteristic of glutathione adducts.
41–43
 
In the product ion spectra obtained in the negative mode, the corresponding fragment of m/z 
272 was also observed. The fragment with m/z 253 in both spectra probably corresponds to 
m/z 205 in the parent compound, produced by loss of the side chain nitrogen and its 
substituent. Finally, m/z 227, which is also in both spectra, is proposed to arise from cleavage 
of the entire alkyl side chain to give the mercaptoquinoline derivative. A summary of this 












2.3.4 CYP450 inhibition 
The potential of these molecules to inhibit CYP450s was assessed using human liver 
microsomes. TK900C and TK900E were selected for the assay.   
Unlike the tetrazole deoxyamodiaquines presented in Section 2.2, these compounds did not 
significantly inhibit any CYP450s, except CYP3A4, where the IC50 using both midazolam 
and testosterone as probe substrates was about 0.1µM. Time dependent inhibition was 
assessed for CYP1A2, CYP2C9, CYP2D6 and CYP3A4 but was not observed for any of 
these incubations. 
Table 2.11: CYP450 inhibition profile of TK900C and TK900E 
 IC50 value (µM) 
CYP 
enzyme 
Probe reaction TK900C TK900E 








CYP2B6 bupropion hydroxylation 32.58 ± 2.6
a 
≈ 30.62 ± 5.7
a 
CYP2C8 paclitaxel 6 -hydroxylation 3.98 ± 0.8 12.7 ± 0.8 
CYP2C9 diclofenac 4’-hydroxylation 10.3 ± 2.9 8.91 ± 1.2 
CYP2C19 S-mephenytoin 4’-hydroxylation 52.6 ± 27.5
a 
12.4 ± 1.9 
CYP2D6 bufuralol 1’-hydroxylation 9.88 ± 2.1 4.0 ± 0.4 
CYP2E1 chlorzoxazone 6-hydroxylation >20
b 
≈ 21.9 ± 4.6
a 
CYP3A4 midazolam 1’-hydroxylation 0.17 ± 0.0 0.08 ± 0.0 
CYP3A4 testosterone 6β-hydroxylation 0.31 ± 0.0 0.14 ± 0.0 
a
estimated by extrapolation of experimental data. 
b
No inhibition seen in concentration range used 
While chloroquine is known to inhibit CYP2D6, it does not inhibit CYP3A4.
23
 The inhibition 
of CYP3A4 by all the selected molecules was therefore assessed using a fluorescent assay 




Figure 2.27: Percentage enzyme activity remaining after incubation of 3µm or 20µM 
compound with recombinant CYP3A4 
It is interesting to note that in this assay, chloroquine shows moderate CYP3A4 inhibition. 
This is, however, not observed in the microsomal assay or clinically. The data for these 
compounds are consistent with the microsomal data with both TK900C and TK900E 
showing strong inhibition. The compounds lacking a tert-butyl substituent show less potent 
inhibition at the lower concentration and this could possibly be attributable to their lower 
lipophilicity. On this point, it is also useful to note that TK900A, which is the least lipophilic 
of the tert-butyl substituted compounds, showed the lowest inhibition amongst these 
compounds. The trends are more difficult to follow on the higher end of the lipophilic scale 
because the figures are smaller and experimental variations are likely to have a bigger effect. 
Finally, the interaction of these compounds with 3A4 was modelled by docking TK900C and 
TK900E onto a crystal structure of CYP3A4 (PDB 2V0M, 2.8Ǻ with ketoconazole) using 
glide. The docking protocol was validated by redocking the ketoconazole; the lowest energy 
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 In contrast to chloroquine, these compounds lie almost parallel to the heme. Like with the 
tetrazole deoxyamodiaquines, this orientation may maximise the π-π and π-cationic 
interactions with heme leading to inhibition. This is perhaps also suggested by the binding 
energies, which are about 1kcal/mol higher relative to chloroquine, and which approach the 
binding energy of ketoconazole.  
Table 2.12: Binding energies of the most stable conformers 











Figure 2.28: Lowest binding energy conformations for TK900C (A), TK900E (B) and Chloroquine (C) showing molecular surface binding site 











The metabolism of the tetrazole chloroquines was mainly by hydroxylation on the tert—butyl 
group and by N-oxidation and hydroxylation on the aminoquinoline core. Compounds lacking 
a tert-butyl substitution were therefore more metabolically stable.  A number of 
hydroxylation metabolites tentatively identified as being on the aminoquinoline ring were 
also observed. 
The ability of StarDrop to predict the formation of these metabolites was evaluated using 
TK900E and TK900C. The major predicted metabolite using the CYP3A4 model is on the 
aminoquinoline ring (C31,  
Figure 2.29). This site is also predicted to be the main site of metabolism by CYP2D6 and 
CYP2C9, and also as the most metabolically labile site in the CYP3A4 model. Various 
degrees of metabolism are predicted for all non-substituted positions on the aminoquinoline 
ring and on the 1,2-ethyldiamine linker. The fragmentation pattern suggests that M2 and M3 
are hydroxylation products on the aminoquinoline ring, while for M4 – M8, the metabolic 
transformation could be on the 1,2-ethyldiamine linker or on the aminoquinoline ring. The 
predictions are therefore comparable to the experimental data. Aminoquinoline N-oxidation, 
and t-butyl oxidation, which are the other experimentally observed metabolites, are also 
predicted by all models but are generally lower than the aminoquinoline sites.  
For TK900C where an additional metabolite accounting for more than 50% of the 
metabolites formed was observed, the StarDrop models, correctly identify the additional 
metabolite as forming on the toluyl substituent, just as the MS data suggested, but 
additionally suggest the para- methyl group as the site of metabolism, and also as the most 






Figure 2.29: StarDrop predicted sites of metabolism for TK009E and TK900C assuming metabolism by CYP3A4, CYP2D6 or CYP2C9. (The 
percentages show the expected proportion of metabolites that would result from metabolism at the indicated position. For CYP3A4, the colors indicate the lability of the positions; red – labile, yellow – moderately 
labile, green – moderately stable, blue – stable) 





A glutathione adduct was also observed with these compounds. This is a deviation from the 
known literature on the metabolism of chloroquine which does not form glutathione adducts. 
Nitrogen containing aromatic systems may be considered masked anilines and if 
hydroxylated may undergo further metabolism to form reactive quinone imine species. This 





Figure 2.30: Reactive metabolite formation in Chlorpromazine and Mianserin
44,45
 




While there does not appear to be any literature suggesting that glutathione adduct formation 
occurs on the 4-aminoquinoline nucleus, it is useful to note that other than N-oxidation, the 
site of metabolism usually lies elsewhere in the molecule. Since metabolism is shown to 
occur on the aminoquinoline ring in these molecules, with at least 3 metabolites (excluding 
N-oxidation) formed here, they are more likely to form glutathione adducts.  
Finally, the physicochemical properties of the major metabolites in the hepatocyte 
incubations M1, M5, an aminoquinoline hydroxylation metabolite and its respective 
glucuronide, were determined in order to predict their possible contribution to the in vivo 
activity of the compound.  
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Table 2.13: Predicted properties of TK900E and its metabolites 
Compound   MW LogP LogD TPSA 
TK900E 
 
470 4.36 1.61 81 
t-butylhydroxylation (M1) 486 3.46 1.07 101 
N-oxidation 
 (M5) 
486 4.64 1.49 93 
6-hydroxylation 
(M2/M3/M4) 
486 3.97 1.20 101 
6-O-glucuronidation 
(M9/M12/M13/M14) 
662 0.003 -0.19 184 
 
As expected, metabolism generally lowers the lipophilicity of the resulting metabolites. A 
known exception is the N-oxides which are usually more lipophilic than the parent molecules. 
For the three non-conjugated metabolites, log D is only slightly different relative to the parent 
and the TPSA is only 20Ǻ higher. Lipoidal permeability is therefore unlikely to be 
substantially different compared to the parent.
46,4746,47
  However, assuming that the three 
metabolites are formed at the same rate from TK900E, the next major factor in determining 
the circulating concentration of these metabolites is their rate of excretion and/or further 
metabolism. From the metabolite profiling done for this compound, it is instructive to note 
that while four O-glucuronides were detected, none of these were formed for the tert-butyl 
hydroxylation metabolite, despite this  being amongst the major metabolites formed. It is 
therefore more likely that in vivo the aminoquinoline hydroxylated metabolites will be 
present in higher concentrations as the respective glucuronides. The model glucuronide in 
this case shows a drop of 1 unit in Log D and an increase by almost 100 units in TPSA. It 
would therefore be expected that this metabolite shows reduced lipid permeability. 
Glucuronides usually rely on transporters for excretion from the liver and depending on the 
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relative affinity of the glucuronide to the various transporters; it may be excreted into bile or 
back into circulation.  
For antiplasmodial activity, the metabolites in circulation need to traverse the red blood cell 
membrane and the plasmodial membranes. Assuming passive mechanisms only, the 
glucuronide is unlikely to reach the site of action, and is therefore unlikely to contribute to 
the activity of this compound in vivo. Considering the 3 remaining metabolites, a few general 
conclusions can be drawn. While all three should be permeable enough to get to the site of 
action, modifications on the aminoquinoline nucleus have consistently been shown to result 
in a decrease in activity.
3636
 The aromatic hydroxylation may therefore be less active than 
TK900E. An exception to this rule is N-oxidation which, for chloroquine, produces a more 
active metabolite.
36,48
 The N-oxidation of this derivative could therefore also be active 
assuming a similarity in the mechanism of action.
36,48
 The N-oxidation of this derivative 
could therefore also be active assuming a similarity in the mechanism of action. The 
hydroxylation of the tert-butyl group is remote enough from the aminoquinoline nucleus that 
it can be expected to not substantially affect antiplasmodial activity. Chloroquine and 
amodiaquine derivatives hydroxylated on the ethyl chain are indeed reported to be active with 
hydroxychloroquine actually being slightly more active and less toxic than chloroquine. 
36,49,50
 The tert-butyl oxidation is therefore also likely to be active.  
However, despite the good in vitro activity of these compounds, the percentage reduction in 












% Reduction in parasitaemia 
 
TK900D 
1 x 20 44.5 
1 x 10 41.4 
1 x 5 46.9 
1 x 1 22.7 
Chloroquine 1 x 20 90.6 
 
While this effect was postulated to arise, at least in part, from solubility-limited absorption – 
because of the poor solubility of these compounds, it remains unclear why better activity was 
not seen. This is despite moderate but reasonable in vivo PK parameters – t½ 4hrs, Cmax 
0.94µM and AUC 222min.µmol/L at 20mg/kg. Further work is therefore required to 











The metabolism of a series of tetrazole aminoquinolines was investigated in vitro. The main 
site of metabolism of the tetrazole deoxyamodiaquines was the attachment to the tertiary 
nitrogen. Metabolism was by N-dealkylation in the case of simple alkyl substitutents and by 
hydroxylation through an iminium ion pathway, for cylcoalkyl substituted derivatives. The 
tetrazole chloroquines were metabolised by aminoquinoline N-oxidation, tert-butyl 
hydroxylation and by aminoquinoline hydroxylation. A glutathione adduct was also detected. 
Both series of compounds showed moderate – potent CYP450 inhibition and their inhibition 
of CYP3A4 was shown to result from the orientation in the active site of the enzyme. The 
main metabolites of both tetrazole deoxyamodiaquines and tetrazole chloroquines could be 
predicted using StarDrop and this software could therefore be useful in the further 
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Chapter 3  
METERGOLINE ANALOGUES 
3.1 Chapter overview 
In this Chapter, the microsomal metabolism of metergoline and metergoline analogues is 
investigated. The metabolites are tentatively identified using their product ion spectra, and 
additionally in the case of metergoline H/D exchange data. Differences in metabolic 
pathways among the compounds are discussed on the basis of their structure. CYP450 models 
on StarDrop are then used to predict the sites of metabolism of selected compounds and these 
are discussed relative to the experimentally observed metabolites. 
3.2 Background 
Metergoline is a semi-synthetic ergot-derived drug first described in 1965.
1
 It has been used 
clinically to inhibit lactation in human and veterinary medicine, and for a variety of 
psychiatric uses.
2–4
 These pharmacological actions draw mostly from its actions at serotonin 
and dopamine receptors, though it has also been reported to have high affinity for other CNS 
receptors.
5,6
 It has mostly been overtaken by newer agents in the same class, though it is still 
marketed in several jurisdictions.
7,8
  
More recently, metergoline has been reported to have anti-infective activity. Kang and co-
workers reported potent antifungal activity for metergoline, and showed that cell death 
resulted from generation of reactive oxygen species and disturbance of mitochondrial 
homeostasis.
9,10






The work herein described was motivated by a high-throughput screening conducted by the 
National Institutes of Health, under the Tuberculosis Antimicrobial Acquisition and Co-
ordination Facility, which identified metergoline as a hit compound against Mycobacterium 
tuberculosis H37Rv (IC90 15µM).
13
 The increasing burden of tuberculosis and the dearth of 
novel drugs in the development pipelines have elevated the need for consideration of 
alternative drug discovery approaches, such as drug repositioning and repurposing. The 
derivatives were therefore screened with the aim of identifying derivatives with good 
antimycobacterial activity, whose development might be more feasible because of their 
similarity to a known clinical compound. 
 All derivatives were also screened for antiplasmodial activity. Various high-throughput 
screens have reported antiplasmodial activity in the 1 – 20µM range for metergoline, 
depending on the strain used.
14–17
 This cross screening is an emerging practice in the 
discovery of drugs for neglected diseases; it maximises the value of the compound pool and 
the selectivity against various pathogens maybe of value in understanding the mechanism of 












3.2.1 Metabolism of metergoline 
Metergoline is almost completely absorbed when administered orally. It, however, undergoes 
considerable first-pass metabolism to 1-demethylmetergoline.
19
 Both metergoline and its 
primary metabolite 1-demethylmetergoline have short plasma half-lives (50 minutes and 100 
minutes respectively.
19
 12-Hydroxylation is also observed as a minor metabolite. In rats, 1,6-
dimethyl-8 beta-aminomethylergoline produced by cleavage of the carbamate linker, and its 
1-demethylation and N-acetylation metabolites are observed, together with a number of as yet 
unidentified polar metabolites (Figure 3.1).  
 










3.3 Compound selection 
The compounds in this series were alkyl and aromatic amides, with the ergoline nucleus 
unchanged.
21
 The selection of compounds for in vitro metabolism studies was based on their 
biological activity and on the expected diversity of metabolic reactions. Aromatic amides 
were also selected so as to represent each quadrant of the Craig plot; in order to assess any 
effects of the substituents on the metabolism of these compounds. Alkyl amides longer than 
the pentamidyl derivative selected were poorly soluble in DMSO and/or in the assay medium 
at the test concentrations and were therefore not included in this evaluation. The compounds 
and their biological activity are presented in Table 3.1. 





















IC50  (μM) 
FRM015 
     
24.4 50 27.0 
FRM004 
 
0.5 50 5.0 
FRM001 
     
1.3 25 4.3 
FRM003 
     
0.6 50 103.6 
FRM010 
   
14.2 >50 221.5 
FRM011 
    
8.4 37 7.4 
FRM007 
    
2.0 25 14.5 
GKMG14 
    
199 >50 ND 
GKMG16 
    
89.1 >50 ND 
GKMG22 
    
18.7 >50 105.0 
Metergoline 3.7 25 16.6 
a
Drug sensitive strain of Plasmodium falciparum.  
b
Drug sensitive strain of Mycobacterium tuberculosis. 
c
Chinese Hamster Ovarian cell line 
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3.4 Metabolism studies 
3.4.1 Microsomal stability 
The microsomal stability of the derivatives was evaluated in human and mouse liver 
microsomes (HLM and MLM) using a single point assay at 0.4 mg/ml, for 30 minutes. The 
results are presented in Table 3.2 below. 
Table 3.2: Microsomal metabolic stability of metergoline derivatives 
 
               
   









     
16 62 3.49 
FRM004 
 
89 89 3.46 
FRM001 
     
88 89 4.11 
FRM003 
     
91 39 3.27 
FRM010 
   
92 98 2.76 
FRM011 
    
65 77 3.38 
FRM007 
    
23 65 4.62 
GKMG14     
96 73 2.26 
GKMG16     
71 50 3.39 
GKMG22     
91 33 3.27 
Metergoline 7 29 3.95 




Metergoline was rapidly metabolised in both HLM and MLM, with a projected half-life of 7 
min in HLM and 17 min in MLM. The selected derivatives were more stable. Metabolite 
identification experiments were performed to understand the differences in metabolism 
between these compounds.   
3.4.2 Metabolite identification 
3.3.2.1 Fragmentation of metergoline and FRM015 
The fragmentation of metergoline and one of the derivatives, FRM015, was evaluated to 
allow for tentative metabolite assignments. While no literature is available on the 
fragmentation pathways of metergoline, some work has been conducted on other ergolines 
and this can be extrapolated to elucidate the pathways for metergoline and its derivatives.
22–24
  
Both metergoline and FRM015 undergo cleavage of the carbamate/amide linker. In the case 
of metergoline, this appears to occur through dissociation of the carbamate C – O  bond with 
charge retention on the carbonyl to give a fragment with m/z 296, followed by loss of CO to 
give the m/z 268 fragment. On the other hand, when the benzyl C-O bond is cleaved, the 
characteristic tropylium ion (m/z 91) is formed. A variant of this mechanism is observed for 
FRM015, dissociation of the amide C-N bond with charge retention on the carbonyl gives the 




Figure 3.2: Major fragments of Metergoline and FRM015 
A second pathway, also observed with lysergic acid and its analogues, involves cleavage of 
ring D by loss of CH2=N-CH3 in metergoline, and HNCH3 in FRM015 and the other amide 
derivatives to give m/z 360 in metergoline and m/z 343 for FRM015. The rest of ring D is 
eventually lost and combined with the linker cleavage, a stable aromatic system m/z 168 is 
formed. The proposed fragments are illustrated for FRM015 and metergoline in Figure 3.2 , 




Figure 3.3: Product ion spectrum of FRM015 
GK-MG26
m/z


































Mass Formula Δppm 
374.2222 C24H28N3O -2.7 
343.1786 C23H23N2O -7.0 
222.1271 C16H16N -5.4 
168.0809 C12H10N -2.4 








3.3.2.2 Metabolite identification experiments for metergoline 
Metabolite identification experiments were first performed with metergoline, to establish the 
chromatography and mass spectral characteristics that would be expected of the selected 
derivatives 
Unlike the reported metabolism of metergoline in vivo, where 1-demethylmetergoline is the 
major metabolite, a hydroxylation product was formed as the major metabolite in both human 
and mouse liver microsomal metabolites (Figure 3.4).  
 
Figure 3.4: Extracted ion chromatogram of metergoline and its metabolites in HLM 
 
XIC of +EMS: Exp 1, 420 to 421 Da from Sample 1 (Metergoline HLM 25 May) of Metergoline HLM confirmation.wiff (Turbo Spray) Max. 6.3e8 cps.







































The collision induced dissociation spectra of these metabolites show that all HLM 
metabolism occurs on the ergoline nucleus, as evidenced by the presence of the m/z 91 
fragment in all metabolites (Table 3.3).  
Table 3.3: HLM metabolites of metergoline and their diagnostic ions 
   
Code Rt m/z Fragments   







M1 1.27 286 - 184 - - nd 
M2 3.13 270 - 168 - - 3 
M3 5.70 406 362 184 91 298, 270 nd 
M4 5.74 420 376 184 91 312, 284 3 
M5 6.04 390 346 154 91 282, 254 3 
M6 6.15 420 - 184 91 - nd 
M7 6.21 416 372 - 91 308, 280 2 
M8 6.39 390 346 168 91 282, 254 3 
M9 6.72 420 - - 91  2 
M10 7.05 400 356 168 91 -, 264 nd 
Parent 6.45 404 360 168 91 296, 268 2 
The retention time and fragmentation of M2 corresponded to that of 1,6-dimethyl-8-β-
aminomethylergoline, produced by Pd/C catalysed hydrogenolysis of metergoline.
21
 
Metabolism was similar between HLM and RLM incubations, with both producing 
hydroxylation and demethylation products on the ergoline nucleus, as the major metabolites. 
However, in MLM incubations, an additional hydroxylation metabolite was observed. This 
metabolite had a prominent m/z 107 fragment (in place of m/z 91, Figure 3.5), and the 
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fragments representing the ergoline skeleton were unchanged indicating metabolism on the 
benzyl group.  
 
Figure 3.5: CID product ion spectrum of metergoline and its MLM hydroxylation metabolite 
The mass shift on H/D exchange could only be conclusively established for the more intense 
metabolites. M9 has the same H/D mass shift as metergoline suggesting that it is an N-




The remaining metabolites could be tentatively assigned based on the fragments shown in 
Table 3.3, and the H/D mass shift. For example, M4 could be identified as hydroxylation 
 +EPI (404.27) Charge (+1) CE (70) CES (25) FT (88.0534): Exp 2, 6.019 min from Sample 14 (Metergoline T30_170+25) of MLM.wiff (T... Max. 6.9e6 cps.




























194.3 404.3205.3 234.390.3 268.4158.2 296.2
360.3144.3 197.5 213.6
 +EPI (420.37) Charge (+1) CE (70) CES (25) FT (191.396): Exp 2, 5.467 min from Sample 14 (Metergoline T30_170+25) of MLM.wiff (T... Max. 2.2e6 cps.





































somewhere on rings A, B or C because of the mass shift of the m/z 168 fragment in 




Figure 3.6: Microsomal metabolites of metergoline 
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3.3.2.3 Metabolism of metergoline derivatives 
The metabolism of the metergoline analogues was evaluated in HLM and MLM. Their good 
MS sensitivity allowed the use of the metabolic stability incubations for metabolite 
identification experiments (1µM compound, 0.4mg/ml microsomal protein). The experiments 
were also performed at higher compound and microsomal protein concentrations (10µM 
compound, 1mg/ml microsomal protein) to allow for better characterisation of the minor 
metabolites. 
A major difference in the metabolism of these derivatives, compared to metergoline, was that 
1,6-dimethyl-8-β-aminomethylergoline (M2) was not observed. This is hypothesised to be as 
a result of the better stability of the amide bond, relative to the carbamate bond. 
The metabolism of the aromatic amides was largely similar to that of metergoline. For 
FRM015 for example, an ergoline hydroxylation metabolite, corresponding to M4, is 
observed as the major metabolite in both HLM and MLM. No metabolism is observed on the 
phenyl substituent.  
 
Figure 3.7: Extracted ion chromatograms of FRM015 and its metabolites (The metabolite 
numbering represents the corresponding metabolite in metergoline) 
However, for FRM007, which has a para-butyl substitution, the major site of metabolism 
was this butyl chain, with 3 hydroxylation and 1 dihydroxylation metabolites formed on this 
XIC of +EMS: Exp 1, 374 to 375 Da from Sample 6 (FRM015 T30_1) of HLM MetID.wiff (Turbo Spray) Max. 4.2e7 cps.

























XIC of +EMS: Exp 1, 374 to 375 Da from Sample 12 (FRM015 T30_1 MLM) of HLM MetID.wiff (Turbo Spray) Max. 6.9e7 cps.












































chain (Figure 3.8). The ergoline hydroxylation metabolite was barely detectable. One of the 
butyl hydroxylation metabolites and the dihydroxylated metabolite were only detected in 
HLM incubations. This additional pathway contributes to the lower stability of this 
compound in HLM.  
 
Figure 3.8: Extracted ion chromatograms of FRM007 and its metabolites in HLM and MLM 
For FRM011, the O-demethylated metabolite is observed in both HLM and MLM 
incubations (Figure 3.9) 
 
Figure 3.9: Extracted ion chromatograms of FRM011 and its metabolites in HLM and MLM 
 
Among the alkyl amides, GKMG22 and GKMG16 which have shorter chains are similar in 
their metabolism to metergoline, with ergoline hydroxylation (corresponding to M4) and 
XIC of +EMS: Exp 1, 430 to 431 Da from Sample 3 (FRM007 T30_1) of HLM MetID.wiff (Turbo Spray) Max. 3.3e7 cps.


























XIC of +EMS: Exp 1, 430 to 431 Da from Sample 9 (FRM007 T30_1MLM) of HLM MetID.wiff (Turbo Spray) Max. 1.1e8 cps.


































XIC of +EMS: Exp 1, 404 to 405 Da from Sample 5 (FRM011 T30_1) of HLM MetID.wiff (Turbo Spray) Max. 9.8e7 cps.
































XIC of +EMS: Exp 1, 404 to 405 Da from Sample 11 (FRM011 T30_1 MLM) of HLM MetID.wiff (Turbo Spray) Max. 2.4e8 cps.
















































HLM MLM FRM011 FRM011 
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ergoline N-demethylation (corresponding to M8) as the main metabolites. GKMG14, with a 
butyl chain, is metabolised to 3 alkyl hydroxylation products in MLM, in addition to the 
ergoline hydroxylation metabolite (M4). However, in HLM only the ergoline hydroxylation 
metabolite is detected and this probably explains the better stability of this compound in 
HLM (Figure 3.10).  
 










XIC of +EMS: Exp 1, 354 to 355 Da from Sample 5 (GKMG14 T30_1 HLM) of MLM.wiff (Turbo Spray) Max. 9.4e8 cps.































XIC of +EMS: Exp 1, 354 to 355 Da from Sample 1 (GKMG14 T30_1) of MLM.wiff (Turbo Spray) Max. 1.0e9 cps.














































3.5 Discussion  
The in vitro metabolism of metergoline proceeds by ergoline hydroxylation as the major 
pathway, in contrast to its reported metabolism in vivo where 1-demethylation is the major 
metabolite observed. A possible explanation could be the contribution of gut wall metabolism 
to the metabolite profile observed in vivo.  This difference in metabolic pathways has no 
effect on the clearance of metergoline in vitro and rapid metabolism, as reported in vivo is 
still observed. It would however be of interest, for derivatives further along the development 
chain, to assess the clearance, metabolism and metabolite formation kinetics in intestinal 
fractions (microsomes/s9), to maximise the predictive value of in vitro data. 
The derivatives selected were generally metabolised in a similar way to metergoline, with 
metabolism occurring on the ergoline nucleus. Among the aryl amides with no metabolically 
vulnerable groups (FRM001, 003, 004, 010) the metabolic stability was comparable 
regardless of the lipophilic or electronic properties of the substituent. These derivatives were 
more stable than metergoline. A derivative with a para-Fluoro substitution had a metabolic 
stability comparable to that of FRM015 suggesting that the size of the substituent is 
important. Since metabolism of these derivatives exclusively occurs on the ergoline ring, the 
effects of the phenyl substituents is probably in changing the affinity of these compounds to 
the metabolising enzymes leading to lower metabolism and thus better microsomal stability. 
Metergoline itself is reported to be highly protein bound (>99%), so it is unlikely that the 
higher stability represents higher protein binding.
6
 These compounds would therefore be 
projected to have better in vivo half-lifes compared to metergoline. 
Alkyl hydroxylation was observed with FRM007 and GKMG14. In the case of FRM007 
which has a p-butyl substituent, three hydroxylation products were detected in HLM. 
Assuming CYP450 involvement and hydrogen abstraction and stabilisation of the resulting 
electrophilic intermediate would be most favoured at the benzylic position, and benzylic 
140 
 
hydroxylation should therefore be the preferred metabolic pathway and should in any case be 
one of the three hydroxylation products detected. CYP450s are also known to catalyse 
hydroxylation at ω and ω-1 and these are probably the other two metabolites.
27
 Incubations 
with FRM002, which has a para-ethyl substituent, gave one ergoline hydroxylation 
metabolite and only one hydroxylated metabolite on the substituted phenyl. Comparing 
FRM002 and FRM007, it is probable that benzylic oxidation occurs in both cases but as the 
length of the alkyl chain increases, ω and ω-1 hydroxylation becomes easier, presumably 
because the chain is able to get closer to the active site of the enzyme. In the case of 
GKMG14 alkyl hydroxylation was observed only in MLM, suggesting that an enzyme other 
than the one involved in FRM002 and 007 metabolises this compound. A comparison with 
GKMG22, which has a shorter chain and where hydroxylation is only observed on the 
ergoline core, suggests that chain length has an effect on the ease of alkyl hydroxylation as 
would be expected.  
M2 in metergoline was shown to be 1,6-dimethyl-8-b-aminomethylergoline by comparison of 
its retention time and fragmentation with an authentic compound. This metabolite, formed by 
carbamate hydrolysis was not detected for any of the amide derivatives, presumably because 
of the better stability of the amide bond. This metabolite was also detected in plasma 
incubations of metergoline showing a contribution by hydrolases in plasma to its formation. 
The experimentally observed sites of metabolism were compared with those predicted by 
StarDrop (Figure 3.11) to determine the utility of this software in the optimisation of these 
compounds. For metergoline, the methyl group at N1 is predicted to be the major site of 
metabolism by CYP3A4 and by CYP2C9, possibly by N-demethylation. 
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Figure 3.11: StarDrop predicted sites of metabolism for Metergoline assuming metabolism by CYP3A4, CYP2D6 or CYP2C9. (The percentages 
show the expected proportion of metabolites that would result from metabolism at the indicated position. For CYP3A4, the colors indicate the lability of the positions; red – 




CYP3A4 CYP2D6 CYP2C9 
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While 1-demethylation is the major pathway in vivo, it was of less significance in HLM and 
MLM, with ergoline hydroxylation observed as the major metabolite. This position is also 
predicted to be the most metabolically labile by the CYP3A4 model. 12-hydroxylation, which 
is observed in vivo, is not predicted by this software, though a number of positions on the 
ergoline ring are suggested as sites of metabolism.  
The alkyl hydroxylation pathway is well predicted in StarDrop. Focussing on CYP3A4 where 
both the site of metabolism and the relative lability are available, the ω and ω-1 positions in 
both FRM007 and GKMG14 and the benzyl –CH2 in FRM007 are predicted to be the major 
sites of metabolism of these compounds and are also predicted to be significantly labile. 
 
Figure 3.12: StarDrop predicted sites of metabolism for FRM007 and GKMG14 assuming 
metabolism by CYP3A4. (The percentages show the expected proportion of metabolites that would result 
from metabolism at the indicated position and the colors indicate the lability of the positions; red – labile, 






As discussed in previous chapters, the physicochemical properties of the metabolites, 
specifically, lipophicity and TPSA are important determinants of the contribution of 
metabolites to in vivo activity. These properties are presented for metergoline and some of its 
metabolites below (Table 3.4).   
Table 3.4: Physicochemical properties of metergoline and its metabolites 
Compound MW LogP Log D TPSA 
1-demethylmetergoline 389 3.74 2.72 57 
12-hydroxymetergoline 419 3.54 2.27 67 
1,6-dimethyl-8-β-
aminomethylergoline 
269 1.96 0.74 34 
Metergoline 403 3.95 2.82 47 
 
The lipophilicity (Log P and Log D) and TPSA of 1-demthylmetergoline and 12-
hydroxymetergoline are only slightly changed compared to those of metergoline, suggesting 
that the passive diffusion of these metabolites is likely to be similar to that of metergoline. 
This is demonstrated by the observation that both metabolites possess in vivo antiserotonergic 
activity, and are indeed more active than metergoline.
28,29
 1-demethylmetergoline also has a 
longer plasma half-life compared to metergoline, possibly as a result of its reduced 
lipophilicity which reduces its affinity to metabolic enzymes. The contribution of these 
metabolites to in vivo antiplasmodial or antimycobacterial activity is difficult to predict since 
no information is available on the mechanism of action of these compounds. However, their 
in vivo antiserotonergic activity suggests that they are able to diffuse across cellular barriers 
to intracellular targets. The only unknown is how the structural modifications affect 
interaction with the biological target of these compounds in plasmodia and mycobacteria. 
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The structure and physicochemical properties of 1, 6-dimethyl-8-β-aminomethylergoline are 
quite different from those of metergoline and suggest significant differences in passive 
diffusion across membranes, relative to metergoline. This is also suggested by the 
observation that this compound was inactive in both the antiplasmodial and antimycobacterial 
assays. Therefore, while it is observed as a circulating metabolite, it is unlikely to contribute 
to the in vivo antiplasmodial or antimycobacterial activity of metergoline. 
A complicating factor in the repositioning and repurposing of these agents is their CNS 
pharmacology, especially since the binding affinities against most of their target receptors is 
in the low nanomolar to high picomolar range, with their metabolites being upto 100 times 
more potent against certain receptor subtypes.
28,30
 This is, however, surmountable because 
compounds can be designed such that they have poor blood brain barrier permeability. It may 
also be possible, with a larger compound set, to computationally determine the structural 
features required for activity and thus perform scaffold hoping to obtain compounds that 
retain the antiplasmodial or antimycobacterial activity but have no CNS activity.  
While the first phase of this work was mostly exploratory and targeted only on amide 
derivatives of metergoline, the preliminary data shows that more extensive SAR work may 
yield derivatives that can be pursued as leads for the development of antiplasmodial and 







The metabolism of metergoline and a number of its derivatives with antiplasmodial and/or 
antimycobacterial activity was investigated. The tentative structures of the metabolites could 
be assigned based on the similarities between the fragmentation patterns of these derivatives 
to more widely studied ergolines, and on the mass shift following H/D exchange. For 
metergoline, a hydroxymetergoline metabolite was identified as the main metabolite in vitro, 
in contrast to the in vivo metabolism where 1-demethylmetergoline is reported as the primary 
metabolite. The derivatives were more stable than metergoline in human and mouse liver 
microsomes, partly because of the stability of the amide bond, relative to the carbamate bond 
in metergoline. Their metabolism was broadly similar to that of metergoline but alkyl 
hydroxylation was also observed for two derivatives which had a butyl chain. This metabolic 
pathway showed species differences with para-butyl hydroxylation occurring only in HLM 
and hydroxylation of the pentyl chain observed in MLM only. These sites of metabolism 
were generally well predicted in StarDrop, particularly the ergoline demethylation and the 
alkyl hydroxylation. On the other hand, 12-hydroxylation, a known metabolite in vivo, was 
not predicted by the software. These preliminary data will be useful in further SAR expansion 










(1)  Beretta, C.; Ferrini, R.; Glasser, A. H. 1-Methyl-8 Β-Carbobenzyloxy-Aminomethyl-
10 Α-Ergoline, a Potent and Long-Lasting 5-Hydroxytryptamine Antagonist. Nature 
1965, 207, 421–422. 
(2)  Crosignani, P. G.; Lombroso, G. C.; Caccamo, A.; Reschini, E.; Peracchi, M. 
Suppression of Puerperal Lactation by Metergoline. Obstet. Gynecol. 1978, 51, 113–
115. 
(3)  Gerstenberg, C.; Nöthling, J. O. The Effects of Metergoline Combined with PGF2α 
Treatment on Luteal Function and Gestation in Pregnant Bitches. Theriogenology 
1995, 44, 649–659. 
(4)  Roca, C. A.; Schmidt, P. J.; Smith, M. J.; Danaceau, M. A.; Murphy, D. L.; Rubinow, 
D. R. Effects of Metergoline on Symptoms in Women with Premenstrual Dysphoric 
Disorder. Am. J. Psychiatry 2002, 159, 1876–1881. 
(5)  Eich, E.; Pertz, H. Ergot Alkaloids as Lead Structures for Differential Receptor 
Systems. Pharmazie 1994, 49, 867–877. 
(6)  Hooker, J. M.; Kim, S. W.; Reibel, A. T.; Alexoff, D.; Xu, Y.; Shea, C. Evaluation of 
[(11)C]metergoline as a PET Radiotracer for 5HTR in Nonhuman Primates. Bioorg. 
Med. Chem. 2010, 18, 7739–7745. 
(7)  Colao, A.; Savastano, S. Medical Treatment of Prolactinomas. Nat. Rev. Endocrinol. 
2011, 7, 267–278. 
(8)  Metergoline - Drugs.com http://www.drugs.com/international/metergoline.html 
(accessed Jul 4, 2014). 
(9)  Kang, K.; Wong, K.-S.; Seneviratne, C. J.; Samaranayake, L. P.; Fong, W.-P.; Tsang, 
P. W.-K. In Vitro Synergistic Effects of Metergoline and Antifungal Agents against 
Candida Krusei. Mycoses 2010, 53, 495–499. 
(10)  Kang, K.; Wong, K.-S.; Fong, W.-P.; Tsang, P. W.-K. Metergoline-Induced Cell Death 
in Candida Krusei. Fungal Biol. 2011, 115, 302–309. 
(11)  Huang, Y.-C.; Han, Y.-S. Determining Anti-Betanodavirus Compounds through a GF-
1 Cell-Based Screening Platform. Antiviral Res. 2014, 105, 47–53. 
(12)  Pubchem Bioassay: qHTS for inhibitors of binding or entry into cells for Marburg 
Virus http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=540276 (accessed Jul 8, 
2014). 
(13)  Pubchem Bioassay: Highthroughput screening of inhibitors of Mycobacterium 
tuberculosis H37Rv http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1332 
(accessed May 7, 2014). 
141 
 
(14)  Pubchem Bioassay: qHTS profiling for inhibitors of Plasmodium falciparum 
proliferation 
http://pubchem.ncbi.nlm.nih.gov/assay/asis.cgi?reqid=2312105874255158940&q=r&v
ersion=1.3 (accessed Jul 8, 2014). 
(15)  Pubchem Bioassay: qHTS for differential inhibitors of proliferation of Plasmodium 
falciparum line 3D7 http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1876 
(accessed Jul 8, 2014). 
(16)  PubChem BioAssay: qHTS for differential inhibitors of proliferation of Plasmodium 
falciparum line W2 http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1883 
(accessed Jul 8, 2014). 
(17)  Pubchem Bioassay: Primary qHTS for delayed death inhibitors of the malarial parasite 
plastid, 96 hour incubation 
http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=504834 (accessed Jul 8, 2014). 
(18)  Nwaka, S.; Besson, D.; Ramirez, B.; Maes, L.; Matheeussen, A.; Bickle, Q.; Mansour, 
N. R.; Yousif, F.; Townson, S.; Gokool, S.; et al. Integrated Dataset of Screening Hits 
against Multiple Neglected Disease Pathogens. PLoS Negl. Trop. Dis. 2011, 5, e1412. 
(19)  Martini, A.; Moro, E.; Marrari, P.; Pacciarini, M. A.; Sega, R.; Dell’Osso, L.; Bertelli, 
A.; Tamassia, V. Pharmacokinetics and Bioavailability of Metergoline in Healthy 
Volunteers after Single I.v. and Oral Administration. Int. J. Clin. Pharmacol. Res. 
1983, 3, 27–34. 
(20)  Vicario, G. P.; Battaglia, R.; Bernardi, L.; Arcamone, F. Metabolism of Metergoline in 
the Rat. Farmaco. Sci. 1982, 37, 651–662. 
(21)  Singh, K.; Kaur, G.; Mjambili, F.; Smith, P. J.; Chibale, K. Synthesis of Metergoline 
Analogues and Their Evaluation as Antiplasmodial Agents. Medchemcomm 2014, 5, 
165. 
(22)  Cai, J.; Henion, J. Elucidation of LSD in Vitro Metabolism by Liquid Chromatography 
and Capillary Electrophoresis Coupled with Tandem Mass Spectrometry. J. Anal. 
Toxicol. 1996, 20, 27–37. 
(23)  Lehner, A. F.; Craig, M.; Fannin, N.; Bush, L.; Tobin, T. Fragmentation Patterns of 
Selected Ergot Alkaloids by Electrospray Ionization Tandem Quadrupole Mass 
Spectrometry. J. Mass Spectrom. 2004, 39, 1275–1286. 
(24)  Mohamed, R.; Gremaud, E.; Tabet, J.; Guy, P. A. Mass Spectral Characterization of 
Ergot Alkaloids by Electrospray Ionization , Hydrogen / Deuterium Exchange , and 
Multiple Stage Mass Spectrometry : Usefulness of Precursor Ion Scan Experiments. 
Rapid Commun. Mass Spectrom. 2006, 20, 2787–2799. 
(25)  Ohashi, N.; Furuuchi, S.; Yoshikawa, M. Usefulness of the Hydrogen--Deuterium 
Exchange Method in the Study of Drug Metabolism Using Liquid Chromatography-
Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 1998, 18, 325–334. 
142 
 
(26)  Lu, Y.; He, Y.; Wang, M.; Zhang, L.; Yang, L.; Wang, Z.; Ji, G. Characterization of 
Nuciferine Metabolism by P450 Enzymes and Uridine Diphosphate 
Glucuronosyltransferases in Liver Microsomes from Humans and Animals. Acta 
Pharmacol. Sin. 2010, 31, 1635–1642. 
(27)  Drug Metabolism Handbook: Concepts and Applications; Nassar, A. F.; Hollenberg, 
P. F.; Scatina, J., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009. 
(28)  Arcamone, F.; Francesclii, G.; Glasser, A.; Dorigotti, L. US Patent US360046; 1,6-
Dimethyl-10a-Ergoline Derivatives. US360046, 1972. 
(29)  Di Salle, E.; Praga, C.; Castegnaro, E. US Patent US 4151283A; 6-Methyl-and 1,6-
Dimethyl-8β-Carbobenzyloxy-Aminomethyl-10α-Ergoline as Inhibitors of Prolactin 
Secretion. US 4151283 A, 1979. 
(30)  Cocchi, D.; Locatelli, V.; Carminati, R.; Müller, E. E. Mechanisms Underlying the 
















Chapter 4  
FUSIDIC ACID ANALOGUES 
4.1 Background 
Fusidic acid is a naturally occurring fusidane antibiotic produced by Fusidium coccineum, 
and various other fungi.
1,2
 It has been in use since the 1960s for the management of gram 
positive infections, and more recently against methicillin resistant Staphyloccus aureus. 
While fusidic acid is the only fusidane antibiotic in clinical use, there are a number of 
naturally occurring fusidanes with antibiotic activity (Figure 4.1), including helvolic acid,
3
 
cephalosporin P1 and its analogues,
4
 viridomidic acids (A, B, C)
5
 and a number of fusidic 
acid co-metabolites (keto- ,anhydrofusidic acid analogues and their stereoisomers).
2,6,7
 They 
are in general less active than fusidic acid or have activity against a narrower range of 




Figure 4.1: Examples of naturally occuring fusidanes
7
 
The antibacterial activity of fusidic acid is thought to be a result of its inhibition of protein 
synthesis, by stabilisation of the elongation factor-GDP complex, therefore preventing 
peptide elongation.
8,9
 This unique mode of action prevents cross resistance with commonly 




Various groups have also reported that fusidic acid has activity against Mycobacetrium 
tuberculosis (M.tb), with activity shown against common lab test strains and clinical 
isolates.
11–13
 While this activity has been known for more than 2 decades now, no fusidic acid 
derivatives have been tested against M.tb. Given the slow pace of drug development in 
tuberculosis and the lack of cross resistance between fusidic  acid against other 
antimycobacterial agents, the repurposing and repositioning of fusidic acid and its derivatives 
would represent a ‘low-hanging fruit’ in TB drug discovery. Moreover, fusidic acid has been 





 This work is part of a larger project to explore the activity of fusidic acid 
derivatives and contribute to efforts for identification of potential anti-tuberculosis drugs.
15
 
4.1.2 Metabolism of Fusidic acid 
Hepatic metabolism, followed by excretion in bile, is the main clearance route for fusidic 
acid. The acyl glucuronide is the major metabolite produced, together with the 3-keto-, 27-
carboxy-, and a hydroxylation metabolite as minor metabolites (Figure 4.2). These 











4.2 Metabolism studies 
4.2.1 Compound selection 
The compound set for the metabolic studies was selected based on biological activity and also 
on the availability of similar derivatives to allow for preliminary structure-metabolism work. 
The compounds are C-3 (esters, hydroxylamines) and C-21(esters, amides, hydrazines) 
derivatives with antimycobacterial and/or antiplasmodial activity. A summary of these 
compounds is presented in Figure 4.3 and their biological activity is presented in the relevant 
sections.  
 
Figure 4.3: Summary of C-3 and C-21 derivatives for metabolic studies 
A preliminary analysis of a number of derivatives showed that RLM and MLM metabolism 
was similar. Further, while there were some qualitative differences between the rodent 
microsomes and HLM, the metabolic stability was comparable. The data presented is 
therefore that for RLM stability. Important differences in the qualitative or quantitative data 
are, however, outlined where relevant. It was also anticipated that the 16-acetyl group of 
these derivatives, and the ester and amide functions of some of the derivatives might be 
unstable in plasma. Data on rat plasma stability is therefore also presented, with any 




4.2.2 Analytical considerations 
Unlike the compounds presented in previous chapters, fusidic acid derivatives present a 
number of analytical challenges that are of relevance to the quality and nature of the data. 
First, the MS sensitivity of the respective precursor ions (M+H) is very poor in both positive 
mode electrospray ionisation, and is not greatly improved in negative mode. In its place, a 
number of adducts are detected (Figure 4.4).  
 
Figure 4.4: Mass spectrum of the precursor ion of fusidic acid and its commonly observed 
adducts in ESI positive mode 
Both the sodium and potassium adducts showed poor CID fragmentation. In addition, it has 
been reported that the detection of these adducts is often irreproducible producing wide 
variations in quantitation.
18,19
 However, in the presence of ammonium ions, an ammonium 
adduct was observed that also gave good CID spectra. The derivatives were therefore 
analysed in a mobile phase containing 5mM ammonium formate, to enhance formation of this 
adduct. The presence of the sodium and potassium adducts was used to confirm the molecular 
weight of the metabolites. 
 
 +EMS: Exp 1, 6.159 to 6.182 min from Sample 1 (Fusidic acid T0) of RLM.wiff (Turbo Spray), subtracted (5.927 to 6.112 min and 6.23 to... Max. 7.0e7 cps.











































The second problem involves the in-source lability of these compounds leading to extensive 
in-source fragmentation. This was controlled slightly by using flow injection optimisation to 
optimise the source conditions for the detection of fusidic acid and a number of its most 
unstable derivatives. However, as can be seen in Figure 4, these conditions still produced 
significant fragmentation. However, this paralleled CID fragmentation and it was therefore 
used, together with the presence of adducts to confirm the presence and identity of the 
metabolites.  
 






 +EMS: Exp 1, 6.159 to 6.182 min from Sample 1 (Fusidic acid T0) of RLM.wiff (Turbo Spray), subtracted (5.927 to 6.112 min and 6.23 to... Max. 7.0e7 cps.
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4.2.3 Fragmentation of fusidic acid 
The fragmentation pattern of fusidic acid and its derivatives is generally quite ambiguous. 
Following loss of the 16-acetyl group (to give m/z 457 in fusidic acid), sequential losses of 
water (18Da) and finally the carbonyl produce the fragments from m/z 439 to m/z 393. From 
here, sequential losses of ethylene and other hydrocarbon fragments occur to give the rest of 
the fragments. It is therefore in general more difficult to pinpoint the region of metabolism 
using the data available.  
 





 +EPI (534.40) CE (40): 18 MCA scans from Sample 2 (EPI 534.4 CE40) of NH4 form.wiff (Turbo Spray) Max. 4.1e7 cps.



































4.2.4 Fusidic acid and other C-3 derivatives 




























acid       
<0.1563 61 74 4.45 
GKFA37       1.25 8 74 4.39 
GKFA34 
 
2.5 >99 80 4.68 
GKFA46 
  
20 95 >99 4.96 
a
Drug sensitive strain of Mycobacterium tuberculosis.  
b 
% remaining after 1hr incubation at 0.4mg/ml rat liver microsomes.  
c 
% remaining after 3hrs incubation in rat plasma 
 
The metabolism of fusidic acid in rat liver microsomes gave three products; two were 
tentatively identified as hydroxyfusidic acid, and ketofusidic acid. 
 
Figure 4.7: Extracted ion chromatogram of fusidic acid metabolites from the RLM+NADPH 
incubation 
 
XIC of +MRM (9 pairs): Exp 1, 532.408/455.400 Da  from Sample 32 (Fusidic acid T60 MRM IDA) of RLM.wiff (Turbo Spray) Max. 7000.0 cps.

































The specific position of metabolism is unclear from the fragmentation data. However, the 
ketofusidic acid had a retention time and fragmentation similar to GKFA37 and is therefore 
proposed to be 3-ketofusidic acid. This would also be consistent with the reported in vivo 
metabolism of fusidic acid. 
An additional metabolite was observed with the same m/z and fragmentation (both source 
and CID) as fusidic acid, but eluting about a minute earlier.  
Figure 4.8: CID spectra of fusidic acid (A) and unknown metabolite (B) 
 +EPI (534.41) Charge (+0) CE (40) CES (25) FT (250): Exp 2, 6.121 to 6.175 min from Sample 32 (Fusidic acid T60 MRM IDA) of RLM.... Max. 2.3e6 cps.

























119.3 187.4 201.4133.4 279.3 351.4297.391.2 229.4 375.5403.6 475.4
 +EPI (534.41) Charge (+0) CE (40) CES (25) FT (250): Exp 2, 4.860 to 4.922 min from Sample 33 (3-ketofusidic acid GKFA37 T60 MR... Max. 3.7e6 cps.



































The same metabolite was also observed in incubations of GKFA37 (3-ketofusidic acid), 
where it was formed along fusidic acid as one of the metabolites. In the absence of NADPH, 
these metabolites formed in about equal proportion but the proportion of the unknown 
metabolite was higher in the presence of NADPH. 
 
Figure 4.9: Extracted ion chromatogram of the two metabolites of GKFA37, in the absence 
and presence of NADPH 
 
This metabolite is proposed to be 3-epifusidic acid. Based on its formation in incubations of 
3-ketofusidic acid (GKFA37), it is proposed that in fusidic acid incubations, the metabolite is 
formed through oxidation of the C-3 OH to form the 3-keto, with the reverse reaction 
producing either fusidic acid or 3-epifusidic acid (Figure 4.10). This metabolite is reported to 




Figure 4.10: Proposed pathway for conversion of fusidic acid to 3-epifusidic acid in RLM 
 
XIC of +MRM (9 pairs): Exp 1, 532.408/455.400 Da  from Sample 35 (3-ketofusidic acid GKFA37 T60 -NADPH MRM IDA) of RLM.wiff (T... Max. 2.7e5 cps.


























XIC of +MRM (9 pairs): Exp 1, 532.408/455.400 Da  from Sample 33 (3-ketofusidic acid GKFA37 T60 MRM IDA) of RLM.wiff (Turbo Spra... Max. 1.9e5 cps.





































A similar pathway has been proposed for C-3 epimerisation in a number of steroids.
21
 While 
the same pathway was observed in MLM, no C-3 epimerisation was observed in HLM. 
Instead, the proportion of 3-ketofusidic acid increases, and its hydroxylation metabolite is 
also observed.  
 
Figure 4.11: XICs of the HLM metabolites of fusidic acid 
Despite this difference, the microsomal stability of fusidic acid under these experimental 
conditions was comparable in all three species (65% ± 5%, remaining).  
O-dealkylation was detected for GKFA46, leading to formation of GKFA34. No metabolites 
were detected in incubations of GKFA34. 
In plasma, hydrolysis of the 16-acetyl group followed by spontaneous lactonisation was 
observed as the only product. This process is reported even in aqueous solution, in 




Figure 4.12: C-16 hydrolysis in fusidic acid 
 
XIC of +MRM (18 pairs): Exp 1, 532.408/455.400 Da  from Sample 13 (Fusidic acid HLM T60) of HLM and MLM.wiff (Turbo Spray)
 offset by 0.40 min
Max. 4.5e4 cps.
























4.2.5 C-3 esters 








































19.0 2.5 8 79 5.25 
GKFA16 
 
14.9 1.25 15 74 5.43 
GKFA17 
 
7.46 2.5 20 73 5.62 
ME166 
 
2.0 20 68 79 5.86 
ME168 
 
2.63 20 93 95 5.63 
ME175 
 
0.39 >160 >99 74 6.64 
ME176 
 
1.07 >160 93 >99 6.24 
ME177 
 
1.52 >160 70 81 5.62 
a
Drug sensitive strain of Plasmodium falciparum.  
b
Drug sensitive strain of Mycobacterium tuberculosis.  
c 
% remaining after 1hr incubation at 0.4mg/ml rat liver microsomes.  
d 
% remaining after 3hrs incubation in 50% rat plasma 
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Both the alky and aryl esters are metabolised in RLM almost exclusively to fusidic acid. The 
alkyl esters are in general less stable than the aryl esters and their stability increases almost 
linearly with chain length and lipophilicity. Fusidic acid formation is observed in both cases , 
is not NADPH dependent and occurs quickly enough that it is detectable even in the T0 
incubations. 
 
Figure 4.13: Metabolism of GKFA17 in RLM incubations 
 
XIC of +EMS: Exp 1, 618 to 619 Da from Sample 11 (GKFA17 T0) of RLM.wiff (Turbo Spray) Max. 2.9e8 cps.

























XIC of +EMS: Exp 1, 618 to 619 Da from Sample 12 (GKFA17 T60 -NADPH) of RLM.wiff (Turbo Spray) Max. 5.3e7 cps.





























XIC of +EMS: Exp 1, 618 to 619 Da from Sample 13 (GKFA17  T60) of RLM.wiff (Turbo Spray) Max. 5.8e7 cps.















































Among the aryl esters, a hydroxylated metabolite is also produced. The CID fragmentation 
data show fragments that are 2Da lower than the corresponding fragments in the parent 
compound.  
 
Figure 4.14: CID fragmentation of ME166 and its hydroxylated metabolite 
While the same fragments could also be interpreted as +16Da (for example 437.4 could either 
be 421 + 16 or 439 -2), the relative intensities of the peaks support the earlier interpretation. 
This suggests that hydroxylation occurs somewhere on the fusidic acid core, and that during 
 +EPI (561.61) Charge (+0) CE (40) CES (25) FT (250): Exp 2, 8.911 to 8.974 min from Sample 36 (ME166  T60 MRM IDA) of RLM.wiff (... Max. 5.6e6 cps.
























 +EPI (654.61) Charge (+0) CE (40) CES (25) FT (250): Exp 2, 7.263 to 7.313 min from Sample 36 (ME166  T60 MRM IDA) of RLM.wiff (... Max. 7.0e5 cps.

































ME166 + OH 
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MS analysis the new hydroxyl group is lost as water with a double bond forming at this 
position, hence the loss of 2 Da.  
Metabolism in plasma also produces fusidic acid, though the process is slower compared to 
RLM incubations. The differences between the alkyl and aryl esters are also less pronounced, 
which is expected since different enzymes are involved, as discussed later in this chapter. The 
plasma stability of GKFA17 and ME166 was further evaluated in human and in mouse 
plasma. Compared to their stability in rat plasma, both compounds were more stable in 
human plasma (>99% remaining at 3hrs) and drastically less stable in mouse plasma ( <10% 












4.2.6 C-21 aryl esters  




































ME-29 H 2.40 >160 15 >99 5.71 
ME-32 4-F 2.95 >160 14 96 5.86 
ME-14 4-Cl 2.30 >160 68 >99 6.16 
ME-19 4-Br 2.14 >160 68 67 6.31 
ME-12 3-F 2.64 >160 21 >99 5.80 
ME-11 3-Cl 1.39 160 63 86 6.10 
ME-30 3-Br 2.64 >160 52 >99 6.24 
ME-15 3-OMe 1.75 >160 3 >99 5.49 
ME-23 3,4-Cl 3.56 >160 80 95 6.53 
ME-25 2,4-Cl 3.51 >160 45 >99 6.53 
a
Drug sensitive strain of Plasmodium falciparum.  
b
Drug sensitive strain of Mycobacterium tuberculosis.  
c 
% remaining after 1hr incubation at 0.4mg/ml rat liver microsomes.  
d 
% remaining after 3hrs incubation in 50% rat plasma 
 
A preliminary examination of the data suggests that for comparing the non-substituted and 
the halogen-substituted derivatives, metabolic stability varies in the order  -Br ≈ -Cl > F ≈ H 
at both the 3- and 4- positions. While these data may suggest that metabolism occurs on the 
ester substituent, the metabolism of these compounds is actually similar to the metabolism of 
fusidic acid with the 3-epi, 3-keto and hydroxy- metabolites in RLM and the 3-keto- and 
hydroxyfusidic acid in HLM. Similar to the metergoline derivatives presented in Chapter 4, 
the effect of the substituent may be in aligning the compound within the active site of the 
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CYP450s, with certain orientations resulting in more efficient metabolism. The increase in 
lipophilicity does play a role but as observed with the 2,4- and 3,4 diCl- derivatives ( same 
lipophilicity, different metabolic stabilities), it is not the only factor influencing the patterns. 
ME-15 is in addition also metabolised by O-dealkylation explaining its much lower 
metabolic stability. 
Unlike the C-3 esters, fusidic acid is not observed as a metabolite in microsomal incubations 














4.2.7 C-21 Alkyl esters and amides 



































d Log P 
GKFA48 
   
nd 40 <10 65 4.55 
ME-81 
  




















2.96 20 5 83 4.00 
a
Drug sensitive strain of Plasmodium falciparum.  
b
Drug sensitive strain of Mycobacterium tuberculosis.  
c 
% remaining after 1hr incubation at 0.4mg/ml rat liver microsomes.  
d 
% remaining after 3hrs incubation in 50% rat plasma 
 
Unlike their aryl counterparts, all the alkyl esters are very unstable in RLM and are also less 
stable in rat plasma. Fusidic acid (and 3-ketofusidic acid for GKFA48) is observed as minor 
NADPH dependent metabolite, suggesting that just like for the C-21aryl esters, they do not 




The metabolites are a variety of hydroxylation products as shown in Figure 4.15 
 
Figure 4.15: XICs of the RLM metabolites of GKFA48 
 
An additional metabolite, whose ammonium adduct is 30Da higher than that of GKFA48 is 
also observed. While the fact that this is 2Da lower than the dihydroxylation metabolite may 
suggest a keto- metabolite, the later elution relative to all the dihydroxylation metabolites is 
inconsistent with the observed pattern for the other fusidic acid derivatives where the keto- 
metabolites elute earlier than their respective parent compounds. In addition, the most 
common site of keto- formation, C-3, is already oxidised in this derivative. This metabolite is 
therefore proposed to be the carboxy- derivative of GKFA48.  
XIC of +MRM (21 pairs): Exp 1, 546.508/469.200 Da  from Sample 13 (GKFA48 T60) of RLM.wiff (Turbo Spray) Max. 9350.0 cps.

































Figure 4.16: Enhanced product ion spectra of GKFA48 and its carboxy- metabolite 
 
While carboxyfusidic acid is reported as one of the in vivo metabolites of fusidic acid in man, 
it was not observed in vitro for fusidic acid and was only observed in incubations with 
GKFA48 and ME-81.  
 
 +EPI (469.51) Charge (+0) CE (25) CES (25) FT (250): Exp 2, 7.652 to 7.704 min from Sample 11 (GKFA48 T0) of RLM.wiff (Turbo Spr... Max. 1.1e6 cps.



































 +EPI (578.51) Charge (+0) CE (25) CES (25) FT (250): Exp 2, 3.596 to 3.698 min from Sample 13 (GKFA48 T60) of RLM.wiff (Turbo Sp... Max. 3.8e5 cps.































433.4297.3 405.3 561.3279.4 387.3305.4
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The alkyl amides were detected as their M+H ions rather than as ammonium adducts 
observed with the previously discussed analogues. The precursor ions of the metabolites 
formed suggested hydroxylation and dehydrogenation (-2Da) metabolites.  
 
Figure 4.17: Extracted ion chromatograms of GKFA56 and its RLM metabolites 
The tentative identification of the metabolites relied on the identification of the fragments 
resulting from the fusidane nucleus and those resulting from the amide substituent. This was 
more difficult to do for GKFA52 and -54 where the substituents were smaller and were 
generally not detected in the CID spectra. There was, however, some success with GKFA56. 
A higher collision energy (85V, compared 30 – 40V for other derivatives) was required to 
observe the fragment(s) resulting from the piperidinol substituent. A wide collision energy 
spread (25V) helped ensure that the low energy fragments were still observed. The main 
fragment observed from the piperidinol substituent was m/z 84, probably resulting from a 
loss of water following amide cleavage. This fragment was, however, not observed when 
metabolic transformation occurred on the piperidinol substituent but the site of metabolism 
XIC of +MRM (13 pairs): Exp 1, 596.608/536.300 Da  from Sample 5 (GKFA56 T60 MRM IDA CE 85+25) of RLM.wiff (Turbo Spray) Max. 1.3e5 cps.





































could be inferred from the mass changes (or lack thereof) on the fusidic acid core fragments. 
A summary of the metabolites detected for GKFA56 is presented in Table 4.5 










 Tentative identification 
M1 614 6.28 554 435 84 Hydroxylation and  -2H on 
fusidane core  
M2 616 6.39 556 419
c
 84 Hydroxylation on fusidane core 
M3 616 6.51 556 - 84 Hydroxylation on fusidane core 
M4 614 6.59 554 - - Hydroxylation  – 2H  
M5 614 6.76 554 419
 
- Hydroxylation on piperidinol, 
– 2H on fusidane, 
M6 614 6.87 554 419 100
 
Hydroxylation on piperidinol, 
– 2H on fusidane, 
M7 598 7.12 538 419 84 – 2H on fusidane  
M8 596 7.52 536 419 - – 2H on fusidane, -2H on 
piperidinol 
M9 598 7.64 538 421 - – 2H on piperidinol 
M10 596 7.93 536 421 - -4H on piperidinol 
Parent 600 7.23 540 421 84 Parent 
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While it was not possible to process GKFA54 and GKFA52 metabolism to the same degree, 
the change in m/z of the metabolites relative to the respective parent compounds, (-4, -2, +14, 
+16) suggests a similar metabolic profile. The dehydrogenation site on the fusidane is most 
probably at C-3 to form the keto- metabolite. This is suggested by the retention time of M7 
relative to the parent, which is consistent with the profile observed for the other 3-keto 
metabolites, for example for Fusidic acid (Figure 4.11) where the identity was confirmed 
with the authentic compound (GKFA37). This is in contrast to M9 which elutes after the 
parent, and for which the fragmentation data suggests dehydrogenation of the piperidinol. 
The site of dehydrogenation on the piperidinol is unclear from the data available, because of 













4.2.8 C-21 hydrazides 

































d Log P 
KSFA16 
 
>10 10 34 >99 3.46 
KSFA40 
 




>10 10 39 >99 3.84 
GKFA24 
 
nd 10 84 >99 3.82 
*
24,25 double bond reduced.  
a
Drug sensitive strain of Plasmodium falciparum.  
b
Drug sensitive strain of Mycobacterium tuberculosis.  
c 
% remaining after 1hr incubation at 0.4mg/ml rat liver microsomes.  
d 
% remaining after 3hrs incubation in rat plasma 
 
The microsomal stability of the sulfonohydrazide derivatives was lower compared to the 
single carboxohydrazide (GKFA24) evaluated. The sulfonohydrazides underwent NADPH 
dependent cleavage of the linker to fusidic acid in the case of KSFA16 and -40 or to 24,24-






Figure 4.18: Extracted ion chromatogram of KSFA40 and its RLM metabolites 
 
Cleavage of the linker to release fusidic acid implies that the sulfonohydrazine group is also 
released. This could be considered a structural alert for these compounds since hydrazine 
derivatives are reported to mediate various organ toxicities through metabolic bioactivation to 
a variety of reactive intermediates which bind to biomolecules resulting in cell death or 
immune-mediated reactions.
23,24
 These derivatives would therefore need to be evaluated 
further to investigate the possibility of their metabolic activation.  
GKFA24 is basically an isoniazid-fusidic acid hybrid and isoniazid itself is implicated in 
hepatotoxicity following bioactivation. However, the microsomal metabolism of this 
compound (HLM, MLM, RLM) does not result in cleavage of this linker, as in the 
sulfohydrazides. Instead, just as with most of the fusidic acid derivatives discussed, the 
metabolites were tentatively identified as the 3-keto, 3-epi, and hydroxy- derivatives of the 
compound.  
XIC of +EMS: Exp 1, 555 to 556 Da from Sample 22 (KSFA40  T60) of RLM.wiff (Turbo Spray) Max. 4.1e8 cps.


































Figure 4.19: Extracted ion chromatogram of GKFA24 and its RLM metabolites 
 
4.3 M. smegmatis and M. tb H37Rv incubations  
As has been alluded to in earlier sections, the 16-desacetyl derivative of fusidic acid and its 
lactone have much lower antibacterial activity compared to fusidic acid. Some Nocardia and 




Mycobacteria are reported to possess various hydrolases with activity against xenobiotics. 
Preliminary work was therefore perfomed to establish whether these have any activity 
towards fusidic acid. Incubations were performed with M. smegmatis lysate and the 
supernatant of M. tuberculosis H37Rv.  
Under the conditions used, fusidic acid was stable in the buffer control and in the M.tb 
supernatant. However, its relative concentration reduced with time and the hydrolysis rate 
XIC of +EMS: Exp 1, 634 to 635 Da from Sample 20 (GKFA24 T60 0.1% FA/ACN Mobile phase) of RLM.wiff (Turbo Spray) Max. 5.5e8 cps.
































, leading to a 
half-life of 182 min (± 20min). 
 
Figure 4.20: Stability of fusidic acid in incubations of M. tb supernatant, M. Smeg lysate and 
buffer control 
 
In anticipation of the reported hydrolysis of fusidic acid in other bacteria, the MRM 
transitions of fusidic acid lactone were included in the analytical method, and this compound 
was detected in the M. smegmatis incubations but not in the M. tb or buffer control 






























Figure 4.21: MRM total ion chromatogram of the T360min M. smeg incubation 
 
This preliminary data shows that fusidic acid can undergo inactivation in the cytosol of M. 
smegmatis but is either not hydrolysed or is hydrolysed by a much slower process in M. tb 
H37Rv. It is of relevance to consider that M. smegmatis is a much faster growing organism 
than M. tb H37Rv and even a slow hydrolytic process may be of relevance to the longer 
compound incubation times in M. tb H37Rv. However, the fusidic acid is very active in M.tb 
(MIC99 < 0.1563µM) suggesting that the inactivation process is not of major significance to 
XIC of +MRM (6 pairs): 534.421/457.400 Da  from Sample 11 (Fusidic acid Msmeg T0_1) of curves.wiff (Turbo Spray) Max. 8.0e4 cps.





























XIC of +MRM (6 pairs): 534.421/457.400 Da  from Sample 20 (Fusidic acid Msmeg T360_2) of curves.wiff (Turbo Spray) Max. 2.4e4 cps.







































this organism. This compares with a much higher MIC99 against M. smegmatis (≈ 40µM).  
While there are other biological differences between the two organisms that could contribute 
to this difference, the data presented show that the hydrolase activity is potentially one of the 
contributors.  
16-Deacetylation was observed in all classes of derivatives presented but interestingly, was 
not observed at any other position in derivatives with hydrolysable groups. This implies that 
the hydrolases involved are specific for the 16- position in fusidic acid.  
4.4 Discussion  
The metabolism of fusidic acid in rat and mouse liver microsomes is different from the 
metabolism in human liver microsomes and from that reported in man. The main difference is 
in the formation of a metabolite tentatively identified as the C-3 epimer of fusidic acid. This 
metabolite was also observed in incubations of 3-ketofusidic acid, with the same species 
differences. It is proposed that this metabolite arises from fusidic acid by dehydrogenation at 
C-3 to form the 3-keto derivative, followed by the reverse reaction in a non-stereoselective 
way to produce both fusidic acid and 3-epifusidic acid. A similar mechanism has been 
proposed for another steroid cinobufagin.
27,28
 Interestingly, C-3 epimerisation is also species 
specific in cinobufagin metabolism, with the 3-epi metabolite observed in rat (in vitro and in 
vivo) but not in the mouse or in man. The C-3 epimer was observed for most derivatives with 
a free C-3 OH and was only observed when the 3-keto metabolite was also present. While the 
clearance of fusidic acid is known to be faster in rodents than in man, there is no information 
to suggest that this is due to species specific metabolite pathways.
29
 In addition, fusidic acid 
has been reported to autoinhibit its clearance at higher doses in man, through currently 
unelucidated mechanisms.
17,30,31
 There is again no information on whether this autoinhibition 
is present in animal models and/or whether it contributes to the observed difference in 
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clearance. It will therefore be of interest as these derivatives are progressed to in vivo studies 
to see whether the 3-epi metabolite is observed and to assess its overall contribution to fusidic 
acid clearance in the animal models.  
In plasma, fusidic acid was slowly hydrolysed to its lactone. This process was faster in rodent 
plasma but was unobserved in human plasma. Hydrolysis in plasma was additionally 
observed for the C-3 esters, which were hydrolysed to fusidic acid. The stability in plasma 
varied in the order, mouse>>rat>man which approximates the reported hydrolase activity of 
these species.
32
 The hydrolytic activity is likely to be higher than reported here in vivo 
because of the contribution of esterases on red blood cells and leucocytes.
33
   
C-3 ester derivatives were hydrolysed to fusidic acid in RLM, but this was not observed for 
the C-21 esters. Hydrolysis of the C-3 but not C-21 esters in RLM would appear to indicate 
carboxylesterase-2-like (CES-2) activity, as discussed in Chapter 1.
34
 However, in rats, CES-
2 is mostly located in the small intestines where it contributes to first pass metabolism, and is 
negligible in the rat liver.
35,36
 It is more likely that the RLM hydrolysis of these compounds is 
by CES-1 esterases, which are known to catalyse the same reaction but at slower rates.
37
  It 
has been reported that as CES-1 enzymes contribute as much as 95% of the carboxylesterase 
activity in the rat liver.
38
 Hydrolysis should then be expected in C-21 derivatives, where there 
is the combination of a large acyl group (fusidane core) and small alcohol group, reported as 
the ideal substrate composition for CES-1.
39
 However, even for compounds with 
comparatively small groups (e.g methyl GKFA48, ethyl ME-81) hydrolysis is not observed. 
Hydrolysis is also not observed at C-16 in microsomes of all species tested. This suggests that 
steric factors are at play, protecting these positions from hydrolytic activity. Metabolism at C-
21 was only observed for the sulfonohydrazides which were metabolised to fusidic acid. 
However, this reaction was NADPH dependent.  
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C-16 hydrolysis was also observed in the M. smegmatis lysate but not in the M.tb H37Rv 
supernatant. The half-life of fusidic acid in the M. smegmatis lysate was about 3 hours. This 
observation is of interest because a similar phenotype in some Nocardia and Streptomyces 
species is associated with fusidic acid resistance. Mutant generation work is in progress for 
the larger fusidic acid project and it would be of interest to see whether this hydrolytic 
activity is observed in the fusidic acid resistant M.tb organisms generated.  
A comparison of these experimentally observed metabolites with StarDrop predictions is 
complicated by the fact that unlike the compounds previously discussed, the fragmentation 
pathway is more ambiguous for fusidic acid complicating the identification of the sites of 
metabolism. Both C-27 (labelled as C33,34 in the StarDrop model) and C-3 were predicted 
by StarDrop as the main sites of metabolism by CYP3A4, 2D6, and 2C9, but also as the most 
inherently labile sites (CYP3A4). 27-carboxyfusidic acid and 3-ketofusidic acid are reported 












Figure 4.22:  StarDrop predicted sites of metabolism for fusidic acid assuming metabolism by CYP3A4. (The percentages show the expected proportion 
of metabolites that would result from metabolism at the indicated position and the colors ndicate the lability of the positions; red – labile, yellow – moderately labile, green – 
moderately stable, blue – stable) 
 
 
CYP3A4 CYP2D6 CYP2C9 
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Finally, it is interesting to note that despite the close similarities between the physicochemical 
properties of fusidic acid and most of its metabolites, their biological activity is invariably 
lower than that of fusidic acid. 
Table 4.7: Biological activity and physicochemical properties of fusidic acid and selected 
metabolites 





LogP LogD TPSA 
3-ketofusidic acid 0.622 1.25 4.39 1.56 101 
Fusidic acid 
lactone 
11.8 nd 4.35 4.35 67 
3-epifusidic acid 12.2 nd 4.45 1.38 104 
Fusidic acid 
glucuronide 
17.3 nd 1.59 0.99 200 
Fusidic acid 0.112 <0.156 4.45 1.38 104 
 
This suggests that the structural characteristics required for binding to the target are very 
strict such that any modifications lead to loss of activity. Indeed, of all the structural 
analogues of fusidic acid synthesised, only 24,25-dihydrofusidic acid has antibacterial 
activity comparable to fusidic acid, with all others being less active. This is also illustrated by 
the fact that 3-epifusidic acid and fusidic acid glucuronide retain only 30 -40% of the activity 
of fusidic acid at the target
8
. It has been reported that 3-ketofusidic acid may accumulate in 
plasma to levels about 15% of the fusidic acid concentration and its Cmax is several times 
higher than its MIC against both S. aureus and M.tb.
17,40
  Since this metabolite retains some 
of the activity of fusidic acid (against both M. tb and S. aureus) it would be expected to 
contribute to the in vivo activity of fusidic acid. While the properties of the glucuronide are 
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much more different compared to fusidic acid and the rest of the metabolites, it is notable that 
this metabolite retains activity against the target.
8
 Therefore, if this metabolite could access 
the intracellular space, even through an active transport process, it could contribute to the 
activity of fusidic acid. However, the relevance of this metabolite is likely to be in 
maintaining fusidic acid levels through enterohepatic circulation. While no direct evidence of 




Finally, we have recently reported that drug metabolites may contribute to antimycobacterial 
activity when tested in combination with other antimycobacterials, even when their activity is 
lower than the parent drug.
41
 Since antituberculosis regimens are invariably administered in 
combination, it would be of interest to investigate any synergism between these metabolites 
and other antimycobacterial compounds. This would be particularly interesting with 3-
ketofusidic acid, whose levels in plasma are already established. 
4.5 Summary 
The microsomal and plasma metabolism of fusidic acid and its derivatives was evaluated. 
Fusidic acid was found to undergo species specific metabolism to a metabolite tentatively 
identified as 3-epifusidic acid. This metabolite was also found in all other derivatives with a 
free C3-OH and is hypothesised to result from oxidation at C-3 followed by non-
stereoselective reduction to fusidic acid and 3-epifusidic acid. C-3 esters were metabolised 
almost exlusively by hydrolysis to fusidic acid. This process was observed in both 
microsomes and plasma and was faster in mouse plasma, compared to rat plasma and was 
hardly detectable in human plasma. Interestingly C-21 esters did not undergo hydrolysis to 
fusidic acid. The metabolism of the aryl esters paralleled that of fusidic acid and that of the 
alkyl esters involved multiple hydroxylations, including the formation of a metabolite 
tentatively identified as carboxyfusidic acid. The C-21 alkyl/cycloalkyl esters also underwent 
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multiple hydroxylations, both on the fusidic acid core and on the amide substituent. Among 
the hydrazides, metabolism was by NADPH dependent cleavage of the sulfonohydrazide 
linker to give fusidic acid. The isoniazid prodrug, however, underwent a different metabolic 
pathway that had more in common with that of fusidic acid. The 16-acetyl group of fusidic  
acid was cleaved in M.smegmatis but not M. tb H37Rv to give 16-deacetylfusidic acid and its 
lactone, both of which are reported to have less antibacterial activity compared to fusidic 
acid. 
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Chapter 5  
SUMMARY, CONCLUSIONS AND  
RECOMMENDATIONS FOR FUTURE WORK 
 
5.1 Summary and conclusions 
The broad aim of this work was to investigate the in vitro metabolism of tetrazole 
aminoquinolines, and derivatives of metergoline and fusidic acid. This work was carried out 
as part of medicinal chemistry exploration of these compounds as antiplasmodial and/or 
antimycobacterial agents. 
The tetrazole deoxyamodiaquines with the best biological activity were also the most 
metabolically unstable. In vitro metabolite identification work in microsomes and 
hepatocytes showed that the metabolism occurred exclusively on the tertiary nitrogen 
substituent. Compounds with simple alkyl substituents were metabolised by N-dealkylation 
while those with cycloalkyl substituents were metabolised by multiple oxidations on the 
cycloalkyl ring. The latter derivatives also formed cyanide adducts implying that their 
metabolism follows the classical cycloalkylamine metabolic pathway involving iminium ion 
formation followed by α-hydroxylation on the cycloalkylamine. Compounds lacking a tert-
butyl substitution on the tetrazole were more metabolically stable but also had lower 
biological activity. However, the tetrazole deoxyamodiaquines did not form glutathione 
adducts as reported for amodiaquine. This finding was expected because, as discussed in 
Chapter 2, glutathione adducts of amodiaquine are formed following formation of the 
reactive quinoneimine metabolite, which then reacts with glutathione (See Figure 2.1). These 
compounds are deoxyamodiaquines – in which the 4’-hydroxyl group required for 
183 
 
bioactivation is absent. Moreover, the phenyl ring is not a site of metabolism, and these 
compounds would therefore not be expected to form glutathione adducts.  
 StarDrop correctly predicted the top site of metabolism for both TK2 and TK3. However, it 
also predicted the 8- position on the aminoquinoline ring as a site of metabolism – this was 
not observed experimentally. These compounds were also potent CYP450 inhibitors – TK2 
and TK3 showed potent inhibition of CYP2C8 and CYP3A4 and moderate inhibition of most 
other CYP450s. Only CYP1A2 and CYP2E1 were not inhibited. Docking experiments with 
CYP3A4 suggest that these compounds orient in differently in the active site leading to 
stronger interactions, as suggested by their binding energies which are lower compared to 
amodiaquine. 
The tetrazole chloroquines were in general less metabolically stable than chloroquine. Unlike 
the tetrazole deoxyamodiaquines, the tert-butyl substitution was one of the sites of 
metabolism in these compounds, with N-oxidation and hydroxylation of the aminouinoline 
ring also occurring. In TK900A and TK900C the aromatic ring on the tertiary nitrogen was 
also a site of metabolism. A glutathione adduct formed on the aminoquinoline ring was also 
observed, possibly because the aminoquinoline ring can be regarded as a masked aniline 
leading to formation of a reactive iminoquinone metabolite if the ring is appropriately 
hydroxylated. All sites of metabolism for these compounds were correctly predicted in 
StarDrop.  While the CYP450 inhibition profile of the tetrazole chloroquines was better 
compared to that of the tetrazole deoxyamodiaquines, these compounds displayed sub-
micromolar inhibition of CYP3A4. This inhibition was not time dependent. The docked 
conformations of these compounds suggest that, just like with the tetrazole aminoquinolines, 
they orient differently in the active site of CYP3A4 leading to more efficient interactions and 
lower binding energies.  
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Metergoline was metabolised mainly by hydroxylation on the ergoline nucleus in contrast to 
its metabolism in vivo where 1-demethylation is the main metabolite. Two demethylation 
products on the ergoline nucleus, presumably corresponding to the 1-demethylation and 6-
demethylation metabolite were also observed, together with 1,6-dimethyl-8-β-
aminomethylergoline, the carbamate hydrolysis metabolite. A hydroxylation metabolite on 
the benzyl substituent was observed only in mouse liver microsome incubations. The 
metergoline derivatives were in general metabolised in a similar way. A major exception was 
the absence of 1,6-dimethyl-8-β-aminomethylergoline, indicating the improved stability to 
metabolic hydrolysis of the amide compared to the carbamate linker. Derivatives with alkyl 
substituents longer than ethyl also underwent alkyl hydroxylations (e.g FRM007 and 
GKMG14). Where the alkyl substituent was on a phenyl ring, as in the case of FRM007, 
hydroxylation of the benzyl –CH2 was also observed . StarDrop correctly predicted all of the 
major metabolites. In the case of metergoline where hydroxylation was observed on the 
benzyl group, StarDrop predicts that the benzyl –CH2 is metabolically labile and as the major 
site of metabolism by CYP2D6. 
Fusidic acid underwent species specific metabolism in rat and mouse liver microsomes to 
give a metabolite tentatively identified as 3-epifusidic acid. This metabolite was formed in all 
derivatives with a free C-3 OH and in 3-ketofusidic acid and is hypothesised to form 
following metabolism at this position to form the C-3 keto which is then reduced in a non-
stereospecific manner to give fusidic acid and 3-epifusidic acid. Fusidic acid was also 
metabolised to give 3-ketofusidic acid and a hydroxylation derivative. C-3, but not C-21, 
esters were hydrolysed to fusidic acid in both microsomes and plasma. In plasma, the rate of 
hydrolysis of the C-3 derivatives varied in the order mouse plasma>>rat plasma>human 
plasma. The acetyl group at C-16 was also hydrolysed in plasma in fusidic acid and its 
derivatives but at a much slower rate. This group was also hydrolysed in a lysate of M. 
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smegmatis but not M. tuberculosis H37Rv leading to formation of fusidic acid lactone. This 
process may contribute to the higher MIC99 of fusidic acid in M. smegamtis compared to M. 
tuberculosis H37Rv. 
5.2 Recommendations for future work 
In considering the work that could be performed to improve the metabolic stability issues 
identified with these derivatives, it is important to remember that most of these derivatives 
were synthesised as part of exploratory work into their antiplasmodial and/or 
antimycobacterial activity. This explains why most of the analogues were broadly similar and 
were generally derived from chemistry at one position. In general therefore, where the 
exploratory work yielded derivatives with good antiplasmodial and/or antimycobacterial 
activity, a more systematic medicinal chemistry campaign should yield a wider variety of 
derivatives which may allow the projects to progress to later drug discovery phases. 
However, the fact that metabolic liabilities were identifiable even at this stage, shows the 
value of early incorporation of drug metabolism work. The knowledge of the sites of 
metabolism gleaned during this exploratory work would be useful in the later, more 
systematic medicinal chemistry campaign. 
While the most active tetrazole deoxyamodiaquines were also metabolically unstable, it is 
notable that no glutathione adducts were detected. This implies that appropriately substituted 
deoxyamodiaquine derivatives can give good antiplasmodial activity while avoiding the 
metabolic bioactivation reported for amodiaquine. This finding could be explored with other 
deoxyamodiaquine derivatives to give the optimal balance between activity,  metabolic 
stability and toxicity. 
The tetrazole chloroquines were found to be less metabolically stable than chloroquine itself 
and their in vivo activity was hypothesised to be subject to dose limited absorption. The 
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toxicity of chloroquine has been associated with its long half-life and less metabolically 
stable analogues are therefore not a disadvantage per se. More important will be the balance 
between in vivo activity and duration of action. Further medicinal chemistry work could focus 
on obtaining more water soluble derivatives to get better absorption. In addition, the increase 
in polarity would have effects on the metabolic stability and on reactive metabolite formation. 
Different formulations of the current derivatives could also be explored.  
Metergoline and its analogues, in general, displayed low (>10µM) antimycobacterial activity, 
but the antiplasmodial activity of a number of derivatives would be worth exploring further, 
especially because most derivatives are more metabolically stable than metergoline. It was 
observed that metergoline was metabolised in microsomes to its 12-hydroxy derivative as the 
major metabolite, while 1-demethylation is reported to be the major metabolite in vivo. This 
difference would be interesting to explore with more active derivatives. Investigations could 
involve CYP450 phenotyping with microsomes and recombinant CYP450s to identify the 
main enzymes involved in formation of these metabolites. It would also be of interest to 
assess the contribution of gut wall metabolism to the formation of the metabolites, possibly 
by using intestinal microsomes and/or S9. These findings would be useful in predicting the 
contribution of metabolites to in vivo activity.   
The preliminary data on the in vitro metabolism of fusidic acid raises a number of questions 
that are worth exploring as the project proceeds. First, the species specific metabolism of 
fusidic acid to 3-epifusidic acid, observed in mouse and rat liver microsomes, would be worth 
exploring in vivo because fusidic acid is known to have a shorter half-life in these species 
relative to man. Another possible contributor to the difference in clearance could be the 
difference in esterase activity in cleavage of the 16-acetyl group. While this pathway did not 
significantly contribute to in vitro clearance (in both microsomes and plasma), the in vivo 
environment has additional enzymes that could contribute to the hydrolysis of this group, 
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notably hydrolases in the wall of the small intestines and on the surface of red blood cells. 
These processes would need to be explored if fusidic acid lactone, the product of the 16-
acetyl hydrolysis, is observed as a major metabolite in vivo. This could be performed using 
intestinal microsomes and fresh blood respectively. The difference in glucuronidation 
kinetics is also a possible reason for the difference in clearance if it is assumed that fusidic 
acid undergoes enterohepatic circulation. These hypotheses should be explored to enable a 
proper understanding of the difference in clearance in animal models relative to man, which 
would allow progression of fusidic acid derivatives through the drug discovery chain.  
Finally, the hydrolysis of fusidic acid in M. smegmatis but not M. tuberculosis H37Rv would 
be interesting to follow up. As discussed, this process is associated with fusidic acid resitance 
in certain species of Nocardia and Streptomyces. It would, therefore, be of interest to 
investigate the hydrolytic activity of fusidic acid resistant mutants of M. tuberculosis, in order 












Chapter 6  
EXPERIMENTAL 
6.1 Reagents and solvents 
Microsomal preparations (Human, Rat, Mouse) were purchased from XenoTech (Kansas, 
USA) through their African distributor, African Institute of Biomedical Sciences and 
Technology (Harare, Zimbabwe). The human liver microsomal preparations were pooled (50 
individuals) mixed gender, and the rat liver microsomes were from male IGS rats (pool of 
433), while the mouse liver microsomes were from male BALB/c mice (pool of 800). All 
microsomal preparations were provided as 20mg/ml suspensions transported in liquid 
nitrogen and were stored at -80°C until use. Each individual vial was used for a maximum of 
three times, to eliminate any variation due to freeze-thaw stability. NADPH (as β-
Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate) was 
purchased from Merck (Johannesburg, South Africa) and was divided to 5 -10mg aliquots 
and stored at -80°C until use. Reduced L-glutathione, UDPGA (as Uridine 5′-
diphosphoglucuronic acid trisodium salt) and potassium cyanide were purchased from Sigma-
Aldrich (Johannesburg, South Africa).  
All solvents and additives for chromatography work were purchased from Merck 
(Johannesburg, South Africa) or from Sigma-Aldrich (Johannesburg, South Africa) and were 
of at least HPLC grade. Deionised water (18Ω) for buffer preparation and HPLC mobile 
phases was collected from a Millipore Synergy water purification system (Microsep, 
Tygervalley, South Africa).  
A different set of reagents and solvents was used for the hepatocyte incubations and for the 




Except where otherwise indicated, all LC-MS analysis was performed on an Agilent 1200 
Rapid Resolution (600 bar) HPLC system consisting of a binary pump, degasser, auto 
sampler and temperature controlled column compartment coupled to an AB SCIEX 4000 
QTRAP mass spectrometer. Analyst (vl.4, 1.5, 1.6, AbSciex, Johannesburg, South Africa ) 
was used for LC-MS control and data acquisition.  
6.3 Compounds for analysis  
The procedures and data for synthesis, characterisation and biological evaluation of the 
aminoquinoline tetrazoles (Chapter 2), and the metergoline analogues (Chapter 3) have 
already been published.
1–3
 Synthetic procedures and data for the fusidic acid analogues will 
appear in publication soon (Kawaljit Singh, Marlene Espinoza, Gurminder Singh et al., 
manuscript in preparation). Metergoline HCl, Chloroquine diphosphate and Amodiaquine 
HCl were purchased from Sigma-Aldrich (Johannesburg, South Africa) while fusidic acid 
was purchased from Avachem Scientific (Texas, USA). 
All compounds were received as dry powders and were reconstituted in DMSO (HPLC grade, 
Sigma-Aldrich, Johannesburg, South Africa) as 10mM stocks and frozen at -80°C until 
required for the assays, when they were thawed at room temperature.  
6.4 Mass spectrometry conditions 
Purified air was used as the nebuliser gas (gas 1) and heater gas (gas 2) and both were in 
general set to 50psi and 60psi respectively. Curtain gas (N2) was generally set at 30psi and 
collision gas (N2) was set to ‘medium’ for MRM experiments and ‘high’ for EMS IDA 
experiments. In general, ionspray voltage was set at 5000V and source temperature at 500°C. 
Compound dependent parameters were optimised by infusing at 10µl/min, a 50nM 
(aminoquinoline tetrazoles, metergoline derivatives) or 500nM (fusidic acid analogues) 
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solution of the compound in 50% mobile phase A/B. No further optimisation was required for 
the aminoquinoline tetrazoles and the metergoline derivatives. For the fusidic acid analogues, 
significant source fragmentation was observed and flow injection analysis (FIA) experiments 
were set up to optimise all source parameters. The parameters used for a representative 
compound in each of the classes analysed for this work is provided in Table 5.1. 
Table 6.1: MS source parameters for representative compounds 
 TK3 TK900E Metergoline Fusidic acid 
Curtain gas 
(psi) 
30 30 30 40 
Ionspray voltage 
(V) 
5000 5000 5000 5000 
Source 
temperature 
500 500 500 350 
Gas 1 
(psi) 
50 50 50 40 
Gas 2 
(psi) 
60 60 60 40 
 
6.5 Chromatography 
The mobile phase for the work in Chapter 2 and 3 was 0.1% formic acid containing 5% 
Acetonitrile (A) and Acetonitrile with 0.1% formic acid (B). Because of the need to use 
ammonium adducts for the identification and quantitation of the fusidic acid analogues, the 
mobile phase used was 5mM ammonium formate containing 5% acetonitrile (A) and 5mM 
ammonium formate in 95% acetonitrile (B). 
The column used for the metabolic stability work was a Kinetex C18 2.1mm x 50mm, with 
2.6µM particles, while a Kinetex C18 2.1mm x 150mm, with 2.6µM was used for the 
metabolite identification work.  
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The mobile phase flow rate was 500µl/min and the run time was 3 minutes for metabolic 
stability methods and 400µl/min with a run time of 15 minutes for metabolite identification 
methods. 
The general gradient used for the stability assays in Chapter 2 and 3 is provided in Table 6.1 
while that for the fusidic acid analogues is shown in Table 6.2. Modifications were only made 
when the compound of interest co-eluted with the internal standard. 
Table 6.2: General gradient for metabolic stability work in Chapter 2 and 3  







Table 6.3: General gradient for metabolic stability work in Chapter 4 







The gradients for the metabolite identification work were similar in nature but as alluded to, 
the run time and flow rate were different. In general, the gradient above was ramped up over 
9 min, held at the highest % B for 3 min and then immediately lowered for re-equilibration 
over the last 3minutes. Because of the qualitative nature of this work and the ability of the 
4000Q to give detailed spectra even for co-eluting metabolites, no detailed chromatography 
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method development work was performed other than to check that the compounds did not 
elute too early or too late (first or last 4 minutes in the 15 minute ran) in the gradient. 
6.6 Metabolic stability experiments 
The microsomal stability of the test compounds was evaluated using a single point metabolic 
stability assay.
4
 Incubation mixtures contained microsomes and 1µM compound in 0.1M 
phosphate buffer and were pre-incubated at 37°C for 3 minutes. The reactions were started by 
adding 1mM NADPH and were incubated at 37°C for 30min in the case of the compounds in 
Chapter 2 and 3, and 60 minutes for the fusidic acid derivatives in Chapter 4. Ice-cold 
acetonitrile (-20°C) containing the internal standard was added to stop the reaction at T0 
(before addition of NADPH) and at T30 min. The samples were then centrifuged at 4°C, 
4000g for 30minutes and then filtered through a 0.2µM polyvinylidene difluoride (PVDF) 
filter. The decrease in parent concentration was monitored using MRM methods. Data were 
processed on Analyst v1.5 and analysed on Microsoft Excel 2007.  
6.7 Plasma stability 
Human, rat and mouse plasma was provided courtesy of the Division of Pharmacology, 
University of Cape Town. The procedure for this assay broadly was based on the optimised 
parameters suggested by Di et al.
5
 Compounds were tested at 1µM in a 50% dilution of 
plasma in Phosphate buffered saline (0.1M, PBS pH 7.4) and the negative controls in PBS 
only. Incubations were performed at 37°C for 3 hours and stopped by addition of ice cold 
acetonitrile containing the internal standard. The processing and analysis was then carried out 





6.8 Mycobacterium smegmatis and Mycobacterium tuberculosis lysate hydrolysis 
experiments 
The Mycobacterium smegmatis mc
2
155 lysate and the Mycobacterium tuberculosis H37Rv 
supernatant were provided courtesy of the Molecular Mycobacteriology Research Unit, 
Institute of Infectious Disease and Molecular Medicine, University of Cape Town. The lysate 
was prepared according to a previously published procedure.
6
 Because of the biological 
hazard associated with M.tb, the procedure above was modified to include a centrifugation 
step at the end, followed by filtration through a 0.2µM membrane to ensure that no intact 
cells would end up in the supernatant. This preparative work was carried out in a Biosafety 
Level 3 (BSL3) lab. The analytical work could, however, be safely performed in an ordinary 
analytical lab (BSL1/2). 
Benfluorex, which was used as a positive control for plasma stability, was used here to 
confirm the hydrolytic ability of the M.smeg lysate and M.tb supernatant. 
The fusidic acid experiments involved a 20-fold dilution of the lysate/supernatant in 0.1M 
phosphate buffered saline, pH 7.4 (PBS) mixed with 1µM of fusidic acid and incubated at 
37°C. Aliquots of the reaction were stopped at 0, 30, 180 and 360min with acetonitrile 
containing an internal standard, as discussed in the metabolic stability work. The rest of the 





6.9 Microsomal metabolite identification experiments 
6.9.1 Incubations 
The test compound (10 µM) was incubated at 37 °C with 1mg/ml microsomes (human, rat or 
mouse) in phosphate buffer (100 mM, pH 7.4) which contained magnesium chloride (5 mM). 
Reactions were started after a 5 minute pre-incubation by adding 1mM NADPH (1 mM) and 
were incubated with shaking in a water bath at 37°C for 1 hour. An equal volume of ice cold 
acetonitrile was added to stop the reaction and to precipitate the proteins. After centrifuging 
the mixture at 14000 rpm for 30 minutes the supernatant was transferred to a HPLC vial. 
Control samples with no NADPH, no microsomes and a T0 sample were also included and 
processed in a similar way to the samples.  
Where necessary, Glutathione (5mM), UDPGA (7.5 mM) or potassium cyanide (1mM) were 
added before the pre-incubation and the necessary controls included. 
6.9.2 LC-MS analysis 
The LC-MS method was created using Lightsight v2.1 which relied on Analyst method files 
created during direct infusion of the compounds.
7
 The methods generally consisted of survey 
scans were coupled through information dependent acquisition to enhanced product ion 
scans. For all compounds, a method with an enhanced mass spectrum scan coupled to an 
enhanced product ion scan (EMS-IDA-EPI) was used as the method for the primary data 
acquisition and subsequently, MRM, neutral loss, or precursor ion scans, with or without 
dependent EPI scans were used to get more data on the metabolites. The scan range was 
selected to include the masses of the expected metabolites and their common adducts, and 
also such that the cycle time of the method did not significantly exceed 1s. The collision 
energy and collision energy spread were suggested by Lightsight based on the optimised 
collision energy of the ions selected during direct infusion. This tended to be optimal for most 
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compounds but was adjusted as necessary, depending on the fragment ions required for 
tentative metabolite identification.  
6.9.3 Data analysis 
Metabolites formed in the incubations were identified by comparison of their respective 
chromatograms with chromatograms at T0, in the control without NADPH or in the buffer 
only control using Lightsight. The type of metabolites formed were deduced from the mass 
shift of their [M+H]
+
 ions relative to the parent. Tentative identification of the site of 
metabolism was determined by comparison of the product ion spectra of the parent and the 
metabolite.  Neutral loss and precursor fragment ion filtering was also performed, post-
acquisition, using the IDATraceExtractor script in Analyst 1.5 using precursor ions or neutral 
losses common to the metabolites and their respective parents.
8
   
6.10 Hepatocyte metabolite identification experiments for tetrazole aminoquinolines  
Cryopreserved hepatocytes were thawed and viable cells enriched by centrifugation in the 
presence of percoll (GE Healthcare biosciences, Uppsala, Sweden) according to the 
supplier’s instructions. The cells were resuspended in HepatoZYME culture medium (Gibco 
Invitrogen, Carlsbad, USA) and their viability determined using a Guava EasyCyte 
Minisystem Viacount assay, as described by the supplier. The cells were diluted to 1x10
6
 
viable cells/ml with HepatoZYME and aliquoted into 500µl portions for the reactions. The 
test compounds were added to a final concentration of 5µM, with 0.1% DMSO. The 
incubations were performed for 6 hours under a humidified atmosphere containing 5% CO2. 
The test compounds were also incubated in HepatoZYME only, under the same conditions to 
identify products of chemical instability.  
The reactions were stopped by adding an equal volume of acetonitrile. They were then stored 
at -20°c for 4hrs to fully precipitate the proteins before centrifugation at 4000g for 30min. 
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The supernatant was transferred to analysis vial and evaporated with nitrogen then 
reconstituted with 5µM ammonium acetate in water containing 10% acetonitrile. 250µl of 
this solution was injected for analysis. LC-MS/MS analyses were performed on an Agilent 
1100 HPLC (Agilent technologies, USA) coupled to a Q-Tof Premier mass spectrometer 
(Waters, Manchester, UK).The MS data was acquired in positive electrospray ionisation 
mode, with a Z-spray interface. Data were acquired from 50 to 1000Da with a 1s cycle time. 
Collision energy was set to 5V, 20V and 40V (Function 1, 2 and 3 respectively). The 
desolvation temperature used was 200°C, while the source temperature was 100°C. During 
acquisition, the reference chanel of the LockSpray interface was operated with a solution of 
leucine-enkephalin (200pg/ml), with a reference ion of 556.2771.  
 
6.11 CYP450 inhibition experiments for tetrazole aminoquinolines (Chapter 2) 
The P450 inhibition potential of the compounds was assessed by incubating 0.078–20 lM of 
the compoundswith known specific P450 isoform substrates in human liver microsomes.The 
probe substrate concentrations were less than or equal to their Km. The percentage decrease 
in formation of the specific metabolites was monitored by LC/MS using a triple quadrupole 
Quattro Ultima mass spectrometer (Waters, Milford, USA). The probe substrate reactions 
monitored were; phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation 
(CYP2A6), bupropion hydroxylation (CYP2B6), paclitaxel 6a-hydroxylation (CYP2C8), 
diclofenac 40-hydroxylation (CYP2C9), S-mephenytoin 40-hydroxylation (CYP2C19), 
bufuralol 10-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), 
midazolam 10-hydroxylation and testosterone 6b-hydroxylation (3A4). Known specific P450 
isoform inhibitors were used as positive controls. Further details of the methodology, 






6.12 Docking experiments for tetrazole aminoquinolines 
The docking experiments relied on a crystal structure CYP3A4 in complex with its inhibitor, 
ketoconazole, with a resolution of 2.80 Ǻ (PDB ID: 2V0M). Details of the docking protocol 




6.13 StarDrop predictions of physicochemical properties and CYP450 sites of 
metabolism 
Chemical structures were drawn directly in StarDrop 5.5 or imported in the smiles format 
from ChemBioDraw Ultra 11.0. There were no user adjustable settings. The CYP450 models 
took about 5-10min per compound. Predictions of physicochemical properties were based on 
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